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Abstract 
The function of heat shock protein (hspB1) in vivo is still poorly understood, despite a large 
literature describing in vitro functions of the protein. This research has focussed on the role of 
hspB1 in vivo, an opportunity created by the commercial generation of hspB1-deficient mice 
(hspB1
del/del
). Initial experiments demonstrated an increase in cytokine production in 
hspB1
del/del
 murine embryonic fibroblasts. Two well established and characterised in vivo 
models of acute inflammation, the air-pouch model and the peritonitis model, were used to 
investigate the role of hspB1. Increased cellular infiltration and an increase in chemokine 
expression in response to inflammatory challenge was observed in hspB1
del/del 
mice relative to 
wild-type mice. It was found that the majority of the cellular infiltrate consisted of 
neutrophils, and these cells had reduced viability in hspB1
del/del
 compared to wild-type mice, 
despite the discovery that neither hspB1 protein nor mRNA could be detected in murine 
neutrophils. The work of Anna Aubareda, a post-doc in the laboratory, showed that hspB1 
deficiency results in impaired cell proliferation. The observation of a phenotype of increased 
inflammation and decreased proliferation in hspB1
del/del 
mice and cells led to an investigation 
into the role of hspB1 in wound-healing. It was discovered that hspB1
del/del 
mice have 
significantly impaired healing in response to excisional wounding compared to wild-type 
mice. HspB1 protein expression is increased in the proliferating epithelium of wounds in 
wild-type mice. It was also shown that HspB1 deficiency results in increased chemokine 
production and neutrophil accumulation in wounds. This research proposes an important role 
for hspB1 in inflammatory responses and wound healing in vivo. 
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1.1 Innate immunity and the acute inflammatory response. 
Inflammation is a component of the response of tissues to damage, such a pathogen activity, 
cellular damage or irritation, which allows the restoration of the tissue to homeostasis. The 
classical signs of inflammation are pain, redness, swelling, heat and loss of function. 
Inflammation is considered as a mechanism of innate and adaptive/acquired immunity, which 
may be acute or chronic. Innate immunity represents the first line of defence that defends the 
host against infection and tissue damage in a non-specific manner. Cells involved in 
mounting an innate immune response recognise pathogens in a generic manner, that is to say, 
unlike the antigen-specific response of the acquired immune response. The innate immune 
response provides immediate defence, although it does not confer long-term protection. The 
adaptive immune system is responsible for the recognition of ‘self’ and ‘non-self’ antigens, 
initiation of responses that efficiently and maximally eliminate specific pathogens and 
compile and immunological memory of encountered ‘non-self’ antigens. 
Acute inflammation represents the initial response to harm and is achieved by a responsive 
change in the gene expression by cells in resident tissues and the migration and infiltration of 
leukocytes, including neutrophils and macrophages, the site of the inflammatory stimuli. This 
results in sequence of biochemical events that propagates the inflammatory response and its 
eventual resolution, which is mediated by the resident and infiltrated cells. Prolonged or 
delayed resolution of the inflammatory response may result in chronic inflammation, leading 
to a shift in the number or type of inflammatory cells responding to the site of inflammation 
and can result in harm to the organism by destruction of tissue through uncontrolled 
inflammatory processes. Chronic inflammation is a component of auto-inflammatory 
diseases, such as rheumatoid arthritis and psoriasis, which are leading causes of morbidity 
and require long-term drug management. 
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1.2 Mediators of inflammation. 
Inflammation is usually initiated by disruption of tissue integrity and/or pathogen invasion. A 
variety of mediators regulate the inflammatory response. These include plasma derived 
mediators, such as complement, bradykinin, thrombin and Factor XII, which are instrumental 
in the complement system, vasodilation and the coagulation system.  Leukocytes also 
produce mediators in response to wounding. These include eicosanoids, histamine, 
degranulated lysosomal enzymes and cytokines. Cytokines are small proteins, peptides or 
glycoproteins that belong to a large group of molecules that regulate cell signalling. 
Cytokines bind to specific receptors and activate intracellular signalling which results in the 
induction of the expression of numerous proteins included in the inflammatory response. 
1.2.1 Interleukin-1 (IL-1). 
IL-1α and IL-1β are both the original members of the IL-1 family of cytokines, of which 
there are now 11 members. IL-1 induces gene expression in multiple different cell types, such 
as fibroblasts (Jeong, Kim et al. 2004; Alford, Glennie et al. 2007),  epithelial cells, 
(Hoffmann, Thiefes et al. 2005), vascular endothelial cells and smooth muscle cells 
(Bandman, Coleman et al. 2002). IL-1α and IL-1β also induce their own gene expression by 
autocrine/paracrine signalling (Gaestel, Kotlyarov et al. 2009; Weber, Wasiliew et al. 2010). 
IL-1-induced gene expression occurs within 30 mins and can be sustained for hours. IL-1α 
precursor molecule is biologically active and most cells express constitutive levels of IL-1α 
(Dinarello 2009). IL-1α is not usually found in extracellular fluids, except in cases where it is 
secreted by dying cells and this represents a major cytokine released by necrotic cells that 
induces inflammation (Chen, Kono et al. 2007). IL-1α is primarily membrane-bound and 
signals through paracrine mechanisms (Kaplanski, Farnarier et al. 1994).  
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Inactive Pro-IL-1β is cleaved into active IL-1β by the caspase-1 component of the NALP3 
inflammasome, which is also comprised of NALP3 and the adaptor protein ASC. The 
NALP3 inflammasome belongs to a family of intracellular NOD-like receptors (NLRs) that 
are activated in response to binding with pathogen-associated molecular patterns (PAMPs) 
(Meylan, Tschopp et al. 2006) and danger-associated molecular patterns (DAMPs) such as 
reactive oxygen species (ROS) (Dostert, Petrilli et al. 2008), hsp90 (Mayor, Martinon et al. 
2007) and microbial and host DNA (Muruve, Petrilli et al. 2008). IL-1β is capable of 
inducing the expression of cyclooxygenase (COX)-2 in the hypothalamus, which results in 
the increased production of prostaglandin E2 in the thermoregulatory centre of the brain, 
causing fever (Dinarello 2004). Il-1β also increases the expression of adhesion molecules of 
vascular mesenchymal and endothelial cells and the induction of chemokines, which together 
result in the infiltration of inflammatory leukocytes from the circulation and into tissues 
(Dinarello 2009). The production of IL-8 by fibroblasts (Alford, Glennie et al. 2007) and IL-6 
production by vascular endothelial cells is particularly sensitive to IL-1-mediated induction 
(Dinarello 1996; Dinarello 2005). 
1.2.2 Tumour necrosis factor (TNF) α. 
The biological activity of TNFα was discovered in the 1960/70s (Kolb and Granger 1968; 
Carswell, Old et al. 1975) and the gene was cloned under different names in the 1980s (Gray, 
Aggarwal et al. 1984; Pennica, Nedwin et al. 1984). TNFα is one of the most rapidly 
produced pro-inflammatory cytokines in vivo. The major sources of TNFα are macrophages 
and monocytes, although T cells, neutrophils, mast cells and vascular endothelium are also 
sources under certain conditions. Together with IL-1, TNFα is a key mediator of the 
inflammatory response. TNFα is implicated in the progression of a number of diseases 
(Feldmann and Maini 2001). TNFα can induce apoptotic cell death and is capable of inducing 
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the expression of chemokines and adhesion molecules required for leukocyte recruitment to 
the site of inflammation (Doukas and Pober 1990; Schroder, Sticherling et al. 1990). The 
discovery of the clinical application of anti-TNFα antibodies to treat rheumatoid arthritis was 
made at my research institute (Elliott, Maini et al. 1993). These anti-TNFα biologics, such as 
infliximab and adalimumab, are used to treat RA that is resistant to conventional disease 
modifying anti-rheumatic drugs and NSAIDS, often in a combination therapy with these 
conventional drugs (Upchurch and Kay 2012). 
1.2.3 Interleukin-6 (IL-6). 
IL-6 is a pro-inflammatory cytokine that is produced by a large variety of cells in response to 
a broad range of stimuli. IL-6 is produced by cells involved in the innate immune response, 
such as macrophages, dendritic cells and mast cells, and well as by endothelial cells, 
fibroblasts and epithelial cells (Hirano 1998). IL-6 expression and production is regulated by 
changes in the activity of NF-κB and CCAAT/enhancer binding protein α (C/EBPα). IL-6 
mRNA stability is stabilised by p38 MAPK activity (Zhao, Liu et al. 2008; Tudor, Marchese 
et al. 2009). IL-6 binds to a receptor complex comprised of IL-6Rα and glycoprotein 130 
(gp130), which results in the activation of the Janus kinase (JAK) family of tyrosine kinases. 
Activated JAKs phosphorylate and activate signal transducer and activator of transcription 
(STAT) 1 and 3 (Akira 1997; Fielding, McLoughlin et al. 2008). IL-6 induces angiogenesis 
(Nakahara, Song et al. 2003), chemokine production and monocyte recruitment and fever 
(Fonseca, Santos et al. 2009). 
Gp130 is ubiquitously expressed, although IL-6Rα is not. However, IL-6 is capable of 
regulating gene expression in cells that do not express IL-6Rα. Soluble IL-6R (sIL-6R) can 
complex with IL-6 and associate with membrane bound gp130. Innate immune cells, such as 
neutrophils and macrophages, are the main sources of sIL-6R (Horiuchi, Koyanagi et al. 
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1994). IL-6 signalling through STAT3 has been shown to down-regulate the production of 
the neutrophil attractant chemokine CXCL1 and increased neutrophil clearance in a murine 
model of peritoneal inflammation (Fielding, McLoughlin et al. 2008). 
The concentration of IL-6 is elevated in the serum of patients with RA (Houssiau, Devogelaer 
et al. 1988)and Crohn’s disease (Kishimoto 2010). Serum IL-6 levels are elevated in some, 
but not necessarily all RA patients. Serum IL-6 is a marker of on-going inflammation; 
however, IL-6 levels do not always correlate with other markers of chronic inflammation, 
such as IL-1 and TNFα in RA patients. Tocilizumab, a humanized anti-IL-6R antibody that 
blocks IL-6 binding to surface and soluble IL-6R, has been successfully used to treat the 
symptoms and arrest the on-going inflammation in RA patients and is the primary therapy 
used to treat patients who do not respond to anti-TNFα (Rincon 2012).  
1.2.4 Interleukin-10 (IL-10). 
IL-10 is an anti-inflammatory cytokine and plays a crucial role in limiting the immune 
response to pathogens and preventing damage to the host. IL-10 is broadly expressed by 
many immune cells, including macrophages, dendritic cells, mast cells, neutrophils, T cells 
and B cells (Saraiva and O'Garra 2010), macrophages (Fiorentino, Zlotnik et al. 1991), 
dendritic cells (Boonstra, Rajsbaum et al. 2006) and to a lesser extent in neutrophils (Hu, Paik 
et al. 2006) Induction of IL-10 often occurs together with pro-inflammatory cytokines, 
although pathways that induce IL-10 may actually negatively regulate these pro-
inflammatory cytokines (Saraiva and O'Garra 2010). IL-10 binds to IL-10R1 and IL-10R2 
and induces STAT3 and JAK1 activation. However, unlike STAT3 activation by other 
inflammatory mediators such as IL-6, IL-10-mediated STAT3 activation is sustained and 
enhances the expression of suppressor of cytokine signalling (SOCS) -3 and IL-1Ra and 
soluble p55 and p75 TNFR. IL-10 inhibits the expression of COX-2, which in turn regulates 
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the expression of matrix metalloproteinase through a prostaglandin E2/cAMP pathway 
(Mertz, DeWitt et al. 1994). IL-10 activity potently inhibits the production of IL-1/LPS- and 
TNF-induced pro-inflammatory cytokines, as well as itself, in macrophages and monocytes. 
IL-10 also inhibits the secretion of CC and CXC chemokines. 
1.2.5 Chemotactic Cytokines (Chemokines). 
Chemokines are cytokines that have a crucial role in orchestrating the movement of 
circulating leukocytes to the sites of inflammation and/or injury (Charo and Ransohoff 2006). 
There are four distinct families of chemokines, segregated on the basis of differences in 
structure and function and the adopted nomenclature based on the arrangement of first 
cysteine residues in these molecules (Bacon, Baggiolini et al. 2002). The largest family is that 
of the CC chemokines, which are responsible for attracting mononuclear cells to the site of 
inflammation. The most well understood CC chemokine is monocyte chemoattractant-1 
(MCP-1/CCL2). CC chemokines (CCLs) are potent chemoattractants for monocytes, 
macrophages, dendritic cells, T cells and basophils (Charo and Ransohoff 2006). Other CCLs 
include macrophage inflammatory protein-1α (MIP-1α/CCL3), MIP-1β/CCL4 and 
RANTES/CCL5. CCLs are ligands for CCR receptor family. CCL3 binds to CCR1, 
expressed on monocytes, eosinophils and basophils, while CCL2 binds to CCR2, expressed 
on monocytes, immature dendritic cells, endothelial cells fibroblasts and memory T cells 
(Luster 1998; Gerard and Rollins 2001; Charo and Ransohoff 2006). 
Another group of chemokines are the CXC chemokines, so named due to the single amino 
acid residue between the first two cysteine residues of their amino acid sequence. IL-8 
(CXCL8) in humans, and its functional murine orthologues GROα/KC (CXCL1) and MIP-2α 
(CXCL2), are the canonical prototypes (Charo and Ransohoff 2006; Kolaczkowska and 
Kubes 2013). CXCL1 is produced by endothelial cells, fibroblasts and neutrophils to a 
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greater extent than macrophages, whereas CXCL2 is predominantly produced by neutrophils 
and macrophages, with very little production by endothelial cells (Armstrong, Major et al. 
2004). These chemokines signal via CXCR2 to activate and promote the adhesion of 
neutrophils (Kolaczkowska and Kubes 2013) and mast cells (Hallgren and Gurish 2007).  
Leukocyte recruitment and extravasation follows a sequence of steps, commonly named as 
tethering, rolling, adhesion, crawling and transmigration. Leukocyte adhesion and tethering is 
initiated by changes to the surface of the vascular endothelium in response to stimulation by 
pro-inflammatory mediators that are produced by resident leukocytes when they are activated 
by pathogen recognition.  
Activation and recruitment of neutrophils by CXC chemokines induces a conformational 
change in the in the structure of integrins expressed neutrophil cell surface, which results in 
higher affinity toward their respective immunoglobulin-like cell adhesion molecules (CAMs). 
Neutrophils have high expression levels of the integrins lymphocyte function-associated 
antigen 1 (LFA1, comprised of CD18/CD11α) and the complement receptor macrophage-1 
antigen (CR3/MAC1, comprised of CD18/CD11β), which having undergone this 
conformational change, bind to the endothelial cell surface molecules intercellular adhesion 
molecule 1 (ICAM1), and is essential for neutrophil adhesion and migration.  
1.2.6 Cyclooxygenase-2 (COX-2). 
There are two functional forms of COX, COX-1 and COX-2. These enzymes are crucial for 
the synthesis of eicosanoids from free arachidonic acid. COX-1 was first purified in 1976 
(Miyamoto, Ogino et al. 1976) and is constitutively expressed in many tissues (Kargman, 
Charleson et al. 1996). It is thought that COX-1 activity is important for the production of 
prostacyclin and PGE2, which are cytoprotective and maintain the integrity of gastric mucosa 
(Allison, Howatson et al. 1992). COX-2 is not constitutively expressed but is induced by a 
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variety of stimuli, such as LPS, IL-1 and TNF (Williams, Mann et al. 1999). COX-2 is 
responsible for the increase in the production of prostaglandins, leukotrienes and 
thromboxanes that cause inflammation, pain and fever (Smith, DeWitt et al. 2000). Non-
steroidal anti-inflammatory drugs that do not selectively inhibit COX-2 typically result in 
gastric mucosal damage, and in severe cases, gastric ulcers and bleeding, if the use of NSAID 
treatment is prolonged (Steinmeyer 2000). COX-2 selective inhibitors, also known as coxibs, 
were developed to prevent the production of prostaglandins synthesised by COX-2. Although 
these were heavily prescribed in the early 2000s, clinical trial data revealed that there was a 
significant increase in the rate of incidents such as non-fatal myocardial infarction, non-fatal 
stroke and death from one of these events (Antman, Bennett et al. 2007). The cause of these 
cardiovascular incidents has become a major subject of research (Cannon and Cannon 2012). 
1.2.7 Lipopolysaccharide (LPS). 
TNFα secretion is induced by activation of pattern recognition receptors (PRRs), such as the 
toll-like receptors (TLRs). These receptors recognise structural elements common to 
pathogens, such as lipopolysaccharides, peptidoglycans, and bacterial DNA. TLRs are 
expressed on the surface of epithelial cells and resident macrophages, dendritic cells and mast 
cells, activation of which leads to induction of pro-inflammatory cytokine expression. 
LPS is ligand for TLR4, and in fact the discovery of the receptor was a result of research into 
identifying the cause of sensitivity to LPS (Poltorak, He et al. 1998). LPS is a component of 
the outer membrane of gram-negative bacteria and is crucial for the structural integrity of 
these bacteria. LPS is also known as endotoxin, (Rietschel, Kirikae et al. 1994) and is one of 
the most studied inflammatory stimuli. It is capable of causing excessive inflammation and 
endotoxic shock in high concentrations or if prolonged inflammatory signalling processes 
occur (Freudenberg, Tchaptchet et al. 2008). LPS consists of 3 components; lipid A, an 
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oligosaccharide core, and a distal O-antigen polysaccharide side chain. Lipid A has been 
identified and the endotoxic component (Raetz and Whitfield 2002).  
1.2.8 Zymosan. 
Zymosan is a particulate cell wall extract from yeast, Saccharomyces cerevisiae. It is 
composed of many polysaccharides, of which mannose and β-glucan are the major 
constituents (Di Carlo and Fiore 1958), and is a TLR-2/6 and dectin-1 ligand (Sato, Sano et 
al. 2003). Zymosan induces recruitment and respiratory burst of neutrophils (Paya, Terencio 
et al. ; Su, Raghuwanshi et al. 2005) and induces TNFα, IL-1 and IL-6 production by 
monocytes and macrophages (Sanguedolce, Capo et al. 1992) (Young, Ye et al.). Zymosan 
induces the the expression of IL-6 and IL-8 in human fibroblasts (Nomi, Kimura et al. 2010). 
Zymosan has also been shown to promote the production of IL-10 in macrophages (Elcombe, 
Naqvi et al. 2013). 
1.3 Inflammation and wound healing. 
A normal and regulated acute inflammatory response is a necessary component of the wound 
healing response. It has been shown, using various animal models and study of human skin 
wounds, that the inflammatory response during normal healing is characterised by a sequence 
of changing patterns of various leukocyte subsets (Martin 1997; Singer and Clark 1999; 
Eming, Krieg et al. 2007).  
The immediate response to wounding involves the consequence of damage caused to local 
blood vessels. Platelets activate and aggregate to produce a fibrin clot to stop local 
haemorrhage and provide a provisional matrix through which infiltrating cells can migrate 
(Nurden, Nurden et al. 2008). These platelets are also a source of transforming growth factor 
(TGF) β, platelet derived growth factor (PDGF) and vascular endothelial growth factor 
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(VEGF) (Bahou and Gnatenko 2004).The inflammatory response to wounding involves the 
recruitment and infiltration of leukocytes to the wound site. This infiltration is induced by 
stimulation of local resident cells, such vascular endothelial cells and activated resident mast 
cells, by serum components and TLR activation which results in the of pro-inflammatory 
cytokines and chemokines  (Gillitzer and Goebeler 2001; Noli and Miolo 2001; Shaw and 
Martin 2009). Excessive inflammation is associated with impaired wound healing, although 
the positive and negative consequences of the inflammatory response to the outcome of 
wound healing are controversial. 
Neutrophils are activated and are the first inflammatory cells to arrive at the wound site (Kim, 
Liu et al. 2008). The main function of the neutrophil is to act as an effector cell to 
decontaminate the wound bed and kill invading pathogens. Neutrophils release highly active 
anti-microbial substances, such as ROS, proteases (including as neutrophil elastase and PR-3) 
and produce small amounts of pro-inflammatory cytokines. However, these factors can delay 
healing by causing damage to the developing structures required for the progression of 
wound healing. For example, neutrophil elastase can degrade almost every component of the 
extracellular matrix, which is exacerbated by the release of ROS that inactivate endogenous 
protease inhibitors (Weiss 1989). Considering that the extracellular matrix provides a 
supporting scaffold for proliferating and migrating cells, impairment to the integrity of this 
structure might have negative consequences for wound repair and closure. 
It has been demonstrated that anti-Gr-1 antibody-mediated neutrophil depletion in mice 
results in accelerated wound re-epithelialisation (Dovi, He et al. 2003). In the same study, 
using genetically diabetic mice which show an excessive neutrophil infiltrate in response to 
wounding, wound closure was accelerated in response to systemic neutrophil depletion 
(Dovi, He et al. 2003). However, Gr-1 is also present on monocytes, and the study did not 
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investigate the extent of monocyte and macrophage depletion mediated by anti-Gr-1 
antibody-mediated leukocyte depletion. 
CXCL1 and CXCL2 are the agonists for CXCR2 and promote neutrophil infiltration. CXCR2
-
/-
 mice have impaired neutrophil recruitment and delayed wound healing (Devalaraja, Nanney 
et al. 2000). However, the authors also demonstrated impaired keratinocyte proliferation 
angiogenesis, which are CXCR2-dependent processes, in CXCR2
-/-
 mice compared to wild-
type mice (Devalaraja, Nanney et al. 2000).   
Neutrophils are largely absent from wounds that heal very well. Fetal dermal wounding often 
heals in the absence of an inflammatory response (Adzick, Harrison et al. 1985; Longaker, 
Whitby et al. 1990), and results in the complete restoration of dermal architecture without 
scarring. Adult skin in a fetal environment undergoes an inflammatory response to wounding 
with scarring (Longaker, Whitby et al. 1994). Wound healing experiments using PU.1 null 
mice, which lack both macrophage and neutrophils, demonstrate scar-free wound healing, 
although in the same time frame as wild-type mice (Martin, D'Souza et al. 2003). These 
findings suggest that the reduction in the magnitude of the inflammatory response, 
particularly the infiltration of leukocytes, to wounding results in rapid and improved repair of 
wounds.  
Neutrophil influx peaks at 1-2 days post-wounding, in the absence of excessive infection 
(Kim, Liu et al. 2008). Unless the stimuli for the recruitment of neutrophils persist, resident 
macrophages and blood monocytes are recruited and infiltrate to the site of wounding 2 - 4 
days after injury (Eming, Krieg et al. 2007). Macrophage infiltration to the wound site is 
regulated by gradients of chemotactic factors, such as growth factors, pro-inflammatory 
cytokines and the chemokines CCL2 and CCL3 (DiPietro, Burdick et al. 1998; Werner and 
Grose 2003). As the monocytes extravasate from the blood into the wound site, they 
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differentiate into mature tissue macrophages (Gordon 2003; Mosser 2003). These pro-
inflammatory , M1 macrophages produce cytokines such as IL-1, IL-6 and TNFα, amplifying 
the inflammatory response (Barrientos, Stojadinovic et al. 2008). 
Macrophages represent the single most effective means of removing neutrophils form the site 
of injury. Macrophages induce apoptosis of neutrophils (Meszaros, Reichner et al. 2000). 
Macrophages phagocytose and remove the large load of apoptotic neutrophils. This process is 
called efferocytosis and is thought to be essential to resolve wound inflammation and 
complete repair (Savill, Wyllie et al. 1989; Acosta, del Barco et al. 2008; Khanna, Biswas et 
al. 2010). There is evidence to suggest that phagocytosis of neutrophils promotes the 
differentiation of  macrophages into a M2-like anti-inflammatory, growth promoting and 
reparative lineage (Fadok, Bratton et al. 1998). 
Chronic and non-healing wounds, such as those associated with clinical disorders such as 
venous insufficiency (Singer and Clark 1999), diabetes (Eming, Smola et al. 2002) and 
vasculitis (Wlaschek and Scharffetter-Kochanek 2005), often fail to progress through the 
normal phases of wound healing and remain in a chronic inflammatory state (Loots, Lamme 
et al. 1998). Increased TNFα expression is found systemically and the local issue of 
ulcerative wounds in human patients compared to a control age population without 
underlying pathology and wounds. Neutralisation of TNFα in wounds accelerates resolution 
of healing (Ashcroft, Jeong et al. 2012). Factors such as hypoxia, amplified pro-inflammatory 
cytokine expression, unbalanced protease activity, fragments of necrotic tissue and the 
presence of bacteria all induce a prolonged and continued influx of neutrophils and 
macrophages (Singer and Clark 1999). These inflammatory cells are instrumental in further 
amplifying the inflammatory response which results in the creation of a proteolytic and 
oxidative hostile microenvironment, which over-whelms local mechanisms tissue protection 
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(Barrick, Campbell et al. 1999). The development of strategies to mitigate excessive 
inflammation to enhance wound healing represents a promising target for therapeutic 
intervention. 
1.4 Inflammatory cellular signalling 
1.4.1 IL-1R and TLR signalling. 
Cell signalling is initiated by ligand binding to a receptor and inducing a conformational 
change resulting in receptor activation. There are nine members of the IL-1 receptor 1 (IL-
1RI) family. IL-1α or IL-1β bind to the IL-1RI receptor, which then recruits the co-receptor 
accessory protein (IL-1RAcP) and forms a complex. This in turn results in recruitment of 
myeloid differentiation primary response gene (88) (MyD88) via the toll-IL-1R domain (TIR) 
(Dinarello 2011). The recruitment of MyD88 leads to the association of interleukin-1 
receptor-associated kinase (IRAK) 1, 2 and 4, likely through the death domains of these 
molecules. IRAK4 then phosphorylates IRAK1, which results in the dissociation of IRAK1 
and IRAK4 from MyD88 (Brikos, Wait et al. 2007). This IRAK complex then interacts with 
TNFR-associated factor 6 (TRAF6), which is an E3 ubiquitin ligase (Deng, Wang et al. 
2000). TRAF6 then undergoes autoubiquitination, through a process involving E2 ubiquitin 
conjugating enzymes Ubc13 and Uev1a, which results in K63-polyubiquitination of TRAF6. 
K63-TRAF6 can then recruit transforming growth factor β-activated protein kinase (TAK1) 
in a complex with TAK-1 binding protein (TAB) 1, 2 and 3. TAK1 is then activated, which 
then associates with the inhibitor of NF-κB (IκB) kinase (IKK) complex, containing the NF-
κB essential modulator (NEMO) scaffold protein and IKKβ, which is the kinase responsible 
for IκBα phosphorylation and subsequent degradation which results in NF-κB activation. 
Phosphorylated IRAK 1 also undergoes K63-polyubiquitantion caused by the recruitment of 
E3 ubiquitin ligases Pellino-1 and Pellino-3b (Ordureau, Smith et al. 2008), resulting in 
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NEMO recruitment which binds to polyubiquitinated IRAK1 (Conze, Wu et al. 2008). 
Eventually, the ubiquitinated components of this signalling pathway are eventually degraded 
which results in termination of the signal (O'Neill 2008). Activation of TAK1 also 
phosphorylates and activates mitogen activated protein kinases kinases (MAPKKs), which 
propagate downstream signalling and phosphorylate MAPKs, which will be introduced later. 
IL-1 also binds to the IL-1RII receptor, which is incapable of inducing downstream 
signalling, due to a lack of a TIR domain and the inability to dock with MyD88. IL-1-
complexed IL-1RII is also capable of recruiting IL-1RAcP, sequestering the accessory 
protein for participating in IL-1RI-mediated signalling. This receptor acts as a decoy receptor 
and is mostly expressed on macrophages and B cells (Dinarello 2011). IL-1 receptor 
antagonist (IL-1Ra) competitively prevents the binding of IL-1 to IL-1RI and is used as in the 
treatment of rheumatoid arthritis, where it is used under the trade name Anakinra.  
The downstream TIR domain common to the signalling pathways of IL-1R and TLRs ensures 
that many downstream signalling events as a result of the activation of these families of 
receptors are shared. LPS stimulation involves interactions with a complex of proteins 
including LPS binding protein, CD14, MD-2 and TLR4 itself. Stimulation results in TLR4 
oligomerisation and interacts with TIR to recruit downstream signalling adaptors, such as 
MyD88 and MyD88-adaptor like protein (Mal), which results in activation of TAK1. LPS-
activated TLR4 is capable of undergoing endocytosis where it recruits two more TIR domain 
adaptors, translocating chain-associated membrane protein (TRAM) and TIR domain-
containing adaptor-inducing interferon-β (TRIF) leading to activation of interferon regulatory 
factor (IRF) 3 and induction of genes that contain interferon responsive elements (Kagan, Su 
et al. 2008). The C-Terminal region of TRIF also contains a Rip homotypic interaction motif 
(RHIM) which interacts with receptor-interlacing protein (RIP) 1. RIP1 is a serine/threonine 
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kinase and has been identified as an important component of TNFα-induced NF-κB 
activation. This capacity of TLR4 to signal from two locations is thought to be unique among 
TIR-containing receptors (O'Neill 2008). TLR2 will dimerise with TLR6, and this has been 
shown to be required for the coordination of pathogen recognition and macrophage activation 
by zymosan through TIR domain signalling (Ozinsky, Underhill et al. 2000). IRAK2 has also 
been shown to be essential for TLR2-induced TRAF6-mediated signalling. IRAK2 activity 
has been shown to peak at 8 h, in contrast to IRAK1 which peaked at 1 h post TLR2 
stimulation. This suggested sequential control of IRAK1 in early-stage and IRAK2 in late-
stage responses to TLR stimulation (Kawagoe, Sato et al. 2008). 
1.4.2 TNFR Signalling. 
Research on TNF has characterised the largest known family of cytokines, the TNF 
superfamily, which are ligands for and signal through interaction with the TNF receptor 
(TNFR) superfamily (Wiens and Glenney 2011). TNFRs bind to adaptor proteins in order to 
activate intercellular signalling pathways. TNFRs can be grouped depending on which 
adaptor proteins they recruit. TNFR1 is expressed on almost all cell types and recruits 
adaptor proteins with a death domain such as TNFR-associated death domain (TRADD) or 
Fas-associated protein with death domain (FADD) which are important for TNF-mediated 
cell death. TNFR2 is expressed on astrocytes, T cells, myocytes and thymyocytes and 
endothelial cells and does not recruit adaptor proteins with a death domain. TNFR2 instead 
recruits TRAF. 
TNFR1 is activated by soluble TNF and membrane bound TNF. Depending on the 
microenviromental conditions TNFR1 activation can result in the induction of proliferation, 
apoptosis or necrosis. Activation of TNFR1 results in the formation of two different 
signalling complexes. The first, complex I, controls activation of downstream signalling that 
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results in the expression of genes that prevent the triggering of cellular death processes. The 
second complex, complex II or the death-inducing signalling complex (DISC) is formed after 
the internalisation of TNFR1 (Micheau and Tschopp 2003). Complex I recruits TRAF2, 
baculoviral IAP repeat-containing protein (cIAP) 1, cIAP2 and RIP1. After this integration 
RIP1 is rapidly modified with polyubiquitin chains, which results in recruitment and 
activation of the TAK1 and the IKK complex, resulting in activation of MAPKKs and NF-
κB, respectively. TNFR1- induced TRAF2 activation also results in the recruitment of the 
linear ubiquitin chain assembly complex (LUBAC), comprised of haeme-oxidised IRP2 
ubiquitin ligase (HOIL) 1, HIOL-1-interacting protein (HOIP) and Sharpin (Emmerich, 
Schmukle et al. 2011). LUBAC is an E3 ubiquitin ligase and binds ubiquitin chains to RIP1 
and NEMO, enhancing NF-κB activation. TNFR1 activation may also result in an 
endocytotic process which results in a change the assortment of adaptor proteins that may 
occupy it (Schneider-Brachert, Tchikov et al. 2004). RIP1 may be de-ubiquitinated by 
cylindromatosis (turban tumor sundrome) (CYLD), resulting in negative regulation of NF-κB 
activation and instead frees RIP1 for recruitment by RIP kinase into a complex with TRADD, 
FADD and procaspase-8. This activity of this complex, known as DISC, is dependent upon 
NF-κB. If NF-κB is active, cellular FADD-like IL-1β-converting enzyme-inhibitory protein 
(cFLIP) translocates to DISC and prevents the activation of caspase 8. If NF-κB is absent, 
cFLIP remains absent from DISC resulting in activation of caspase-8, an initiator caspase 
required for the induction of the cell to enter apoptosis (Micheau and Tschopp 2003). 
TNFR2 belongs to the second group in the TNFR superfamily and is only activated by mTNF 
(Grell 1995). Activation of TNFR2 results in TRAF2-mediated activation of TAK1 and IKK 
as for complex I for TNFR1. However, TNFR2 activation induces changes in the cellular 
localisation of TRAF2 resulting in K48-linked ubiquitantion and proteasomal degradation 
(Wu, Conze et al. 2005). This has important implications for the survival of the cell. 
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Although TNFR2 is not a death receptor in of itself, the degradation of TRAF2 inhibits the 
binding of cIAP1 and cIAP2 to the TNFR1 complex I, preventing activation of NF-κB, and 
thus enhancing the activity of DISC and apoptosis. Thus is it clear that not only the extent of 
TNFR activation, but also the proportions in which TNFR1 and TNFR2 are activated and the 
conditions other cellular stresses the cell might be exposed to, leads to a delicate balance 
between the pro-inflammatory and pro-apoptotic actions resulting from TNFα stimulation 
(Cabal-Hierro and Lazo 2012). 
1.4.3 Mitogen-activated protein kinases (MAPK). 
MAPKs are serine/threonine kinases that are responsible for signal transduction of 
extracellular stimuli in to cellular responses. All eukaryotic cells have multiple MAPK 
pathways, which together regulate gene expression, metabolism, apoptosis and 
differentiation, to name but a few processes (Cargnello and Roux 2011). The classical and 
most commonly studied MAPKs are extracellular signal-regulated kinases (ERK) 1 and 2, c-
Jun animo N-terminal kinases (JNK) 1, 2 and 3 and the p38 isoforms (α,β,γ and δ). Each of 
these MAPK groups is controlled by a set of sequentially activating kinases; a MAP3K, a 
MAP kinase, (MKK) and finally the MAPK itself (Cargnello and Roux 2011). IL-1/TLR 
and/or TNFR activation results in the phosphorylation and activation MAP3Ks, which then 
phosphorylate MAPKKs, which then induce MAPK activity through phosphorylation within 
a conserved Thr-X-Tyr motif located within the kinase domain of MAPKs. Phosphorylation 
of these residues is essential for MAPK activity (Cargnello and Roux 2011). The wide 
assortment of functions induced by MAPK activation is regulated through phosphorylation of 
substrates, such as p90 ribosomal S6 kinases (RSKs), mitogen and stress-activated kinases 
(MSKs), MAPK-interacting kinases (MNKs) and MAPK-activated protein kinases (MK2, 3 
and 5). 
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1.4.4 Extracellular signal-related kinases (ERK). 
ERK1 was the first MAPK to be characterised. Both ERK1 and ERK2 were cloned by the 
early 1990s (Cooper, Bowen-Pope et al. 1982) (Boulton, Nye et al. 1991) and share 83% 
amino acid identity. ERKs are expressed in various levels in all tissues and are activated by 
growth factors, such as platelet-derived growth factor (PGDF) and epidermal growth factor 
(EGF) (Boulton, Yancopoulos et al. 1990), cytokine stimuli and osmotic stress (Raman, Chen 
et al. 2007).  
The activation pathway of ERKs consist of the MAP3Ks A-Raf, B-Raf and Raf-1 and the 
MAPKKs MAPK ERK kinase (MEK) 1 and MEK2. Activated ERKs phosphorylate a large 
number of substrates, such as MNKs, monocyte enhancer factor 2, c-Fos, c-Myc and STAT3 
among, others. 
The ERKs play a role in the control of cell proliferation and is required for G1 to S-phase 
progression (Meloche and Pouyssegur 2007). ERKs phosphorylate and stabilise c-Fos, 
resulting association with c-Jun and the formation of transcriptionally active AP-1 complexes 
(Whitmarsh and Davis 1996). Active AP-1 is required for cyclin D1 expression. This protein 
interacts with cyclin-dependent kinases (CDKs) and permits G1 to S phase transition and cell 
cycle progression (Shaulian and Karin 2001). ERKs phosphorylate RSKs, MSKs and MNKs, 
which are important regulators of ERK-induced biological processes (Cargnello and Roux 
2011). 
1.4.5 c-Jun amino (N)-terminal kinases (JNK). 
JNKs, also known as stress-activated protein kinases (SAPKs), were also discovered in the 
early 1990s (Kyriakis and Avruch 1990; Hibi, Lin et al. 1993; Kracht, Truong et al. 1994) 
and are phosphorylated on Thr and Tyr residues in response to stress stimuli (Kyriakis, 
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Brautigan et al. 1991). There are 3 known JNK isoforms, JNK1, JNK2 and JNK3, which 
share 85% amino acid homology. JNK1 and JNK2 are expressed win a wide range of tissues. 
JNK3 expression seems to be restricted to neuronal tissue, testis and cardiac monocytes 
(Bode and Dong 2007). 
JNKs are activated in response to cellular stresses such as ionizing radiation, oxidative stress, 
DAMPs, cytokines, growth factors, serum sensitivity and heat shock (Bogoyevitch, Ngoei et 
al. 2010). Inflammatory stimulation results in the phosphorylation of JNK mediated through 
activation of MAP3Ks such as MEKK1-4, TAK1 and ASK1 (Kyriakis and Avruch 2001), 
which results in activation and phosphorylation of MAPKKs MKK4 and MKK7, which 
together phosphorylate JNKs (Lawler, Fleming et al. 1998). 
Activated JNKs are capable of relocating from the cytoplasm to the nucleus of the cell 
(Mizukami, Yoshioka et al. 1997) where they phosphorylate the transcription factor c-Jun and 
positively regulate cell proliferation (Jaeschke, Karasarides et al. 2006) through regulating 
AP-1 activity (Sabapathy, Hochedlinger et al. 2004). JNK activation is required for 
cytochrome-c release from mitochondria in MEF exposed to UV-induced cell stress 
(Tournier, Hess et al. 2000), which results in caspase 9 and caspase 3 activation and 
apoptosis. JNK phosphorylates activating transcription factor (ATF) 2 which results in the 
promotion of CRE-dependent transcription (Gupta, Campbell et al. 1995). The limited 
availability of JNK specific inhibitors has prevented the full understanding of JNK-dependent 
signalling. 
1.4.6 p38 MAPK. 
The p38α isoform was identified simultaneously in 1994 by 3 research groups (Han, Lee et 
al. 1994; Lee, Laydon et al. 1994; Rouse, Cohen et al. 1994). There are 3 isoforms of p38 
MAPK in addition to p38α; p38β, p38γ and p38δ. P38α and p38β are ubiquitously expressed 
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cells, whereas p38γ and p38δ have more restricted expression and may have specialised 
functions. p38α expression is generally greater than that of p38β, and as consequence most of 
the published literature of p38 MAPK refers to p38α. There exist specific p38α and p38β 
inhibitors, which have also aided in developing the understanding of these isoforms.  
p38 MAPKs are strongly activated by oxidative stress, hypoxia, ischemia and inflammatory 
cytokines such as IL-1 and TNFα (Cuadrado and Nebreda 2010). As described previously, 
TRAF recruitment promotes activation of TAK1 which then phosphorylates the MAPKKs 
MKK3 and MKK6 which then phosphorylate a conserved Thr-Gly-Tyr motif in p38 MAPKs 
(Derijard, Raingeaud et al. 1995; Han, Lee et al. 1996; Cuadrado and Nebreda 2010).  
Isoforms of p38 MAPKs are located in the cytoplasm and nuclei of cells and accumulate in 
the nuclei of cells under cell stress (Raingeaud, Gupta et al. 1995). p38 MAPK 
phosphorylates MK2, MK3 and MK5, which results in the sequestering of p38 MAPK in the 
cytosolic compartment (Gaestel 2006). Activated p38 MAPKs phosphorylate a large number 
of substrates in various cellular compartments, including cytoplasmic cPL2, MNK1/2, 
MK2/3, Bax and Tau, p53 and MSK1/2, amongst others (Cuadrado and Nebreda 2010).  
p38 MAPK has a crucial role in immune and inflammatory responses. Activation of p38 
MAPKs can result from stimulation of the cell by cytokines, chemokines and LPS. P38 
MAPKs induce pro-inflammatory cytokine expression by modulating the activity of 
transcription factors such as NF-κB (Karin 2006), or modulating mRNA stability through 
regulation and MK2/3 (Ronkina, Kotlyarov et al. 2008). 
The p38 MAPKs have also been shown to be important regulators of cell proliferation and 
survival. Activation of p38 MAPK has been shown to result in negative regulation of cell 
cycle progression at both the G1-S and G2-M transition points by a variety of mechanisms, 
including deceased expression of cyclins and increased CDK inhibitor expression (Thornton 
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and Rincon 2009). P38 MAPK activity has been shown induce apoptosis in response to 
cellular stresses by both transcriptional and post-transcriptional mechanisms (Cuenda and 
Rousseau 2007). 
1.4.7 Mitogen and stress-activated kinases (MSKs). 
MSK1 and MSK2 were discovered in the late 1990s as substrates for p38 MAPK-mediated 
phosphorylation (Deak, Clifton et al. 1998; New, Zhao et al. 1999) and have approximately 
63% amino acid sequence homology. ERK1/2 and p38 MAPKs interact and phosphorylate 
MSKs at their Leu-Ala-Lys-Arg-Arg-Lys MAPK-binding domains (Tomas-Zuber, Mary et 
al. 2001). 
MSKs have been implicated in negatively regulating inflammation. MSK1 and MSK2-
deficient mice are hypersensitive to LPS challenge. MSKs phosphorylate cAMP response-
binding protein (CREB), with greater efficacy than any other MAPKAP (Pierrat, Correia et 
al. 1998), which results in the expression of c-Fos, JunB. MSK1 also activates CRE-binding 
activating factor (ATF1). MSKs have been shown to bind to and phosphorylate the p65 
subunit of NF-κB, which results in interaction with histone acetylation cofactors and 
enhances NF-κB gene expression (Zhong, Voll et al. 1998). MSK1 and MSK2-deficient 
fibroblasts have reduced IL-6 mRNA expression in response to TNF stimulation compared to 
wild-type cells (Vermeulen, De Wilde et al. 2003). This suggests that MSK activity is 
important for NF-κB-dependent transcription. MSKs have also been shown to phosphorylate 
and activate STAT3 (Wierenga, Vogelzang et al. 2003). MSK2 has also been shown to 
inhibit p53 activity in resting cells (Llanos, Cuadrado et al. 2009). A recent study has shown 
that activation of MSKs and CREB by zymosan induces IL-10 transcription via a dectin-1 
specific pathway in macrophages and also results in low level of IL-12p40 production 
(Elcombe, Naqvi et al. 2013). The same study has shown that dectin-1 activation results in 
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the induction of genes associated with regulatory/M2 polarised macrophages (Elcombe, 
Naqvi et al. 2013), suggesting a role for MSK activation the control of macrophage 
inflammatory phenotype. 
1.4.8 MAPK-activated protein kinase 2 (MK2). 
MK2 was originally discovered as a substrate of ERKs that could phosphorylate heat-shock 
protein beta 1 (hspB1) (Stokoe, Engel et al. 1992), although it was later discovered that is 
activated by p38 MAPK in response to pro-inflammatory stimuli (Freshney, Rawlinson et al. 
1994). MK3, which has 75% amino acid homology with MK2, has also been identified as a 
substrate for p38 MAPK-mediated phosphorylation (McLaughlin, Kumar et al. 1996). MK2 
is located in the nuclei of resting cells, and is exported to the cytoplasm as a result of stressful 
cellular stimuli, such as IL-1R/TLR and TLR activation, oxidative stress and UV radiation 
(Freshney, Rawlinson et al. 1994; Rouse, Cohen et al. 1994; Guay, Lambert et al. 1997; 
Engel, Kotlyarov et al. 1998). 
MK2 plays a role in control of the cell cycle. MK2 has been shown to phosphorylate and 
activate CDC25B and CDC25C in response to UV radiation stress (Manke, Nguyen et al. 
2005), which results in phosphorylation of CDCs and initiation of mitosis (Aressy and 
Ducommun 2008). MK2 is capable of promoting arrest of cell division at the G2/M 
checkpoint in response to DNA damage-inducing stress (Manke, Nguyen et al. 2005). 
Phosphorylated MK2 has been shown to phosphorylate and activate HDM2 resulting in 
degradation of p53, suggesting that MK2 may decrease the duration and extent of the p53 
response to stress and DNA damage (Weber, Ludwig et al. 2005; Johansen, Vestergaard et al. 
2009). 
MK2 regulates the p38-MAPK inflammatory response by through post-transcriptional 
mechanisms. MK2 activity increases the production of TNF, IL-6, COX-2, chemokines and 
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other inflammatory mediators by promoting the stability of mRNA encoding for these 
proteins. The stability of these mRNAs is dependent on the presence of AU-rich elements 
(AREs) located on the 3’-untranslated regions (UTRs). Tristetraprolin (TTP) initiates ARE-
containing mRNA decay by promoting removal of the poly A tail by a process called 
deadenylation (Lai, Carballo et al. 1999). MK2 activation results in phosphorylation of TTP, 
which results in inhibition of TTP-dependent degradation of LPS-induced TNFα mRNA 
expression (Chrestensen, Schroeder et al. 2004; Stoecklin, Stubbs et al. 2004; Brook, Tchen 
et al. 2006). Recent work in my lab has suggested that phosphorylation of TTP inhibits its 
ability to recruit CCR4 CAF1 deadenylase, preventing deadenylation of ARE-containing 
mRNAs (Marchese, Aubareda et al. 2010).  This work also demonstrated that 14-3-3 does not 
have a role in the mechanism of TTP-mediated mRNA deadenylation, as was previously 
thought (Stoecklin, Stubbs et al. 2004), although it could still have a role in mediating TTP 
subcellular localisation (Marchese, Aubareda et al. 2010). 
A recent study has showed that MK2-mediated signalling is crucial for wound healing. MK-
deficient mice have severely delayed wound healing compared to wild-type mice 
(Thuraisingam, Xu et al. 2010). In the same study, cytokine and chemokine levels were 
reduced in the wounds of MK2-deficient mice, however, no difference in the numbers of 
neutrophils and macrophages infiltrating the wounds was observed in MK2-deficient mice 
compared to wild-type mice (Thuraisingam, Xu et al. 2010). The authors suggested that a 
lack of the inflammatory response correlated with diminished capacity for wound healing in 
MK2-deficient mice (Thuraisingam, Xu et al. 2010). 
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Figure 1.1 Schematic of pro-inflammatory signalling cascades resulting in activation of 
hspB1. 
IL-1R, TLR and TNFR2 activation results in downstream signalling events that result 
formation of the TAK1 complex with TAB 1, 2 and 3. This results in TAK1 activation and 
phosphorylation of MKKs MKK3 and MMK6. These phosphorylate and activate p38 MAPK, 
which then phosphorylates and activates MK2. MK2 phosphorylates serine residues 15, 72 
and 82 of hspB1, resulting in dimerisation and activation. Activated hspB1 has been shown to 
have a role as a inflammation, cytoprotetion, cell migration and acts as a protein chaperone. 
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1.5 Heat shock protein beta-1 (hspB1). 
The cells of practically all organisms respond to stress stimuli by the rapid synthesis of a 
conserved group of proteins known as hsps. These proteins are ubiquitous, are expressed in 
all organisms, and are categorised by their different forms into families based on their 
molecular weights.  The major families are hsp100/104, hsp90, hsp70, hsp60 and the small 
heat shock proteins, or shsps. (Kregel 2002)  Many functional roles for hsps have been 
described, but the mechanisms for many of these roles are not entirely understood. Hsps have 
been shown to be induced by heat shock and a variety of other stresses, behave as molecular 
chaperones for other cellular proteins and have strong cytoprotective effects (Welch and 
Suhan 1986; Hightower 1991). 
HspB1, also known as hsp27 in humans and hsp25 in mice, belongs to a family of small heat 
shock proteins (shsp). There are 10 proteins in this family which similar structure and have a 
monomer size typically in the range of 16-25 kDa. Examples include hspB1, αA-
crystallin/hspB4 and αB-crystallin/hspB5 (Kappe, Franck et al. 2003). They all contain a 
highly conserved -crystallin domain and have a less conserved N-terminal WDPF region (so 
called due to the sequence of amino acid residues (Lambert, Charette et al. 1999). These 
regions are thought to be important for the oligomerisation of hspB1. The C-terminal region 
is known as the ‘flexible region’ as it has little sequence homology within the shsp family, 
although it too has been suggested to be involved with hspB1 oligomerisation and to be 
important for hspB1 solubility (Lelj-Garolla and Mauk 2005). 
Constitutive hspB1 expression is restricted to only a few cell types. HspB1 is strongly 
expressed in mouse skeletal muscle tissue with lower levels in epithelial cells. In adult mice, 
hspB1 was found to be expressed in the ear, skin (including panniculous carnosus and hair 
follicles), tongue, oesophagus, fallopian tubes and the interventricular septum of the heart, 
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but barely in any other cardiac compartments (Huang, Min et al. 2007). It is also expressed 
during mouse embryonic development, in particular in the cardiac tube and cerebral 
vasculature (Huang, Min et al. 2007). HspB1 is not expressed in lung, liver, pancreas, spleen, 
small intestine and colon (Huang, Min et al. 2007). HspB1 expression is induced in response 
to heat shock (Chretien and Landry 1988), oxidative stress (Okada, Otani et al. 2005), 
osmotic stress (Garmyn, Mammone et al. 2001). Previous work in my laboratory has been 
unable to detect hspB1 in mouse bone marrow derived macrophages, RAW 264.7 mouse 
macrophage-like cells, human monocytes, human neutrophils or T-cells (Brennan 2009). 
HspB1 was not detected in resting human monocytes, however, it is detectable in human 
monocytes differentiated into macrophages using either macrophage colony-stimulating 
factor (M-CSF) or granulocyte-monocyte colony-stimulating factor (GM-CSF) (Brennan 
2009). HspB1 was detected in human endothelial cells, fibroblasts, HeLa cells (Alford, 
Glennie et al. 2007) and hypertrophic chondrocytes, but not resting or proliferating 
chondrocytes (Otsuka, Kubo et al. 1996; Vanmuylder, Evrard et al. 1997). 
1.5.1 Phosphorylation of hspB1. 
HspB1 is phosphorylated in response to heat shock (Chretien and Landry 1988), TNF and 
IL-1-treatment (Kaur, Welch et al. 1989; Saklatvala, Kaur et al. 1991; Guesdon, Freshney et 
al. 1993), oxidative stress (Okada, Otani et al. 2005), osmotic stress (Garmyn, Mammone et 
al. 2001) and other cellular stresses (Kostenko and Moens 2009). Investigation of hspB1 
phosphorylation in vitro led to the purification of the upstream kinase cascade, which is now 
known to be the p38 MAPK pathway (Freshney, Rawlinson et al. 1994). Human hspB1 is 
phosphorylated at three serine residues, Ser-15 (located on the WDPF domain), Ser-78 and 
Ser-82 (Landry, Lambert et al. 1992) by mitogen-activated protein kinase MK2 (Ahlers, 
Belka et al. 1994). HspB1 is also phosphorylated by MK3 in vitro (Clifton, Young et al. 
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1996) and MK5 in response to activation by cAMP/PKA (Gerits, Mikalsen et al. 2007). PKD 
has also been shown to phosphorylate hspB1 (Doppler, Storz et al. 2005; Stetler, Gao et al. 
2012). However, it is thought that MK2 is the main kinase responsible for hspB1 
phosphorylation. Murine hspB1 is phosphorylated by MK2 at serine residues 15 and 86 (Ser-
86 in hsp25 being the equivalent of Ser-82 in hsp27 (Stokoe, Engel et al. 1992)). 
Phosphorylation of hspB1 has been postulated to modulate the structural and functional 
properties of the protein. Unphosphorylated hspB1 exists in the cytoplasm with an average 
mass of ~530-700 kDa, which equates to an oligomer comprised of approximately 24 
subunits, which upon phosphorylation, dissociates into dimers and monomers (Lambert, 
Charette et al. 1999; Rogalla, Ehrnsperger et al. 1999; Lelj-Garolla and Mauk 2005). 
1.5.2 The role of hspB1 as a protein chaperone. 
Like the other hsps, hspB1 has chaperone-like properties and refolds denatured proteins, 
preventing their aggregation. The chaperone activity of hspB1 is ATP-independent (Knauf, 
Jakob et al. 1994), unlike the ATP-dependent chaperone activity of larger hsps, such as hsp70 
and hsp90 (Young 2010; Neckers and Workman 2012). HspB1 has been shown to prevent 
aggregation of denatured -glucosidase under thermal stress and to be required for correct 
refolding and reactivation of the enzyme following denaturation with urea (Jakob, Gaestel et 
al. 1993). It has been demonstrated that hspB1 can adopt a number of oligomerisation sates, 
and that larger oligomers are formed at higher temperatures (Lelj-Garolla and Mauk 2006). In 
addition, the chaperone activity of hspB1 is increased at higher temperatures, as indicated by 
inhibition of dithiothretiol-induced insulin aggregation, with a sharp increase in activity at 
34-43
o
C. This suggests that the protein chaperone function of hspB1 is increased as 
temperature is increased within a range that is relevant to physiological heat shock (Lelj-
Garolla and Mauk 2006). Considering large oligomeric structures of hspB1 separate into 
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hspB1 dimers upon phosphorylation, it is thought that the protein chaperone function of 
hspB1 is dependent upon its oligomeric structure. It has been suggested that a part of the N-
terminal region (amino acid residues 31-95) of hspB1 is involved in oligomerisation and 
chaperone function (Haslbeck, Ignatiou et al. 2004). It has been demonstrated that 
phosphorylation and dimerisation of hspB1 is not required to provide thermoresistance and 
the assisted refolding of denatured proteins (Knauf, Jakob et al. 1994). In fact, the ability of 
hspB1 to act as a protein chaperone has been shown to be decreased when hspB1 is 
phosphorylated (Rogalla, Ehrnsperger et al. 1999). It has been shown that during thermal 
stress hspB1 binds to the cap-binding mRNA translation initiation factor, eIF4G, which is 
critical for the translation of most cellular mRNAs (Cuesta, Laroia et al. 2000). This 
interaction was proposed to prevent eIF4G from initiating translation (Cuesta, Laroia et al. 
2000). However, these findings have yet to be corroborated.  
HspB1 has also been demonstrated to mediate ubiquitination of proteins and induce 
proteasomal degradation. It has been recently shown that phosphomimetic mutations of 
phosphorylation target serines to aspartic acid residues in hspB1 promotes degradation of 
AUF1 isoforms by proteasomes, thus promoting stabilisation of ARE-containing mRNAs (Li, 
Defren et al. 2013). These data would suggest that hspB1 phosphorylation stabilises the 
mRNA encoding for pro-inflammatory genes. HspB1 also induces the ubiquitination of 
cyclin-dependent kinase inhibitor p27
Kip1
 and facilities cell cycle transition through G1/S, 
enhancing cell proliferation (Parcellier, Brunet et al. 2006). 
1.5.3 The regulation of the cytoskeleton by hspB1. 
HspB1 has been suggested to act in vitro as an F-actin cap binding protein which inhibits 
actin polymerisation and maintains cytoskeletal integrity in response to stress (Landry and 
Huot 1995). Phosphorylation of hspB1 by p38 MAPK has been shown be required for actin 
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microfilament stability and increased rate of recovery of disrupted filaments (Guay, Lambert 
et al. 1997), however, this experiment used very high concentrations (10 µM and 25 µM) of 
SB203580 to achieve p38 MAPK-inhibition, which may introduce non-specific effects. The 
Induction of hspB1 in bovine arterial endothelial cells resulted in an increase in migration, 
whereas transfection with non-phosphorylatable hspB1 resulted in a decrease in migration 
(Piotrowicz, Hickey et al. 1998). It has been demonstrated that p38 MAPK activation and 
subsequent hspB1 phosphorylation is required for rearrangement of actin cytoskeleton and 
cell migration in human umbilical vein endothelial cells (HUVECs) treated with vascular 
endothelial growth factor (VEGF) (Rousseau, Houle et al. 1997). However, another study has 
shown that inhibition of cell migration by the chemotherapeutic agent cisplatin in HUVECs is 
not p38 MAPK-dependent (Montiel, Urso et al. 2009). 
Wound contraction is a critical process for the healing of wounds, involving re-
epithelialisation, connective tissue deposition and contraction, which is mediated by cells 
within the wound granulation tissue (Watts, Grillo et al. 1958; Martin 1997). The fibroblast-
collagen matrix model provides a way to study the mechanisms of wound contraction, 
whereby mechanical loading is applied to the proliferating cells in culture (Grinnell 2000). 
Inhibition of hspB1/27 phosphorylation has been shown to result in delayed fibroblast-
populated collage lattice (FPCL) contraction and the transient delay of wound contraction in 
vivo (Hirano, Rees et al. 2002). Another study has shown that over-expression of hspB1 
results in enhanced fibroblast migration, elongation, adhesion and matrix contraction in a 
FPCL wound healing model (Hirano, Shelden et al. 2004). 
Interpretation of the results supporting a role for hspB1 on cytoskeletal rearrangement must 
first take into consideration how the earliest experiments in this field were performed. One of 
the first publications suggesting a role for hspB1 inhibition of actin polymerisation were 
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performed using preparations  of hspB1 purified from turkey gizzards (Miron, 
Vancompernolle et al. 1991). These preparations likely contained trace amounts of a potent 
inhibitor of actin polymerisation, cofilin, which has a molecular mass of 20-22 kDa 
(Panasenko, Kim et al. 2003). Purified hspB1 has since been shown to have little effect on the 
rate or extent of actin polymerisation (Panasenko, Kim et al. 2003). 
1.5.4 The cytoprotective role of hspB1. 
There is evidence that hspB1 is involved in the regulation of cell survival. HspB1 is 
cytoprotective against heat shock (Landry, Chretien et al. 1989) apoptosis inducing agents 
such as TNF (Mehlen, Mehlen et al. 1995) and staurosporine (Mehlen, Schulze-Osthoff et 
al. 1996), oxidative stress agents, such as H2O2 (Huot, Houle et al. 1996) and anticancer 
drugs such as doxorubicin and cisplatin (Garrido, Ottavi et al. 1997). It has been 
demonstrated that hspB1 protects against TNF and oxidative stress-induced cell death by its 
ability to increase the intracellular concentration of glutathione (Mehlen, Kretz-Remy et al. 
1996). HspB1 has been shown to regulate ‘intrinsic’, mitochondria-dependent signalling by 
preventing cytochrome c release from the mitochondria, and binding procaspase-3 
(Concannon, Orrenius et al. 2001). This prevents the activation of caspase-3, preventing 
formation of the apoptosome during caspase-dependent apoptotic stress events, such as 
accumulation of aggregated protein (Charette, Lavoie et al. 2000). HspB1 has also been 
shown to bind to apoptosis signal-retulating kinase-1 (ASK1) and DAXX, a FAS-associated 
protein (Charette and Landry 2000). ‘Extrinsic’ initiators of apoptosis, such as TNF and 
reactive oxygen species, act as ligands at the FAS ‘death’ receptor. HspB1 binds to DAXX 
and prevents it from binding FAS at the cell surface membrane, an interaction that is required 
downstream FAS activation of pro-caspase-8, an initiator caspase for pro-caspase-3 (Charette 
and Landry 2000; Concannon, Orrenius et al. 2001; Gabai and Sherman 2002).  
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Overexpression of human hspB1 in mice has demonstrated that hspB1 protects against liver 
and kidney damage after liver ischemia-reperfusion injury (IRI) (Park, Chen et al. 2009). In 
addition, the overexpression of human hspB1 in mice showed decreased induction of several 
pro-inflammatory mRNAs, a decrease in neutrophil migration and a decrease number of cells 
undergoing apoptosis in the kidney after IRI (Park, Chen et al. 2009). Another study came to 
the opposite conclusion, showing that mice overexpressing human hspB1 had decreased renal 
function and increased renal expression of TNFα, ICAM1 and CCL2 mRNA and CXCL1 
protein, although this study also shows that the overexpression of human hspB1 in murine 
renal tubular cells protects against H2O2-induced necrosis in vitro (Chen, Kim et al. 2009). 
PKD-mediated phosphorylation of hspB1 has been shown to be required for neuroprotection 
against transient focal cerebral ischemia in hspB1-overexpressing mice, (Stetler, Gao et al. 
2012). However, these over-expression studies do not address the role of the murine hspB1 in 
mice. There is currently no agreed common mechanism that explains the function of hspB1 in 
cytoprotection. 
1.5.5 HspB1 in disease. 
The cytoprotective functions of hspB1 was been implicated in providing protection to cancer 
cells against the cellular stress induced by many chemotherapeutic drugs. High hsp27 
expression has been shown to be associated with a poor clinical outcome in colon cancer 
(Bauer, Nitsche et al. 2012). Strategies to reduce hspB1 expression in cancer such as breast 
(Song, Ethier et al. 2004), colon (Garrido, Mehlen et al. 1996), ovarian (Song, Zhang et al. 
2009), prostate (Andrieu, Taieb et al. 2010), bladder (Hadaschik, Jackson et al. 2008), and 
pancreatic (Xia, Liu et al. 2009) have been shown to reduce slow tumour growth and 
metastatic potential. Cell-cell contact has been show to promote the oligomerisation of hspB1 
into large structures, regardless of phosphorylation state, which enhance its cytoprotective 
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activity. This has been suggested to a mechanism to describe the method by which hspB1 
increases cell tumorigenicity (Bruey, Paul et al. 2000). There is limited data to suggest that 
hspB1 has a role in protecting the cell through autophagy. siRNA-mediated HspB1 depletion 
in A549 human alveolar epithelial cells inhibited prevented apoptosis and instead resulted in 
necrosis in response to heat shock (Lim, Duong et al. 2010).  
HspB1 has been shown to play an important role in inhibiting ER stress-mediated apoptosis 
(Gupta, Deepti et al. 2010). Hepatocellular carcinoma (HCC) is a common solid malignancy 
and has a high degree of drug resistance (Wakamatsu, Nakahashi et al. 2007). Cisplatin is an 
anti-cancer drug that is one of the few drugs capable of treating HCC (Yoshikawa, Ono et al. 
2008). The endoplasmic reticulum (ER) is an organelle that is required for the synthesis and 
maturation of proteins. ER stress can result in to disruption of ER functions and leads to the 
accumulation of misfolded proteins, and initiates the unfolded protein response (UPR), which 
promotes cell survival in the event of ER stress (Rutkowski and Kaufman 2004). Autophagy 
is a component of the UPR (Hoyer-Hansen and Jaattela 2007) and is a catabolic process 
required for the degradation and recycling of cellular components (Lum, DeBerardinis et al. 
2005). Autophagy promotes cell survival under conditions of cell stress and nutrient 
starvation (Baehrecke 2005) and is one of the most important mechanisms enabling cancer 
survival and recurrence following long-term chemotherapy (Chen, Dai et al. 2011). siRNA 
mediated depletion of hspB1 suppresses ER stress and cisplatin-induced autophagy and 
apoptosis in HCC cells. This suggests that targeting of hspB1 regulation of the UPR might 
provide therapeutic benefits in the treatment of HCC (Chen, Dai et al. 2011). HspB1 
inhibition by OGX-427, an antisense oligo therapy, has been shown to reduce tumour 
metastasis in a murine model of prostate cancer and castration resistant prostate cancer in 
patients in a phase I clinical trial (Shiota, Bishop et al. 2013) and is currently in six phase II 
clinical trials for the treatment of four cancer types. 
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Diseases such as distal hereditary motor neuropathies (dHMN) and Charcot-Marie-Tooth 
disease (CMT) involve motor and/or sensory neuronal abnormalities. As of 2012 fifteen 
different autosomal dominant mutations have been identifies in families with CMT and/or 
dHMN. The majority of these mutations are within the α-crystallin domain of hspB1. 
Mutations in the C-terminal domain of hspB1 present a more severe phenotype with earlier 
onset. The loss of the ability of hspB1 to clear aggregated neurofilaments due to increased 
and defective chaperone activity has been proposed to be the cause of these diseases 
(Almeida-Souza, Goethals et al. 2010; Rossor, Kalmar et al. 2012). An accumulation and 
impaired clearing of protein aggregates is also associated with Alzheimer’s disease (AD) 
(Smith, Rosen et al. 2005). HspB1 expression has been found to be enhanced in neurons with 
amyloid beta fibril plaques, which are associated with the pathogenesis of AD. However, the 
association of hspB1 and amyloid beta actually increases the toxic effect, which has been 
suggested to be a result of hspB1 altering conformation of amyloid beta into a non-fibrile 
toxic form (Stege, Renkawek et al. 1999). Hyper-phosphorylated tau is a pathological 
hallmark and neurotoxic component of AD. Tau is a microtubule associated protein which 
has a role in the maintenance and stability of the microtubule network. Phosphorylation of tau 
releases it from the microtubule assembly, which can lead to neurofibil plaque formation. 
HspB1 interacts with and induces ubiquitination-independent degradation of pathological 
hyper-phosphorylated tau, which has been suggested a therapeutic basis for the treatment of 
AD (Shimura, Miura-Shimura et al. 2004). 
Atherosclerosis is a chronic disease that underlies the pathology of cardiovascular disease and 
peripheral vascular disease and is a major cause of global mortality. It is a chronic 
inflammatory response in the arterial wall, caused by the accumulation of macrophages, low 
density lipoproteins and proliferation of vascular smooth muscle endothelial cells which form 
plaques within the arterial wall (Ghayour-Mobarhan, Saber et al. 2012). HspB1 expression 
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has been observed to be elevated in vascular tissue adjacent to atherosclerotic plaques 
compared to healthy reference tissue, although reduced hspB1 expression was observed in the 
lesion core. It has been suggested that the diminished hspB1 expression in the core is 
attributable to increased proteolytic activity in this area of the plaque (Wick 2006).  
1.5.6 Extracellular hspB1. 
Some studies have attempted to elucidate a role for extracellular hspB1 as a mediator of 
cellular processes. However the preparation of recombinant protein often results in 
contamination of the protein of interest with bacterial proteins, such as LPS or other 
contaminants. Hence, any such research where recombinant hspB1 is used as stimulus on 
cells must be considered with this in mind. 
One such study has shown that treatment of human monocytes with recombinant human 
hspB1 resulted in a strong induction of IL-10 that p38 MAPK-dependent (De, Kodys et al. 
2000). The authors proposed that this induction of IL-10 by recombinant hspB1 is 
independent of the effects of contaminating LPS, by demonstrating that the kinetics and 
extent of IL-10 production in response to a combination of Staphylococcal enterotoxin B 
(SEB) and muramyl dipeptide (MDP) (De, Kodys et al. 2000). The authors showed that this 
combination treatment resulted in significantly decreased IL-10 production compared to 
recombinant hspB1 treatment. Curiously, the authors did not determine the effect of LPS 
stimulation of IL-10 production in their experiment (De, Kodys et al. 2000). This, arguably, 
would have been a much more relevant experimental control. The authors proposed that 
treatment of monocytes resulted in p38 MAPK activation and increased hspB1 expression. 
This was determined by western blot (De, Kodys et al. 2000), a technique that would not 
have allowed the investigators the possibility of being able to differentiate between 2 µg/ml 
of recombinant hspB1 added and intracellular hspB1. 
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Another study has proposed a role for extracellular hspB1 in the suppression of the 
differentiation of monocytes into dendritic cells (Laudanski, De et al. 2007). Monocytes 
treated with recombinant hspB1, IL-4 and GM-CSF produced significantly greater levels of 
IL-10, M-CSF and IL-6 stimulated with IL-4 and GM-CSF alone. This effect was specific to 
recombinant human hsp27, as recombinant murine hsp25 did not mediate the same effect 
(Laudanski, De et al. 2007). The authors proposed that the regulation of the expression of 
these cytokines might affect monocyte/macrophage differentiation, and subsequently found 
that recombinant hspB1 and M-CSF derived macrophages had decreased phagocytic activity 
toward acetylated low-density lipoprotein, which is implicated in cardiovascular disease 
(Laudanski, De et al. 2007). The proposed mechanism for recombinant hpsB1 involved TLR 
and p38 MAPK signalling (Laudanski, De et al. 2007). The authors went the lengths to 
demonstrate that their observed recombinant hspB1-induced dysfunction of dendritic cell 
maturation was independent of the action of bacterial contaminants. Boiling and antibody-
mediated neutralisation of hspB1 preparations rendered it inactive and did not induce the 
effects observed with functional recombinant hspB1 (Laudanski, De et al. 2007). However, 
the assays used to detect LPS were not very sensitive and the data directly confirming the 
absence of LPS and the activity of other proposed bacterial contaminants was not shown 
(Laudanski, De et al. 2007). 
Another group showed that heterozygous heat shock factor (hsf1
+/-
) mouse plasma, which 
contains 4 times higher extracellular hspB1 compared to plasma from wild-type mice, 
improved cardiac function and survival post-doxorubicin treatment in mice pre-treatd with 
hsf1
+/-
 mouse plasma compared to mice pre-treated with normal mouse serum 
(Krishnamurthy, Kanagasabai et al. 2012). Mice treated with ehspB1-enriched serum or 
recombinant human hspB1 had elevated serum levels of IL-6 and TNFα, although the 
production of these cytokines was diminished post-doxorubicin treatment in these mice 
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control mice (Krishnamurthy, Kanagasabai et al. 2012). The authors acknowledged their 
previous findings, showing that deceased serum ehspB1 levels resulted in increased 
cardiomyocyte protection via a mechanism involving deceased p53-indcuced expression of 
the pro-apoptotic mediate bax (Vedam, Nishijima et al. 2010), contrasted with the recent 
findings (Krishnamurthy, Kanagasabai et al. 2012). The research in the field of the function 
of extracellular hspB1 is complicated by contradictory results from different groups, or even 
within the same group, and often poor control for the effects of contaminating bacterial 
products in recombinant ehspB1 preparations.  
1.5.7 The role of hspB1 in inflammation. 
A number of reports have shown that pro-inflammatory signalling is regulated by hspB1; 
however, different conclusions have been reached. HspB1 has been shown to be required for 
IL-1 induced activation of MK2 (Alford, Glennie et al. 2007). HspB1 depletion, using 
multiple siRNA oligo duplexes, has been shown to decrease IL-1 induced p38 and JNK 
activity, as well as inhibit the activity of upstream p38 MAPK activators (MKK3 and MKK6) 
and JNK activators (MKK 4 and MKK7) (Alford, Glennie et al. 2007). HspB1 was shown to 
be required for maximal activation of TAK1 by IL-1 and activation of JNK by TNFα in HeLa 
cells (Alford, Glennie et al. 2007). IL-1 induced ERK activity is not regulated by hspB1 
(Alford, Glennie et al. 2007). HspB1 is also involved in the NF-κB inflammatory pathway. 
HspB1 depletion results in an inhibition of IKKβ but does not regulate IκBα degradation in 
IL-1-stimulated human fibroblasts (Alford, Glennie et al. 2007). This suggests that hspB1 is 
required for the activation of IKKβ. Depletion of TAK1 or hspB1 did not block IκBα 
degradation, although this may be the result of residual IKKβ activity in the hspB1 depleted 
cells (Alford, Glennie et al. 2007).  
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 A different study showed that hspB1 regulates IL-1β-induced NF-кB activation by 
augmenting IL-1β-induced TRAF6 ubiquitination and IKK activation in human embryonic 
kidney 293 (HEK293) cells (Wu, Liu et al. 2009). IL-1β stimulation was also shown to 
reduce endogenous hspB1/TRAF6 association in these cells (Wu, Liu et al. 2009). Inhibition 
of hspB1 phosphorylation by p38 inhibition or MK2 siRNA depletion using a single oligo 
duplex increases hspB1/TRAF6 association, resulting in increased TRAF6 ubiquitination, 
IKK phosphorylation and NF-кB activation in HeLa cells (Wu, Liu et al. 2009). Another 
report using a single siRNA-mediated depletion of hspB1 showed that TNFα-induced NF-κB 
activation and inflammatory gene expression in HUVEC was inhibited (Gorska, Liang et al. 
2007). These results suggest that phosphorylation of hspB1 results in a negative feedback 
loop in the regulation of IL-1/TNFα-induced signalling. All three of the above mentioned 
studies suggest that depletion of hspB1 inhibits signalling or inflammatory gene expression 
but in each case the proposed mechanism differs. 
A different study has shown that p38 and MK2 activation is required for ICAM1 and IL-
8 expression in human lung vascular endothelial cells (Acosta, del Barco et al. 2008). 
Another study also demonstrated, using a single siRNA oligo duplex to deplete hspB1 
protein, that hspB1 is not involved in the regulation of ICAM-1 and IL-8 by p38 and MK2 
(Su, Ao et al. 2008). The results suggesting that hspB1 is not involved in p38/MK2 signalling 
(Su, Ao et al. 2008) do not correlate with those indicating that hspB1 is required for 
activation of TAK-1, p38 and MK2 (Alford, Glennie et al. 2007). Inhibition of p38 MAPK in 
HeLa cells disrupted the association of hspB1 with IKKβ, resulting in increased IKKβ 
activity (Park, Gaynor et al. 2003). This study indicated that hspB1 phosphorylation results in 
down regulation of IKKβ activity following stimulation with TNF (Park, Gaynor et al. 
2003). Yet another study demonstrated that siRNA-mediated depletion of hspB1 resulted in 
increased PGE2 and IL-8 production in TNFα stimulated keratinocytes, which was associated 
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with increased NF-κB activity (Sur, Lyte et al. 2008). The different cells used and the 
different protocols for siRNA transfection used in these experiments may account for the 
different results. These results also indicate that hspB1 may have a different role in the 
regulation of inflammatory gene expression in different cell types. 
1.5.8 The in vivo function of hspB1 in mice. 
Investigations on hspB1 knockout mice by another research group have shown that despite 
constitutive hspB1 expression in many tissues in wild type mice, there were no apparent 
morphological abnormalities in new-born or adult hspB1
-/-
 mice (Huang, Min et al. 2007). 
HspB1 has been shown to act synergistically with hsp70 to provide thermoprotection, 
although hspB1 protein expression was not up-regulated in response to heat shock in mice 
tissues (Huang, Min et al. 2007). This contrasted with increased hsp70 protein expression in 
mouse tissues in response to heat shock (Huang, Min et al. 2007). These findings using 
hspB1
-/-
 mice have developed the hypothesis that a multitude of heat shock proteins are 
required for cells to develop maximal resistance to thermal challenge. HspB1
-/-
 mouse 
embryonic fibroblasts (MEF) did not have significant changes in sensitivity to apoptotic 
stimuli, including X-rays, etoposide, serum starvation or oxidative stress, compared to wild-
type (Huang, L. et al., 2007). However, the method of genetic disruption of hspB1 in the mice 
used in this study involved targeted insertion of a 3.5 kb fragment containing the lacZ 
reporter sequence. After recombination this insert only replaced the start codon, the first exon 
and a portion of the first intron of hspB1, which meant that the second and third exons were 
still intact (Huang, Min et al. 2007). This technique did not eliminate the possibility of 
expression of structurally altered but potentially active hspB1 expressed in these mice.  
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1.6 Project Aims. 
The aim of the project outlined in this thesis was to investigate the role of hspB1 in 
inflammation through the use of in vivo physiologically relevant murine models. Previous 
work in my laboratory demonstrated, by depletion of hspB1 protein by RNAi, that hspB1 is 
required for IL-1- and TNFα-induced receptor-proximal and downstream signalling, and is 
required for the IL-1-induced expression of the pro-inflammatory mediators COX-2, IL-6 and 
IL-8 in HeLa cells (Alford, Glennie et al. 2007). We have commercially generated hspB1 
knockout hspB1
del/del 
mice by Cre–recombinase/LoxP deletion, which we then backcrossed 
onto a C57BL/6 background. Despite being identified as a substrate of MK2 and a 
component of the p38 MAPK signalling pathway, there is disagreement about the role of 
hspB1 in inflammation and the function of hspB1 in vivo is still unknown. The availability of 
an established colony of hspB1
del/del
 mice afforded us the opportunity to investigate the 
physiological role of hspB1 in the regulation of inflammation in vivo and avoid potential 
artefacts arising from transient protein depletion strategies or the existence of truncated 
hspB1. Based on previous work performed in my lab demonstrating that hspB1 is required 
for the IL-1 induced inflammatory response in HeLa cells, the aim of this project was to 
determine the role of hspB1 in the inflammatory response in vivo and in vitro using 
hspB1
del/del
 mice and cells. 
Chapter 2 
 
41 
 
 
 
 
Chapter 2 
Materials and Methods 
  
Chapter 2 
 
42 
 
2.1 Materials. 
2.1.1 General Reagents. 
Deionised water purified by reverse osmosis was used for all applications, unless otherwise 
stated.  
Reagent Supplier Product Code 
10x phosphate buffered saline 
(PBS) 
VWR 427117K 
4mm Biopsy Punch Stiefel 0372 
Agarose Invitrogen 16500 
Ammonia VWR 10004703 
Aprotonin Sigma A6279 
Bovine serum albumin (BSA) PAA K41-001 
Bromophenol Blue sodium salt Sigma B8026 
Cell culture water, EP grade, 
sterile 
PAA 515-012 
Cell proliferation kit (MTT) Roche 11 465 007 001 
Coomassie Brilliant Blue G Sigma B1131 
Dithiothreitol (DTT) Alexis 280-001-G025 
DMEM Lonza BE12-604F 
Dulbecco’s PBS without Ca2+, 
Mg
2+
 
PAA H15-011 
EDTA VWR 20302.266 
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EGTA Sigma E4378 
Fetal Bovine Serum (FBS) Gibco 10500-064 
FITC Annexin V apoptosis 
Detection Kit II 
BD 556570 
Glacial Acetic acid VWR 20104.334 
Glycerol VWR 24388.260 
Glycine Sigma G8898 
H2O2 Sigma 21676-3 
H2SO4 VWR 102761C 
HCl VWR 20252.335 
Igepal Sigma CA-630 
Isofurane-Vet
TM
 Merial AP/DRUGS/220/96 
LPS from E.Coli serotype EH 
100 (TLRgrade
TM
) 
Alexis 581-010-L002 
MACS MS columns Miltenyi Biotec 130-042-401 
Methanol VWR 20847.320 
Microcystin– LR Enzo ALX-350-012-C100 
Neutrophil isolation Kit Miltenyi Biotec 130-097-658 
Non-fat dried milk powder Marvel 92964 
Nuclease free water Promega P1195 
Pentobarbitone Animalcare BN7352 
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Penicillin/Streptomycin  PAA P11-010 
Pepstatin A Sigma P5318 
phenylmethanesulfonylfluoride 
(PMSF) 
Sigma P7626 
Pierce
®
 BCA protein assay kit Thermo Scientific 23227 
Protease Inhibitor Cocktail Sigma P3840 
‘Polysceen’ PVDF transfer 
membrane 
Perkin Elmer NEF1005001PK 
Qiashredder homogeniser kit Qiagen 79656 
Quadro-MACS magnetic 
separator 
Miltenyi Biotec 130-090-976 
Red blood cell lysing buffer Sigma R7757 
Sodium Azide Sigma S2002 
Sodium chloride VWR 31535.292 
Sodium citrate dehydrate Sigma C0909 
Sodium dodecyl sulphate (SDS) Sigma L4390 
Sodium fluoride Sigma S1504 
Sodium orthovanadate Sigma S6508 
Streptavidin HRP R&D 890803 
TEMED Sigma T9281 
Thioglycollate medium, Brewer’s 
modification 
BD 211716 
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Tris HCl Sigma 3253 
triton X-100 Fischer Chemical T/3751/08 
Trizma base Sigma T1503 
Trypan blue solution (0.4%) Sigma T8154 
Zymosan A from Saccharomyces 
cerevisiae 
Sigma Z4250 
Table 2.1.1 General Reagents 
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2.1.2 Antibodies. 
Primary antibodies for western blot were prepared by diluting in 5% non-fat dried milk 
powder/0.05% Tween20/PBS. Horse radish peroxidase (HRP)-conjugated secondary 
antibodies were used for western blotting and were prepared in the absence of sodium azide, 
which is a potent inhibitor of HRP. Biotinylated secondary antibodies were used for 
immunohistochemistry.  
Antibody Clone Host/ 
Species 
Supplier Product 
Code 
Anti-Hsp70 [505] Monoclonal Mouse Abcam ab2787 
Anti-Hsp90 Polyclonal Rabbit Abcam ab13495 
Anti-PARP (46D11) Monoclonal Rabbit Cell Signalling 9532 
Anti-neutrophil elastase Polyclonal Rabbit Abcam 21595 
Anti-mouse Ly-6C FITC Monoclonal Rat BD 553104 
Alexa Fluor® 488 anti-mouse 
CD31 
Monoclonal Rat BioLegend 102513 
Anti-mouse CD11b PE/Cy7 Polyclonal Rat BioLegend 101215 
Anti-mouse F4/80 Polyclonal Rat BioLegend 123101 
Anti-mouse COX-2 Polyclonal Rabbit Cayman 160126 
P38 MAPK antibody Polyclonal Rabbit Cell Signalling 9212 
Phospho-p38 MAPK 
(Thr180/Tyr182) 
Polyclonal Rabbit Cell Signalling 9211 
Anti-mouse CD115 (c-fms) 
PE 
Monoclonal Rat eBiosciences 12-1152-82 
Anti-mouse F4/80 e450 Monoclonal Rat eBiosciences 48-4801-80 
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Anti-mouse Ly-6G (Gr-1) PE Monoclonal Rat eBiosciences 12-5931-81 
Anti-HspB1 Polyclonal Rabbit Enzo ADI-SPA-
801 
Anti-ERK-1 Polyclonal Rabbit Santa Cruz SC-94 
Anti-actin antibody Polyclonal Rabbit Sigma A2066 
Anti-a-tubulin Monoclonal Mouse Sigma T3526 
Swine anti-rabbit 
immunoglobulins/HRP 
Polyclonal Swine Dako P0217 
Rabbit anti-mouse 
immunoglobulins/HRP 
Polyclonal Rabbit Dako P0260 
Biotinylated goat anti-rabbit 
IgG Antibody 
Polyclonal Goat Vector BA-1000 
Biotinylated rabbit anti-rat 
IgG Antibody 
Polyclonal Rabbit Vector BA-4001 
Table 2.1.2 Antibodies 
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2.1.3 PCR and RT-PCR reagents. 
Reagent Supplier Product Code 
Wizard SV Genomic DNA 
purification System 
Promega A2361 
Roche (Expand Long 
Template) 
Roche 11 681 842 001 
RNeasy Mini Kit Qiagen 74106 
Proteinase K Promega V3021 
GelRed Nuclei Acid Stain Biotium 41003 
High Capacity cDNA reverse 
transcription Kit 
ABI 4368814 
FailSafe PCR 2x PreMix 
Buffer D, Buffer J 
Epicentre FSP995D 
FSP995J 
Ethidium Bromide BDH 443922U 
BIOTAQ DNA Bioline BIO-21039 
2 Kb Plus DNA ladder Invitrogen 10787-018 
Table 2.1.3 PCR and RT-PCR reagents. 
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2.1.4 SDS-PAGE and western blot reagents. 
Reagent Supplier Product Code 
10x Plus Strong ReBlot Millipore 2564 
10x 0.25M Tris, 1.92M 
glycine, 1% SDS (SDS-
PAGE running buffer) 
National Diagnostics EC-870 
Precision Plus Protein 
Standards, All Blue 
Bio-Rad 161-0373 
Chemiluminescence 
detection kit (ECL) 
GE Healthcare RPN2209 
Table 2.1.4 SDS-PAGE and western blot reagents 
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2.1.5 Enzyme-linked immunosorbent assay (ELISA) reagents. 
ELISA KIT Blocking solution and  
reagent diluent 
Supplier Product Code 
Mouse IL-1α 1% BSA R&D DY400 
Mouse IL-1β 1% BSA R&D DY401 
Mouse IL-6 OptEIA 10% FCS BD 555240 
Mouse IL-10 OptEIA 10% FCS BD 555252 
Mouse IL-23 Ready-
SET-GO!
®
 
Supplied eBioscience 88-7234 
Mouse TNF OptEIA 10% FCS BD 555268 
Mouse CCL2 1% BSA R&D DY479 
Mouse CCL3 1% BSA R&D DY450 
Mouse CXCL2/MIP-2 
DuoSet 
1% BSA R&D DY452 
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Mouse CXCL1/KC 
DuoSet 
1% BSA R&D DY453 
Paremeter PGE2 Supplied R&D KGE004B 
Table 2.1.5 ELISA reagents  
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2.1.6 Immunohistochemistry (IHC) reagents. 
Reagent Supplier Product Code 
DPX mounting medium Cell Path SEA-0302-00A 
Paraformaldehyde (Cell Stor
TM
) Cellpath BAF-6000-08A 
Trichrome Stain (Masson) Tcsbiosciences HS773 
Vectastain Elite ABComplex 
kit 
Vector PK-6100 
Immedge hydrophobic pen Vector H-4000 
3, 3’-diaminobenzidine (DAB) 
peroxidase substrate kit 
Vector SK-4100 
OCT VWR 25608-930 
Acetone Sigma 534064 
Table 2.1.6 IHC reagents 
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2.1.7 Buffers: 
50x Tris-Acetate-EDTA (TAE): 
242 g Tris, 57.1 ml glacial acetic acid, 18.6 g EDTA pH 8.0 in brought to 1 L volume. 
TBS: 
20 mM Tris HCl, 137 mM NaCl, pH 7.6. 
4x Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) sample 
buffer: 
250 mM Tris pH 6.8, 35% glycerol, 8 % SDS, 0.2 mg/ml bromophenol blue.  Prior to use, 
DTT was added for a final concentration of 50 mM. 
Whole cell lysis buffer: 
(50 mM Tris HCl pH 7.5, 240 mM NaCl, 3mM EDTA, 3 mM EGTA, 1% triton X-100, 0.5% 
igepal, 10% glycerol, 1 mM PMSF, 5.5 g/ml aprotonin, 1 ng/ml pepstatin, 2 mM DTT, 1 
mM sodium vanadate, 2 mM sodium fluoride, 1 nM microcystin) 
Western blot transfer buffer: 
25 mM Tris, 192 mM Glycine, 20% (v/v) methanol. 
PVDF membrane blocking solution: 
(5% (w/v) Marvel non-fat dried milk powder, 1xPBS/1xTBS, 0.05% Tween-20) 
TBS was used if the membrane was to be probed for phosphorylated protein. 
Coomassie blue staining solution: 
0.1 % (w/v) Coomassie Brilliant Blue G, 0.05 % (v/v) ethanol, 8.5 % (v/v) H3P04. 
Chapter 2 
 
54 
 
Coomassie destain: 
70 % (v/v) methanol. 
Mouse tissue homogenisation buffer: 
150 mM NaCl, 50 mM Tris HCl. 
Sodium citrate buffer: 
10 mM Sodium citrate dehydrate, 0.05 % Tween 20, pH 6.0. 
MTT assay solubilisation solution: 
10% SDS, 0.01M HCl. 
FACS Buffer: 
2% FCS, 2mM EDTA, PBS. 
6x DNA loading buffer: 
30 % glycerol, 0.25 % bromophenol blue 
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2.2 Methods. 
2.2.1 Mice. 
Targeting vector construction and knock-out strategy was designed and performed by 
genOway (Lyon, France). The genomic region of interest containing the murine hspB1 locus 
was isolated by PCR from 129Sv/Pas ES cell genomic DNA. PCR fragments were subcloned 
into the pCRXL-TOPO or pCR4-TOPO vector (Invitrogen, Carlsbad, California). The 
resulting sequenced clones (containing whole hspB1 gene sequence from promoter region to 
sequence downstream of exon 3) were used to construct the targeting vector. Briefly, a 3.3 kb 
region comprising exons 1 to 3 was flanked by a Neo cassette (FRT site-PGK promoter-Neo 
cDNA-FRT site-LoxP site) and a distal LoxP site in order to allow the generation of 
constitutive or conditional knock-out lines by deleting the whole gene (exons 1 to 3) of the 
hspB1 gene. Linearised targeting vector was transfected into 129SvPas ES cells (genOway, 
Lyon, France) according to genOway's electroporation procedures (ie 10
8
 ES cells in 
presence of 100 µg of linearised plasmid, 260 V, 500 µF). Positive selection was started 48 h 
after electroporation, by addition of 200 µg/ml of G418 (150 µg/ml of active component, Life 
Technologies, Inc.). 111 resistant clones were isolated and amplified in 96-well plates. The 
set of plates containing ES cell clones amplified on gelatin were genotyped by PCR: by 
amplification of the targeted locus: sense (Neo cassette), 5’-
TGACTAGGGGAGGAGTAGAAGGTGGC-3'); antisense 5'-
TCTTGCTACAAGCCTGGGACTCTGG-3'). Recombination of the targeted locus was 
confirmed by Southern blot analysis using internal and external probes on both 3’ and 5’ 
ends. Two clones were identified as correctly targeted at the hspB1 locus. Clones were 
microinjected into C57BL/6 blastocysts, and gave rise to male chimeras with a significant ES 
cell contribution (as determined by an agouti coat colour). Mice were bred to wild-type 
C57BL/6 mice (hspB1
flox 
mice) and to C57BL/6 mice expressing Cre-recombinase to 
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generate a germline deletion of hspB1 (hspB1
+/del 
mice). Animals were then validated by Spe 
I Southern blot analysis using a 3’ external probe. This confirmed that the founders were 
heterozygous for the 9.8 kb wild-type fragment with hspB1
flox 
mice displaying a 3.1 kb 
targeted Neo-excised signal and hspB1
+/del 
mice showing a 6.5 kb hspB1-deleted signal. 
The C57BL/6 mouse strain has been the standard choice for the creation and investigation of 
transgenic and knock-out mice (Zurita, Chagoyen et al. 2011). There are two major strains of 
these mice; C57BL/6J and C57BL/6N. The original strain is C57BL/6 J, or ‘Jax’ derived by 
The Jackson Laboratory in 1921. C57BL/6N is a subline that originated at the NIH in 1951. 
The C57BL/6 mouse strain was the second mammal and the first inbred mouse strain whose 
genome was sequenced (Waterston, Lindblad-Toh et al. 2002). The International Knockout 
Mouse Consortium has made progress on using embryonic stem (ES) cells isolated from 
C57BL/6N mice to systematically knockout every mouse gene (Pettitt, Liang et al. 2009; 
Skarnes, Rosen et al. 2011).  
HspB1
+/del
 mice were backcrossed for 12 generations (n = 12) onto a C57BL/6J background 
(Charles River). Heterozygotes were intercrossed to generate homozygous hspB1
del/del
 and 
hspB1
+/+
 littermate mice, which were expanded by incrossing for use in experiments. All 
mice were maintained at 21 °C ± 2 °C on a 12 h light/dark cycle with feed and water ad 
libitum. All animal experiments were approved by the local Ethical Review Process 
Committee and the UK Home Office.  
2.2.2 Genotyping. 
Mouse genotyping was assessed by PCR reactions on DNA extracted from mouse tail tips. 
DNA extraction was performed using the Wizard SV Genomic DNA purification System 
according to the manufacturer’s instructions. Each tail tip was digested with proteinase K at 
55 
o
C for 16 h. The DNA was extracted using a silica gel micro-column centrifugation with 4 
Chapter 2 
 
57 
 
wash steps. The DNA was eluted in two steps with washes of 250 l of distilled water each 
giving a total of 500 l and stored at 4 oC.  
Our commercially generated constitutive hspB1
+/del 
mouse line was supplied with instructions 
on how to genotype the mice. From this colony we derived hspB1
del/del
 and littermate control 
wild-type mice. The ability to correctly identify the genotype of individual mice and cells 
obtained from them was critical to every aspect of the research undertaken using them. At the 
start of my project I had to overcome the difficulty of successfully amplifying the PCR 
products identifying the CRE-excised hspB1
del
 knock-out allele and the hspB1
+
 wild-type 
allele. The instructions for genotyping the mice described the use of the Expand Long 
Template PCR system (Roche) but this approach was unsuccessful. It was very difficult to 
reproducibly amplify the wild-type allele. The decision was made to optimise the components 
of the PCR reaction mix. Previous work in my laboratory involved the use of pre-mixed 
‘FailSafe’ (Epicentre) PCR buffers containing all of the reagents required for PCR, with the 
exception of the template DNA and DNA polymerase. Epicentre FailSafe buffer D had 
previously been successfully used to amplify long PCR products. This buffer was 
incorporated into the protocol for PCR amplicon of the wild-type allele and resulted in 
successful amplification compared to the ‘Expand’ Roche kit (Fig. 2.1A). This result made it 
possible to identify the genotype of individual mice and cells (Fig 2.1B). 
The PCR reactions were set up immediately following DNA isolation and performed as 
follows. 10 l of eluted DNA was added to a PCR reaction mixture containing 25 l of 
FailSafe PCR 2x PreMix Buffer, (buffer J for amplification of the hspB1
del/del
 amplicon, 
buffer D for the amplification of the wild-type amplicon), 14.35 l of nuclease free water, 
0.25 l (1.25 U) of BIOTAQ DNA polymerase, and 0.2 l of both the forward and reverse 
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primers required for the amplification of the specific amplicon, giving a final volume of 50 l 
of PCR reaction mix. Primers were obtained from Eurofins MWG Operon. 
The following primers were used to amplify a 600 bp fragment of hspB1
del/del
 allele (forward: 
5
’
 AAT TCT AGC ACC CAC CTG GCA TTC C – 3’, and reverse: 5’- AGC AGG GAG 
AGA AAT TAG CAG ATT GGC – 3’). The PCR programme was as follows: DNA was 
denatured (96 
o
C for 2 min), followed by 35 cycles of amplification (96 
o
C for 30 sec, 60 
o
C 
for 30 sec, and 68 
o
C for 7 min) with a final elongation step (68 
o
C for 8 min). The following 
primers were to amplify a 3.8 Kb sequence from the wild-type allele (forward: 5
’
- CTG GTG 
CAT CTG AAG GCA GTT ACG G -3
’
, and reverse: 5
’
- TCT TGC TAC AAG CCT GGG 
ACT CTG G -3
’
). The PCR programme was as follows: DNA was denatured (96 
o
C for 2 
min), followed by to 35 cycles of amplification (96 
o
C for 30 sec, 65 
o
C for 30 sec, and 68 
o
C 
for 300 sec), with a final elongation step (68 
o
C for 8 min).  
10 l of 6x DNA loading buffer was added to each 50 l PCR product. PCR products were 
loaded and resolved on 2% agarose gels stained with 1 g/ml ethidium bromide or 1 g/ml 
GelRed Nuclei Acid Stain for visualisation. 2 Kb Plus DNA ladder was used to determine the 
sizes of the PCR amplicon.  
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Figure 2.2.1 Successful amplification of wild-type PCR amplicon using Epicentre 
‘FailSafe buffer D’ and an example of successful mouse genotyping for hspB1del and 
wild-type PCR amplicons. 
A, Four mouse tail genomic DNA samples, previously shown to be from wild-type mice, 
were used in a PCR amplification reaction using either ‘Expand’ PCR long template kit 
(Roche) or ‘FailSafe’ Buffer D. The successful amplification of the 2916 bp wild-type PCR 
amplicon is shown. B, successful mouse genotyping by PCR amplification of the 601 bp 
hspB1
del
 and 2916 bp wild-type alleles. A Gel Red-stained agarose gel showing PCR products 
for a litter of mice containing homozygous hspB1
del/del 
(-/-), wild-type (+/+) and heterozygous 
hspB1
+/del
 (+/-) is shown. 
  
2916bp 
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amplicon
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2916bp 
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2.2.3 Timed matings and mouse embryo extraction. 
Breeding pairs of 8 – 10 week old hspB1+/- mice were set up on day 0 and checked for 
cervical plugs early each morning following partnership. Discovery of a plug was designated 
as day 0.5. On day 12.5 the pregnant female mouse was sacrificed by CO2 asphyxiation.  All 
of the following procedures were performed under sterile conditions. The uterus from the 
mother was isolated, immersed in 30 ml of PBS and washed with a further 30 ml PBS. The 
uterus was then transferred to a Petri dish containing PBS. Embryos were excised, washed 
and the heart and liver removed and discarded. The majority of the head was removed and 
placed in a 1.5 ml eppendorf tube, 100 l of PBS added and the tissue was homogenised by 
passing it through a 30 G blunt ended needle to allow efficient digestion for DNA extraction 
and genotyping. The remaining tissue was cut into small pieces using a scalpel and forceps. 2 
ml of trypsin (prewarmed to 37 
o
C) was added to each dish and the tissue homogenised as 
before. This was incubated at 37 
o
C with 5% CO2 for 15 min. 8 ml of complete medium 
(DMEM + 10% FCS + penicillin and streptomycin) pre-warmed to 37
o
C was added to each 
dish. Cells were plated out using one 10 cm dish per embryo and incubated at 37 
o
C with 5% 
CO2. These murine embryonic fibroblasts (MEF) were designated as ‘passage 0’. 
2.2.4 Primary MEF culture. 
Upon reaching confluence, the media on the cells was aspirated away and the cells washed 
with 5 ml of serum free DMEM. The media was gently swirled over the cells and aspirated. 5 
ml of trypsin was added to the cells and the dish swirled to ensure even coverage. The dish 
was then placed in an incubator at 37 
o
C with 5% CO2 for 2 min. The dishes were then briefly 
removed, tapped gently on the side to dislodge the cells and incubated at 37 
o
C with 5% CO2 
for 3 min. Once the cells had detached 5 ml of complete medium was added. The cell 
suspension was transferred to a 20 ml Falcon tube. Lumps of tissue, if present, were allowed 
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to settle to the bottom of the tube and the suspension transferred to a fresh tube. The cells 
were centrifuged at 2000 g for 5 min, the supernatant was discarded and the cells were 
resuspended in 5 ml of complete medium. The viable cell count was determined using 0.4% 
trypan blue and a haemocytometer. Cells were resuspended and seeded at a density of 
1.2x10
6
 cells per 10 cm dish. Cells were used at passage 2 (P2) or three (P3) for experiments 
and seeded at a density of 2x10
5 
cells per well in 6 well plates. 
2.2.5 Isolation of mRNA, reverse transcription into cDNA and quantitative real time 
reverse-transcription polymerase chain reaction (qRT-PCR). 
Cells were rinsed with PBS and total RNA was extracted using the RNeasy Mini Kit. 1 g of 
total RNA was reverse transcribed into cDNA using random primers and High Capacity 
cDNA reverse transcription Kit. qRT-PCR was performed using Taqman Gene expression 
assays (COX-2 Mm0478374_m1, IL-6 Mm99999064_m1, CXCL1 Mm00433859_m1 and 
GAPDH Mm99999915_g1) in a Corbett Rotor-Gene 6000 real time PCR cycler (Qiagen). 
The standard curve method was used for the quantification of the results and gene expression 
was normalized to GAPDH. These techniques were performed by Anna Aubareda, a post 
doctorate researcher in my lab. 
2.2.6 Cell lysis. 
Cells were placed on ice and culture medium was removed, which was then centrifuged at 
2000 g for 5 min to pellet insoluble fragments. The resulting supernatants were then 
transferred to fresh eppendorf tubes and stored at -20 
o
C. Cells were washed twice with 1ml 
of ice cold PBS and lysed in 200 l of complete lysis buffer for 10 min on ice. The lysates 
were then scraped from the wells and centrifuged at 13,000 g for 10 min at 4 
o
C. The 
supernatant was transferred to a fresh eppendorf tube and the lysate and a sample of lysis 
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buffer stored at -20 
o
C. PMSF was added immediately before use and the complete lysis 
buffer vortexed to ensure complete solubilisation.  
2.2.7 Bradford assay. 
Protein concentration in the samples was determined by Bradford assay (Bradford 1976). A 
small aliquot of lysate was added to 1ml of Bradford reagent and vortexed to mix. Lysis 
buffer was used as a blank. BSA was used to generate a standard curve.  Absorbance at 595 
nm was measured using a Biophotometer (Eppendorf) and protein concentrations were 
calculated. 
2.2.8 Gel preparation. 
Gels were prepared according to standard techniques (Garfin 1990) using tris-buffered 
polyacrylamide gels containing SDS with a stacking gel. A greater concentration of 
acrylamide was used if the proteins of interest were of a low molecular weight.   
2.2.9 Protein sample preparation. 
Lysates were thawed at room temperature and prepared in 4x SDS-PAGE sample buffer, 
which were then heated at 90 
o
C for 10 min. 
2.2.10 SDS - polyacrylamide gel electrophoresis (SDS-PAGE). 
Mini-gels were electrophoresed using Ultra-Pure 10X Electrophoresis Running Buffer diluted 
to 1X and run at 30 mA per gel with Bio Rad PowerPac Basic. 5 l Precision Plus Protein 
Standards, All Blue was used as a molecular weight marker. 
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2.2.11 Transfer. 
6 pieces of 3 mm paper and one sheet of PVDF membrane were cut to 5 cm x 8 cm. PVDF 
membrane was soaked in methanol for 2 min. The membrane was then rinsed twice with 
distilled water. The paper and membrane were then immersed in transfer buffer. A Bio-Rad 
Trans-Blot Cell western electroblotting tank was filled 2/3 full with transfer buffer and a 4 
o
C 
cooling element placed inside. 
The transfer sandwich was assembled, containing the soaked 3 mm paper, the rehydrated 
PVDF membrane, and the SDS polyacrylamide gel containing the electrophoresed proteins, 
carefully rolling over at each stage of the assembly with a clean 10 ml stripette to remove any 
bubbles between the gel and PVDF membrane. The transfer sandwich was secured within a 
cassette and placed in the transfer tank, which was then filled with transfer buffer. The 
proteins were transferred to the PVDF membrane by electrophoresis at 100 V for 1 h. After 
completion of the transfer the PVDF membrane was stained with Coomassie Brilliant Blue 
staining solution to visualise the protein and then washed with Coomassie destain solution. 
2.2.12 Blocking and detection. 
The following incubation steps were carried out with agitation on a shaking platform. The 
membrane was blocked with blocking solution for 1 h at room temperature. The membrane 
was then treated with primary antibody at the appropriate dilution in blocking solution with 
0.01% sodium azide for 1 h at room temperature or overnight at 4 
o
C. The membrane was 
washed three times with PBS-T/TBS-T followed by three 10 min washes. The membrane was 
then incubated with the appropriate dilution of horseradish peroxidise-conjugated secondary 
antibody in blocking solution for 1 h at room temperature. The membrane was washed as 
before. Protein bound antibody was then visualised using enhanced chemiluminescence 
(ECL) detection kit. 
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2.2.13 Stripping PVDF membrane of antibodies. 
The membrane was rehydrated in methanol for 2 min before being washed in distilled water 
as before. The membrane was incubated with 1xReBlot for 15 min with vigorous shaking. 
The membrane was washed as before and blocked for 30 min at room temperature with fresh 
blocking solution. The membrane was then re-probed with the appropriate primary and 
secondary antibodies. 
2.2.14 Preparation of Zymosan. 
0.5 g zymosan A from Saccharomyces cerevisiae was reconstituted in 20 ml PBS until fully 
resuspended, and aliquoted in 1 ml volumes into 1.5 ml sterile eppendorf tubes. These were 
then heated at 95 °C for 30 min in order to eliminate endogenous phospholipase A2 activity, 
as recommended by (Dieter, Altin et al. 1987). The zymosan was then centrifuged at 10,000g 
for 5 min. The pellet was washed twice with PBS and resuspended in 1ml sterile PBS to yield 
a 25 mg/ml final stock concentration. 
2.2.15 Air pouch model of acute inflammation. 
A variation on the air-pouch model, as previously described (Edwards, Sedgwick et al. 1981), 
was used. Male mice 8-12 weeks of age were anaesthetised using isofluorane. An air pouch 
was created on the dorsal surface of the mouse. This was achieved by pinching the mouse 
skin mid-way on the back and lifting to form a tented sheet of tissue. The needle was inserted 
at the base of this flap and 5 ml of sterile air was injected. If done correctly the air should 
accumulate under the pinched sheet of skin. Four days later the air pouch was topped up by 
injecting 3 ml sterile air directly into the established air pouch without anaesthesia. The 
following day 100 l 1 mg/ml zymosan was then injected into the air pouch without 
anaesthesia. After the desired stimulation time had expired the mice were culled by 
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asphyxiation in CO2. The pouches were then injected with 2 ml PBS, massaged, and 1 ml of 
exudate removed. This exudate was then spun at 1500 g for 5 min to pellet the infiltrated 
cells. The supernatant was removed and stored at -20 
o
C for cytokine content analysis. The 
cells were resuspended in 1 ml 1x PBS. 10 µl of this re-suspension was mixed with 10 µl of 
0.4% trypan blue solution and manually analysed for total cell count per ml using a 
haemocytometer. Humane procedures were used in all animal work, adhering to Home Office 
guidelines. 
2.2.16 Peritoneal model of acute inflammation. 
Male mice 8-12 weeks of age were injected intra-peritoneally (IP) with zymosan suspension. 
This was achieved by picking the mouse up by the scruff off the neck to impair resistance and 
biting, and inverting to expose the abdomen. A volume of 500 µl 1 mg/ml zymosan 
suspension was injected towards the hind-quarter of the mouse, either side of the abdominal 
midline, for a total of 1 ml/mouse. This location of injection was important, as it avoided 
potential disruption by the needle to the viscera and branches of the superior mesenteric 
vessels. At the desired time point the mice were culled by CO2 asphyxiation. The peritoneal 
cavity was lavaged with 5 ml of ice-cold PBS, massaged and the exudate retrieved. Exudates 
were centrifuged at 1500 g, cells counted as described for the air pouch model, and cytokine 
concentrations in supernatants measured by ELISA. 
2.2.17 Excisional cutaneous wound healing model. 
The dorsal surfaces of anaesthetised female mice 8-12 weeks of age were shaved with 
clippers and disinfected by swabbing with 70 % ethanol. Four full thickness excisional 
wounds (4 mm diameter) were created on the dorsum of the mouse using a 4mm biopsy 
punch. The wounds were digitally imaged on days 0, 3, 5 and 7 post-wounding. Mice were 
culled on day 1, 3 or 7 post-wounding. Skin sections were surgically removed and fixed in 4 
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% paraformaldehyde and embedded in paraffin for histology. 5 µm thick sections were cut 
using an Accu-Cut SRM 200 Rotary Microtome (Sakura). Tissue sections were 
deparaffinised by heating at 60 
o
C for 30 min before being washed twice in xylene and twice 
in 95 % ethanol and stained with Masson’s Trichrome or processed for IHC. The wound 
areas and distances between epithelial tongues in 3 day old wound histological sections were 
calculated using Image J software (Bethesda, MD).  
2.2.18 Enzyme-Linked Immunosorbent Assay (ELISA). 
ELISA was used to determine cytokine concentrations in MEF culture supernatants and air 
pouch exudates. The ELISA kits used are shown in table 2.1.5 and were used according to the 
manufacturer’s instructions. Capture antibodies were diluted in PBS and seeded to a 96 well 
flat bottomed polystyrene microwell plate (Corning) overnight at 4 
o
C with gentle shaking. 
2.2.19 Immunohistochemistry. 
The preparation of surgically isolated wounded mouse skin presented a challenge. 
Established techniques within my research institute were unsatisfactory, as they involved the 
dissection of each individual wound, followed by fixation and embedding in paraffin. This 
often resulted in the skin rolling or folding, and made it impossible to determine the 
orientation of the tissue. The folded tissue made it impossible to accurately measure the size 
of the wound by microscopy. The tissue would also lose structural integrity and often display 
many cutting artifacts.  
I developed a technique whereby the entire wounded dorsum was removed and pinned flat to 
cardboard using needles at the corners of the skin. The skin was mounted with the external 
surface of the skin facing the board to prevent the internal dermal matrix adhering to the 
board and being detached when the skin was removed. A notch was made in the skin at the 
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top right corner nearest the head of the mouse so that the orientation of the skin could be 
identified later. Care was taken not to stretch the skin and increase the size of the wounds 
during this procedure. The mounted skin was immersed and fixed in 4 % formalin as before. 
This resulted in skin that was fixed, flat and rigid before being processed for paraffin 
embedding. During paraffin embedding, the skin was cut into strips, horizontally relative to 
the orientation of the skin, directly through the centre of the wounds, using a scalpel. The 
skin strips were then placed in paraffin wax with the wound faces orientated to the face of the 
wax that would be exposed to the cutting blade. These techniques resulted in improved 
structural integrity of wound tissue during the cutting process, the ability to identify the 
orientation and identity of individual wounds and were highly reproducible.  
Optimisation of the anti-hspB1 antibody for use in IHC resulted in the discovery that heat-
induced antigen retrieval was best performed using citrate buffer pH 6.0 in a pressure cooker 
for 90 s. The slides were allowed to reach room temperature naturally in the buffer, to avoid 
shock cooling the tissues which would often cause the tissue to contract suddenly and cause 
structural artifacts. Slides were blocked with 10 % serum/PBS, raised against the host in 
which the secondary antibody was raised, for 1 h and incubated with 1:1000 hspB1 antibody 
overnight at 4 
o
C. Endogenous peroxidase was blocked by incubation in PBS / H2O2 (0.3 %) 
for 15 min. Slides were incubated with 1:400 biotinylated goat anti-rabbit IgG for 1 h and 
with streptavidin-biotin HRP macromolecular complex for 45 min. All incubations were 
performed in a humid chamber at room temperature. Slides were rinsed with PBS/ Tween-20 
(0.05%) between incubations. Sections were developed with DAB substrate and 
counterstained with haematoxylin, cleared in acid alcohol, dehydrated through sequential 
washes in 50 %, 70 %, 95 % and 100 % ethanol and cleared by washing twice in xylene. 
Coverslips were mounted using a Tissue Tek – Glas G2 (Sakura) and DPX mounting 
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medium/ Images were captured using an Olympus BX-51 microscope and Olympus DP-71 
camera using the DP Controller software. 
2.2.20 Frozen histology of mouse carotid arteries.  
Carotid arteries from wild-type mice and hspB1
del/del
 mice were embedded in OCT and frozen 
at -80
o
C. The tissue was sectioned onto slides on a cryostat cryotome at -20
o
C and the tissue 
fixed and permeabalised with acetone pre-cooled to -20
o
C. The tissue was then stained by 
IHC and imaged. No heat induced antigen retrieval techniques were used, as this would 
destroy the tissue. 
2.2.21 Magnetic, indirect isolation of thioglycollate elected peritoneal neutrophils. 
Male mice 8–12 weeks of age were injected IP with 1ml 4 % Thioglycollate/PBS. 
Neutrophils were allowed to accumulate for 4 h. The peritoneal cavity was lavaged with 10 
ml ice cold PBS and the collected cells counted. The Neutrophil Isolation Kit was used to 
indirectly purify the peritoneal neutrophils. Briefly, the cells were counted and resuspended 
in 200 µl FACS buffer/5x10
7
 cells. The cells were then incubated with neutrophil biotin-
antibody cocktail followed by anti-biotin microbeads, with washing, as per the 
manufacturer’s instructions. The cells were then transferred into MACS MS columns 
attached to a QuadroMACS magnetic separator (Miltenyi Biotec). The non-magnetically 
labelled neutrophils were rinsed with buffer and collected as described by the manufacturer’s 
instructions. The MACS MS tubes were then washed and plunged into a fresh collection tube 
to collect the remaining magnetically labelled leukocytes. The successful enrichment of 
neutrophils was confirmed by Ly-6G and CD-11b detection of the enriched neutrophils and 
magnetically labelled flushed leukocytes by flow cytometry. 
2.2.22 Identification of neutrophil population and apoptotic cells by flow cytometry. 
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Cells were counted and re-suspended in PBS /1 % BSA. For identification of neutrophils, and 
detection of apoptosis, cells were stained with anti-mouse Ly-6G PE and FITC Annexin V 
apoptosis Detection Kit II, respectively. Samples were analysed using a BD FACSCanto II 
flow cytometer and BD FACSDiva software. Data analysis was performed using FlowJo 
software.  
2.2.23 Cardiac puncture for collection of circulating blood cells. 
Male mice 10 – 14 weeks of age were anaesthetised by IP injection of pentobarbitone and 
blood collected by cardiac puncture. The erythrocytes were removed using red blood cell 
lysing buffer according to the manufacturer’s instructions.  
2.2.24 Cell proliferation (MTT) assay. 
250,000 cells were seeded to 96 well microplates in a final volume of 100 µl and incubated at 
37 
o
C, 5 % CO
2
 for 24 h. 10 µl 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) was added (0.5 mg/ml final concentration) and cells incubated for 4 h at 37 °C, 5 % 
CO2. The formazan salt formed was solubilized by adding 100 µl MTT assay solubilisation 
solution and incubating at 37 °C for 16 h. A570 was measured using A690 as a reference. 
2.2.25 Excision and homogenisation of wounds for cytokine analysis. 
A technique to harvest and homogenise wounded tissue to isolate a lysate suitable for protein 
concentration measurements was adapted from a previous study (Armstrong, Major et al. 
2004). It was difficult and time consuming to homogenise fresh tissue and it was a concern 
the cytokine concentration in the samples would deplete over time as the samples were kept 
on ice before they were processed. During the initial wound excision step some of the wound 
tissues were cut using surgical scissors within the eppendorf tubes used to store them in 
homogenisation buffer. This did not improve the effectiveness of homogenisation. The 
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decision was made to freeze the samples at -20 
o
C overnight. This reduced the mechanical 
integrity of the wound tissue and made the tissue easy to homogenise using mechanical 
disruption. After homogenisation the sample represented a viscous suspension of lysate and 
mouse hair and cellular debris. I decided to use centrifugal disruption to fully isolate an 
aqueous lysate. The samples were loaded into QIAShredder homogeniser microcentrifuge 
spin-columns and centrifuged at 13,000 g for 10 min at 4 
o
C. This resulted in a dark, solid 
pellet of hair and other debris, a salmon-pink aqueous lysate and a fatty surface precipitate. 
Female mice were wounded as before and culled 6 h post-wounding. The wounded skin was 
excised and 2 wounded skin sections per mouse were added to 600 µl tissue homogenisation 
buffer and stored at -20 
o
C for 24 h to disrupt tissue integrity. The tissue was homogenised 
using a Fisher Scientific PowerGen 125 homogeniser. The element was washed with 95 % 
ethanol followed by water to reduce cross-sample contamination. The tissue homogenates 
were than centrifuged at 13,000 g for 10 min at 4 
o
C in QiaShredder columns to fully 
homogenise the tissue. The aqueous phase was removed and the protein concentration 
determined by BCA assay according to the manufacturer’s instructions. Cytokine content was 
determined by ELISA. 2 ug/ml of wound homogenate protein was loaded/sample. 
2.2.26 Statistical analysis. 
All statistical analysis was performed using an unpaired student’s t-test, unless otherwise 
stated. 
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Chapter 3 
The function of hspB1 protein in 
inflammatory gene expression in embryonic 
fibroblasts and acute inflammation in the 
air pouch model in mice. 
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3.1 Introduction. 
The function of hspB1 in inflammatory gene expression is unclear and the reasons for the 
discrepancies in the literature are unknown. Studies involving siRNA-mediated depletion of 
hspB1 have often come to opposite conclusions. The different cell types used and the 
employment of different siRNAs, each with different off-target profiles, make interpretation 
of these data difficult and demonstrate the need for a complete genetic knockout (Park, 
Gaynor et al. 2003; Alford, Glennie et al. 2007; Gorska, Liang et al. 2007; Sur, Lyte et al. 
2008; Wu, Liu et al. 2009). The decision was made to generate an hspB1-deficient murine 
strain which would allow for the investigation of the physiological function of hspB1 in 
inflammation. Fibroblasts were chosen to investigate the function of hspB1 in inflammatory 
gene expression because hspB1 is expressed in these cells. Primary adult murine fibroblasts 
are difficult to culture, which led to the decision to use MEF. Treatment of MEF with IL-1 or 
TNFα results in the induction of several pro-inflammatory mediators such as COX-2, IL-6 
and CXCL1. Macrophages express a range of cytokines in response to pro-inflammatory 
stimuli, but were not an ideal candidate cell for these experiments, as previous work has 
demonstrated that murine bone marrow derived macrophages do not express hspB1 (Alford, 
Glennie et al. 2007). 
To investigate the role of hspB1 in acute inflammation in vivo it was decided to use the air 
pouch model which allows straightforward analysis of leukocyte trafficking and 
inflammatory gene expression. The creation of the air pouch, produced by the subcutaneous 
injection of air into the dorsum of the mouse, results in the growth of granulation tissue in the 
cavity lining with a structure and cellular composition resembling the joint synovial 
membrane (Edwards, Sedgwick et al. 1981). This procedure allows for the creation of readily 
available facsimile synovial tissue in mice. The model is used primarily as a technique to 
study the effect of a wide variety of agents on leukocyte trafficking in vivo. The commonly 
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believed mechanism for the air pouch model is that pro-inflammatory stimuli (typically TLR 
ligands) directly activate resident macrophages to produce TNFα and IL-1 (Tessier, Naccache 
et al. 1997). These cytokines, in turn, induce the production of other cytokines and 
chemokines by connective tissue cells (Arima, Nasu et al. 2000; Li, Farthing et al. 2000; 
Garcia-Ramallo, Marques et al. 2002) and induce the expression of adhesion molecules, such 
as ICAM-1, in vascular endothelium (Tessier, Naccache et al. 1998). Together these effects 
result in the egress of leukocytes (initially neutrophils) from capillaries to the site of 
inflammation. CXCL1 is thought to be the major neutrophil chemotactic stimulus in mouse 
models of acute inflammation (Garcia-Ramallo, Marques et al. 2002), and is a murine 
orthologue of human IL-8 (Hol, Wilhelmsen et al. 2010). 
Zymosan was used as a pro-inflammatory stimulus in the air pouch model in which it is well 
characterised and has been used to determine the kinetics of inflammatory responses 
(Cabrera, Blanco et al. 2001). LPS is also a common pro-inflammatory stimulus for use in the 
air pouch model, but was not used as it was not covered by the project license under which 
the procedure was carried out. 
3.2 Commercial development of an hspB1 conditional knock-out (hspB1
del/del
) mouse 
line.  
The generation of floxed hspB1 and heterozygous hspB1 knock-out (hspB1
+/del
) mice was 
perfomed by genOway, Lyon, France. Targeted deletion of the hspB1 gene in mice was 
achieved by homologous recombination in 129Sv ES cells of all three exons of the hspB1 
gene with a targeting vector that introduced LoxP sites either side of the gene (Fig. 3.1A). 
This strategy resulted in creation of a floxed hspB1 mouse line and allowed for the generation 
of constitutive or conditional hspB1 knock-out mice from the same colony of mice by 
breeding with CMV-CRE or tissue specific CRE-expressing mice for in vivo CRE-mediated 
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excision of hspB1. This strategy reduced the risk of embryonic lethality associated with the 
creation of a constitutive knock-out. The ES cells were injected into blastocysts which were 
impregnated in pseudo-pregnant female C57BL/6 mice. Chimaeras were identified and 
crossed with C57BL/6 mice constitutively expressing CRE recombinase to generate 
heterozygous hspB1
+/del
 mice. Successful introduction of LoxP sites and deletion of the hspB1 
gene was confirmed by Southern blotting by genOway (Fig. 3.1B). HspB1
+/del
 mice were 
crossed to generate homozygous hspB1
del/del
 mice that are viable, fertile and after 2 years 
show no obvious signs of disease, abnormalities, or increased morbidity compared to wild-
type mice. A program of backcrossing the hspB1
+/del
 mice onto a C57BL/6 background began 
with the offspring of the original chimera, which were considered to be 1
st
 generation 
backcrossed (50% C57BL/6). This reduced the proportion of 129Sv genetic material from the 
original implanted stem cells with each successive generation and increased the contribution 
of genetic material from the C57BL/6 mouse strain, whilst preserving the hspB1
del
 allele (Fig. 
3.1C). 
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Figure 3.1 Generation of hspB1
del/del
 mice. 
A, Schematic showing the size of Spe I fragments detected by Probe Q in Southern blot. Spe I 
sites separated by 9.8 kb flank the endogenous hspB1 locus containing exons 1-3 (hashed 
boxes). Translational start (ATG) and stop codons are indicated. The introduction of an Flp-
recombinase (FRT)-flanked neomycin cassette (NEO) and LoxP sites at 5’ and 3’ positions of 
exons 1-3 by homologous recombination introduces a new Spe I site, and Probe Q now 
recognises a 3kb fragment. The CRE-recombinase-excised locus produced by crossing floxed 
hspB1 mice with a CMV-CRE deleter strain is indicated in which the endogenous Spe I sites 
are separated by 6.5 kb. B, Southern blot with Probe Q for four founder mice showing wild-
type, knockout and recombined alleles of the expected sizes. M denotes DNA ladder (lengths 
in kb). C, table shows increasing C57BL/6 % genetic material in offspring after successive 
backcrosses. The Southern blot shown was performed by genOway.  
HspB1 endogenous locus
HspB1 recombined locus
HspB1 Cre– excised locus
A
B
C
Backcross 
Generation
129/SV 
(%)
C57BL/6 
(%)
1 50.00 50.00
2 25.00 75.00
3 12.50 87.50
4 6.25 93.75
5 3.13 96.88
6 1.56 98.44
7 0.78 99.22
8 0.39 99.61
9 0.20 99.80
10 0.10 99.90
11 0.05 99.95
12 0.02 99.98
13 0.01 99.99
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3.3 The effect of hspB1 deficiency on basal and IL-1-induced COX-2 protein expression 
in murine embryonic fibroblasts (MEF). 
To investigate the effect of complete hspB1 deficiency on inflammatory gene expression, 
wild-type and hspB1
del/del
 MEF were left untreated, or treated with IL-1 for 4 h or 20 h. The 
cell culture medium was collected and centrifuged to remove cellular debris and stored for 
cytokine analysis. The cells were lysed with whole cell lysis buffer. A Bradford assay was 
carried out and the samples normalised for protein concentration and proteins were then 
separated by SDS-PAGE on a 12% polyacrylamide gel. COX-2, hspB1 and -tubulin 
proteins (the latter as a loading control) were detected by western blot. Two identical 
experiments were performed using different batches of MEF. 
Basal expression of COX-2 protein in resting hspB1
del/del
 MEF appeared greater than that in 
wild-type MEF (Fig. 3.2A and B) but the difference in expression was small. IL-1 treatment 
weakly induced COX-2 protein expression in both hspB1
del/del
 and wild-type cells compared 
to unstimulated cells in both batches of MEF (Fig. 3.2A, B). In one experiment there was 
slightly greater expression of IL-1-induced COX-2 protein in hspB1
del/del
 MEF compared to 
wild-type cells (Fig. 3.2A). The other experiment showed no difference (Fig. 3.2B). The 
weak induction of COX-2 by IL-1 in MEF contrasts the strong induction of COX-2 by IL-1 
in human fibroblasts (Ridley, Dean et al. 1998).  
In a separate experiment I decided to investigate if MEF display stronger induction of COX-2 
protein in response to a longer period of IL-1 treatment. For this, wild-type and hspB1
del/del 
MEF were treated with IL-1 for 4 or 20 h, or left untreated. In wild-type MEF, COX-2 
protein expression was not increased at 4 h post-IL-1, but was weakly increased at 20 h post-
IL-1 compared to resting wild-type cells (Fig. 3.2C). Basal expression COX-2 protein and its 
induction following treatment with IL-1 for 4 h or 20 h appeared lower in hspB1
del/del 
MEF 
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than that observed in the wild type cells (Fig. 3.2C). There appeared to be little induction by 
IL-1 of COX-2 protein in wild-type or hspB1
del/del
 MEF. It was apparent that there was no 
regulation of COX-2 protein expression by hspB1 in MEF. These results were somewhat 
surprising, given the observation of strong inhibition of IL-1-induced COX-2 protein 
following hspB1 protein depletion in HeLa cells and human fibroblasts that was previously 
observed in my lab (Alford, Glennie et al. 2007).   
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Figure 3.2 The effect of hspB1 deficiency on IL-1-induced COX-2 expression in MEF. 
Heterozygous hspB1
+/del
 male and female mice were set up as timed matings, 12.5 day 
embryos were isolated and MEF were prepared. The parents had been backcrossed onto a 
C57BL/6 background for 3 generations from the original chimera. MEF were used at passage 
2 and seeded at a density of 2x10
5
 cells/well in a 6 well plate (A and B) or 4x10
4
 cells/well in 
a 12 well plate (C). MEF were treated with 20 ng/ml IL-1 for 4 h (A and B) or for 4 h and 20 
h (C), or left untreated. Cells were lysed and protein concentration in the lysates measured by 
Bradford assay. Equal amounts of protein were separated by SDS-PAGE on a 12% 
polyacrylamide gel. COX-2, hspB1 and -tubulin (as a loading control) proteins were 
detected by western blot. The results shown in (A) were performed by Dr. Francesco 
Marchese. n.s indicates non-specific band. 
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3.4 The effect of hspB1 deficiency on IL-1-induced IL-6 and CXCL1 protein expression 
in MEF. 
I attempted to quantify the effect hspB1 deficiency on COX-2 expression by measuring 
PGE2; however, I had little success with this owing to the difficulty in controlling the 
inherent variability of the PGE2 ELISA kit used. The availability of robust ELISAs for IL-6 
and CXCL1 meant that I would be able to determine any effects of hspB1 deficiency on 
expression of these cytokines even if it was small. The concentrations of IL-6 and CXCL1 
protein in the cell culture supernatants from resting and IL-1-treated cells were measured by 
ELISA. Three different batches of MEF were used in these experiments.  
A small amount of IL-6 protein was detected in the culture medium of resting wild-type and 
hspB1
del/del
 MEF culture supernatants. There was a trend towards increased IL-6 expression in 
unstimulated hspB1
del/del
 MEF and hspB1
del/del
 MEF treated with IL-1 for 4 h compared to 
corresponding wild-type MEF (Fig. 3.3A). There was variability in the amount of IL-6 
protein produced in individual experiments, and the induction of IL-6 protein by IL-1 was 
weak (Fig 3.3A), as seen for COX-2 protein (Fig. 3.2). This led to the decision to normalise 
the data to the IL-1-1 treated wild-type samples. When the values for IL-6 production were 
normalised to the IL-1-treated wild-type samples, there was a 2.2-fold increase in IL-6 
protein production in resting hspB1
del/del
 MEF compared to wild-type, and a 1.7-fold increase 
in IL-6 protein production in IL-1-stimulated  hspB1
del/del 
MEF compared to wild-type MEF 
(Fig 3.3B). This normalisation prevented statistical analysis of the data by unpaired Student’s 
t-test. The increased expression of IL-6 in IL-1-treated hspB1
del/del
 MEF compared to wild-
type cells contrasts the observation that hspB1 depletion inhibits IL-1-induced expression of 
IL-6 protein in HeLa cells (Alford, Glennie et al. 2007).  
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There was variation in the amount of CXCL1 produced by MEF in individual experiments 
(Fig. 3.3C). The inducibility by IL-1 of CXCL1 in MEF was stronger than that of IL-6 (Fig 
3.3A and C) but hspB1 deficiency did not appear to affect the expression of CXCL1 in either 
resting cells or MEF treated with IL-1 for 4 h (Fig. 3.4D). Although IL-6 expression was 
consistently found to be greater in hspB1
del/del
 cells than in wild-type cells, the effect of hspB1 
deficiency was weak. 
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Figure 3.3 The effect of hspB1 deficiency on cytokine expression in MEF. 
Wild-type or hspB1
del/del
 MEF were seeded at 2x10
5
 cells/well in 6 well plates and treated 
with IL-1 (20 ng/ml) for 4 h or left untreated. A, IL-6 and C, CXCL1 protein concentrations 
in MEF culture supernatants were measured by ELISA (points show means from n=3 
experiments). Graphs B and D show mean fold-changes in cytokine protein concentrations (± 
SEM) relative to values for IL-1-treated wild-type MEF for IL-6 and CXCL1, respectively. 
Data show results from three separate experiments, each using different batches of wild-type 
and hspB1
del/del
 MEF. 
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3.5 The effect of hspB1 deficiency on IL-1-induced expression of COX-2, IL-6 and 
CXCL1 mRNAs. 
The expression of the corresponding mRNAs was also measured in the same experiments in 
which the effect of hspB1 deficiency on inflammatory mediator protein production was 
tested. MEF were left untreated, or treated with IL-1 as before, except that in these 
experiments cells were treated with IL-1 for 1, 2 and 4 h. RNA was extracted and reverse 
transcribed into cDNA. COX-2, IL-6 and CXCL1 mRNAs were measured by qRT-PCR 
using the standard curve method for quantification and mRNA values were normalised to 
those for glyceraldehyde-3 phosphate dehydrogenase (GAPDH) mRNA. Three identical 
experiments were performed with different batches of MEFs and the combined data are 
shown in Fig 3.4. 
COX-2 mRNA expression was detected in untreated wild-type cells and only slightly 
increased following IL-1 stimulation, peaking at 2 h post-IL-1 (Fig. 3.4A), in agreement with 
the weak inducibility of COX-2 protein by IL-1 in MEF (Fig 3.2). COX-2 expression was 
approximately 2-fold greater in hspB1
del/del 
MEF treated with IL-1 for 4 h compared to wild-
type MEF (Fig. 3.4A). The mRNA results again clearly contrast those obtained in HeLa cells 
which showed inhibition of IL-1-induced COX-2 mRNA expression following hspB1 
depletion (Alford, Glennie et al. 2007). 
IL-6 mRNA expression peaked in wild-type and hspB1
del/del 
cells at 2 h post-Il-1 and was 
sustained to 4 h post-IL-1 (Fig 3.4B). There was a tendency for increased IL-6 mRNA 
expression in hspB1
del/del
 MEF but the differences in IL-6 mRNA expression in wild-type and 
hspB1
del/del 
cells were within experimental error. IL-6 mRNA expression was very low in 
untreated hspB1
del/del 
MEF and wild-type MEF (Fig. 3.4B) and IL-6 mRNA in resting cells 
did not appear to be regulated by hspB1 deficiency.  
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CXCL1 mRNA was barely detectable in resting cells and strongly induced by IL-1, peaking 
in hspB1
del/del 
and wild-type MEF at 1 h post-IL-1 stimulation. Again, there was a trend 
towards increased CXCL1 mRNA expression in hspB1
del/del 
MEF compared with wild-type 
MEF at all times post-IL-1 treatment (Fig. 3.4C) but the differences were not significant. The 
effect of hspB1 deficiency on the IL-1-induced expression of COX-2, IL-6 and CXCL1 
mRNAs was small. Statistical analysis of the data could not be performed due to the fact that 
they had been normalised.  
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Figure 3.4 The effect of hspB1 deficiency on IL-1-induced COX-2, IL-6 and CXCL1 
mRNA expression in MEF. 
RNA was extracted from the same MEF used for the experiment shown in Fig. 3.3 in which 
cells were treated with IL-1 for 1, 2 or 4 h, or left untreated. 1 g of total RNA was reverse-
transcribed into cDNA. qRT-PCR was performed using Taqman Gene expression assays for 
COX-2, IL-6, CXCL1 and GAPDH mRNAs. The standard method curve was used for the 
quantification of the results and mRNA values were normalised to GAPDH as a control. 
COX-2, IL-6 and CXCL1 mRNA expression was normalised to values for wild-type cells 
treated with IL-1 for 4 h, 4 h and 1 h respectively. Data show fold-changes in expression 
from three separate experiments, each using different batches of wild-type and hspB1
del/del
 
MEF. Error bars represent mean ± SEM. mRNA measurements were performed by Dr. Anna 
Aubareda (n=3). 
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3.6 Investigation of the effect of hspB1 deficiency on the expression and IL-1-induced 
phosphorylation of p38 MAPK in MEF. 
IL-1 signalling, downstream of TAK1 and including the activation and phosphorylation of 
p38 MAPK, was shown to be inhibited by hspB1 protein depletion in HeLa cells (Alford, 
Glennie et al. 2007). I assessed the effect of hspB1 deficiency in MEF on the activation of 
p38 MAPK, which lies downstream of TAK1 and which plays an essential role in 
inflammatory gene expression (Dean, Brook et al. 1999). These experiments were carried out 
to provide a test of the function of hspB1 protein in signalling in response to IL-1 stimulation 
in MEF.  
MEF were treated with IL-1 for 30 mins or 4 h, or were left untreated. HspB1, p38 MAPK, 
phosphorylated p38 MAPK and -tubulin proteins were detected by western blot (Fig. 3.5). 
There was a small increase in the amount of p38 MAPK protein detected in hspB1
del/del
 MEF 
lysates compared to those from wild-type cells (Fig. 3.5A, B). At 30 mins and 4 h post-IL-1 
treatment a slightly higher amount of phosphorylated p38 MAPK was detected in hspB1
del/del 
MEF relative to wild-type MEF. (Fig. 3.5A, B). These findings contrast the inhibition of p38 
MAPK activation observed previously following siRNA-mediated depletion of hspB1 in 
HeLa cells (Alford, Glennie et al. 2007). 
The increased levels of p38 MAPK protein in IL-1-treated hspB1
del/del 
MEF compared to 
wild-type MEF suggests a possible reason for the increased cytokine expression in hspB1-
deficient MEF. The weak activation of p38 MAPK by IL-1 in MEF is consistent with the 
poor inducibility of inflammatory gene expression in these cells and confirmed that MEF 
were not the ideal cell type to investigate the effect of hspB1 deficiency on inflammatory 
gene expression. 
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Figure 3.5 The effect of hspB1 deficiency on the expression and IL-1-induced 
phosphorylation of p38 MAPK in MEF. 
Mouse embryos were isolated from 7th generation backcrossed parents. MEF were seeded at 
2x10
5
 cells/well in 6 well plates and were treated with 20 ng/ml IL-1 for the times shown 
above. Cells were lysed and western blotting was used to detect hspB1, p38 MAPK, 
phosphorylated p38 MAPK (Thr180/Tyr182), hspB1 and -tubulin proteins in MEF lysates 
from 2 separate experiments. 
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3.7 Investigation of the effect of hspB1 deficiency on the expression of hsp70 and hsp90 
proteins in MEF. 
Given the weak effects of hspB1 deficiency on inflammatory gene expression observed in 
MEF, and the differences to data obtained previously in HeLa cells and human fibroblasts 
(Alford, Glennie et al. 2007), the possibility of adaptation of the hspB1
del/del
 MEF was 
considered. It was thought possible that complete removal of hspB1 from the genome and 
subsequent growth of such cells for extended periods would cause the cells to adapt and 
overexpress another compensatory protein chaperone, such as the large heat shock proteins 
hsp70 and/or hsp90. The blot shown in Fig. 3.5 was re-probed for hsp70 and hsp90. This 
showed little difference in the expression of hsp70 and hsp90 proteins in hspB1
del/del 
compared with wild-type MEF (Fig 3.6).   
It was concluded that the responses to IL-1 was weak in MEF, making it hard to assess 
function of hspB1 in inflammatory gene expression in this system; therefore, I decided to use 
the air pouch model of acute inflammation. This is a far more physiological system to 
investigate the function of hspB1 in inflammatory gene expression than MEF. 
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Figure 3.6 The effect of hspB1 deficiency on the expression of hsp70 and hsp90 proteins 
in MEF. 
The blot shown in Fig. 3.5 was re-probed with antibodies against hsp90 and hsp70. Staining 
of hspB1 and α-tubulin performed in the previous experiment is shown for clarity. 
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3.8 An investigation into the function of hspB1 in acute inflammation. 
The establishment of the hspB1
del/del 
murine strain created the opportunity to investigate the 
role of hspB1 in inflammation in vivo. During the MEF experiments a program of 
backcrossing hspB1
+/del
 mice onto a C57BL/6 background had been implemented. By the 
time MEF experiments were completed, the hspB1
+/del
 mice had already been backcrossed for 
7 generations. This meant that knockout mice with a 99.2 % C57BL/6 genetic contribution 
were ready for experiments and that preliminary in vivo data could be obtained. The initial 
goal was to determine the effect of hspB1 deficiency on cellular infiltration and the 
expression of chemokines responsible for the ingress of neutrophils. I also decided to 
determine if IL-6 protein expression was regulated by hspB1 in the air pouch model, as data 
from the MEF studies indicated that IL-6 production might be increased by hspB1 deficiency 
in fibroblasts.  
7
th
 generation backcrossed hspB1
+/del
 parents were used to generate hspB1
del/del 
and wild-type 
mice. Male mice of between 8 and 14 weeks of age were used for the air pouch experiment. 
Approximately half of all the mice used were littermates. A series of small experiments were 
carried out each using approximately 3 mice of each genotype. The mice were anaesthetised 
with isoflurane and injected with 5 ml air on day 1. On day 4 the air pouches were re-inflated 
by injection 1 ml air and on day 5 the mice were injected with 100 l 1 mg/ml zymosan in 
PBS. After 4 h the mice were euthanised with CO2 and the air pouches were injected with 2 
ml PBS and massaged to ensure maximum cell retrieval. 1 ml of exudate was retrieved and 
centrifuged to pellet infiltrated cells. The supernatant was collected and the cell pellet re-
suspended with 1 ml PBS. Cells were counted using a haemocytometer and cells/ml 
calculated (Fig. 3.7A) and the supernatant analysed for IL-6 (Fig. 3.7B) and CXCL1 (Fig. 
3.7C) proteins by ELISA.  
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The data in Fig. 3.7 represents the results for all the mice used in the experiments. Not all 
hspB1
del/del
 mice shown have a wild-type littermate control, and vice versa. There was 
variability in the number of cells migrating into the air pouch in hspB1
del/del 
and wild-type 
mice. The mean number of cells migrating into each pouch in the hspB1
del/del
 mice was 1.3-
fold greater than the wild-type, however, the difference was not statistically significant. (Fig. 
3.7A). 
There was less variability in the concentration of IL-6 protein in air pouch exudates from 
wild-type mice compared to hspB1
del/del
 mice. The mean amount of IL-6 produced in the 
hspB1
del/del 
mice was 2.2-fold greater (P ≤ 0.05) than that produced in wild-type mice (Fig. 
3.7B). CXCL1 and TNF protein concentrations were also measured in the air pouch 
exudates. It was thought that if CXCL1 and/or TNF were regulated by hspB1, with a 
correlating regulation of cell migration, then a mechanism for the regulation of inflammation 
would present itself for investigation. CXCL1 protein expression was not regulated by hspB1 
deficiency (Fig. 3.7C). There was very little difference in the means and large variability in 
CXCL1 protein production in hspB1
del/del 
and wild-type mice. However, overall CXCL1 
protein production in response to zymosan was low (< 1 ng/ml) (Fig. 3.7C). The 
concentration of TNF in these exudates was too low to be detected (< 10-15 pg/ml, data not 
shown). 
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Figure 3.7 Preliminary experiments to investigate the effect of hspB1 deficiency on 
cellular infiltration and cytokine production in the zymosan-induced air pouch model of 
acute inflammation. 
Eight to fourteen week old, male hspB1
del/del 
and wild-type mice were used in the air pouch 
experiment and the exudate retrieved at t = 4 h and centrifuged to isolate cells. 100 µl 1 
mg/ml zymosan was injected into 5 day old air pouches following 1ml air top-up on day 4. 
Infiltrating cells were counted using trypan blue staining and a haemocytometer and plotted 
as cells/ml of exudate (A). The supernatant was analysed for IL-6 (B) and CXCL1 (C) protein 
concentration by ELISA. Points represent mean values from individual mice. All graphs 
show mean ± SEM. * P ≤ 0.05. 
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3.9 Consideration of the importance of littermate controls in the air pouch experiment. 
The data from Fig. 3.7 were re-plotted to represent those that had strict littermate controls to 
isolate mice in which there was the least genetic variability. It was thought that this would 
provide a more rigorous method of investigating whether there really is a difference in 
cellular expression in wild-type and hspB1
del/del 
mice or not. This revealed a statistically 
significant increase in cellular infiltration to the site of zymosan-induced local inflammation 
in hspB1
del/del 
compared with wild-type littermate control mice (P ≤ 0.05). There was close 
agreement in the number of cells migrating in the wild-type mice; however there was greater 
variability in hspB1
del/del 
mice (Fig. 3.8A). 
Mean IL-6 protein concentration in hspB1
del/del 
mouse exudates was also greater than that in 
the littermate wild-type mice (Fig 3.8B). The wild-type IL-6 values were closely grouped, 
however, the variability of IL-6 concentrations in the hspB1
del/del 
mice air pouch exudates, in 
addition to the low number of littermate mice used, prevented the increase in IL-6 production 
from being statistically significant (Fig. 3.8B). Despite the lack of a statistically significant 
difference in IL-6 production between wild-type and hspB1
del/del
 mice, a trend towards 
increased IL-6 production was observed in hspB1
del/del 
mice compared to wild-type mice. 
CXCL1 production was not affected by hspB1 deficiency in the littermate mice. The 
expression of CXCL1 appeared to be lower in the hspB1
del/del 
mice compared to wild-type 
mice although the variability in both groups was high (Fig. 3.8C). 
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Figure 3.8 Consideration of the importance of littermate controls in preliminary 
experiments to investigate the effect of hspB1 deficiency on cellular infiltration and 
cytokine production in the zymosan-induced air pouch model of acute inflammation. 
Data points in Fig 3.7 were re-plotted to display only littermate mice. Total cells/ml (A), IL-6 
(B) and CXCL1 (C) protein concentrations from hspB1
del/del 
and wild-type mice are shown. 
All graphs show mean + SEM. *P ≤ 0.05. 
  
0
110 0 6
210 0 6
310 0 6
410 0 6
510 0 6
C
e
ll
s 
/ 
m
l
0
2
4
6
8
10
[I
L
-6
] 
n
g
/m
l
0.0
0.5
1.0
1.5
2.0
[C
X
C
L
1
] 
n
g
/m
l
A B C
Wild-type
hspB1del/del
*
Wild-type hspB1del/del Wild-type hspB1del/del Wild-type hspB1del/del
Chapter 3 
 
94 
 
The lack of significance on the effect of hspB1 deficiency on IL-6 protein expression in these 
air pouch experiments may be due to the small n number of mice used, the range of ages of 
mice used, and the fact that mice were used on different days with different stocks of 
zymosan. It was thought that removal of these variables might lead to better grouping of the 
data and provide a more rigorous way of investigating if hspB1 regulates IL-6 protein 
expression in the murine air pouch model. 
3.10 Investigation of the effect of hspB1 deficiency on cytokine production in the air 
pouch model at different times post-zymosan.  
The preliminary air pouch experiments were concluded as the original stock of zymosan was 
exhausted. The variation in the inflammatory responses to zymosan in the preliminary air 
pouch experiments prohibited many differences observed from being statistically significant 
when only 5-6 animals were used per genotype. In an attempt to control the variability of the 
results observed in earlier experiments, some improvements were devised to improve the 
reliability and accuracy of the experiment.  
Firstly, a new large stock of Zymosan A was purchased, prepared and frozen at -20
o
C in 
aliquots of sufficient volume for a single experiment. This ensured that for future air pouch 
experiments, the zymosan used would be of the same stock and would only have been thawed 
once.  
Secondly, I noticed that the ‘top-up’ injection of 1 ml air on day 4 post air pouch creation was 
not always sufficient to give a consistent size of air pouch ready for injection on day 4. This 
was especially true of mice that were housed in large litters. I hypothesised that air was being 
forced from the pouch during the course of the experiment. A simple solution was to inject 3 
ml of air on day 4, and to use a 30
1/2
 gauge needle (the smallest available). This volume of air 
and size of needle caused no pain reflex or obvious distress to the mouse during 
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administration of the air or afterwards. This improvement resulted in the creation of air 
pouches of consistent size when the mice were ready for zymosan injection. This change in 
procedure is noted in the Materials and Methods section, and was used for all subsequent air 
pouch experiments.  
Thirdly, the way the mice were bred was changed. During the time taken to undertake the 
initial air pouch experiments, hspB1
del+
 mice were backcrossed for 12 generations. These 
hspB1
del/+ 
mice were then crossed as before to generate wild-type and hspB1
del/del 
littermates. 
These mice were then bred with hspB1
+/+
 or hspB1
del/del 
mice from separate litters to produce 
wild-type x wild-type and hspB1
del/del
 x hspB1
del/del
 breeding pairs, producing litters consisting 
only of the respective genotype of the parents. Synchronisation of breeding allowed for the 
generation of large litters of mice of a single genotype that could be much more accurately 
age-matched. Although this strategy removed the means to produce strict littermate wild-type 
controls for the hspB1
del/del 
mice, it was decided that being able to generate more mice at a 
faster rate and improve the ability to age-match the mice to wild-type controls was of greater 
benefit. The backcrossing strategy also meant that at mice within the colony that were used 
for experiments and further breeding were 99.99% pure Jackson C57BL/6, so the need for 
strict littermate controls was reduced. 
Although increased cell migration was observed in the original air pouch experiment at 4 h 
zymosan stimulation (Fig 3.8A), TNFα concentrations were below the limit of detection at 
this time point and the concentrations of CXCL1 were also very low (Fig 3.8C). I 
hypothesised that the concentration of these cytokines would be greater in the early phase of 
the acute inflammatory response, as their production is a pre-requisite for leukocyte 
infiltration. I decided to determine if the concentrations of TNFα or CXCL1 were greater at 
earlier time points than those measured at 4 h post-zymosan stimulation. If this were the case 
then this would then allow for measurement of protein concentration of these cytokines in 
Chapter 3 
 
96 
 
mouse air pouch exudates and greater insight into the mechanism of increased cell migration 
in hspB1
del/del
 mice compared with wild-type mice. I also decided to measure CXCL2 
(MIP2α), as it is also a potent chemotactic agent for neutrophils in mice with high sequence 
homology to CXCL1 (Wolpe, Sherry et al. 1989; Iida and Grotendorst 1990). CXCL2 
concentration has also been shown to peak at 1 h in a murine air pouch model (Tessier, 
Naccache et al. 1997; Schramm, Liu et al. 2000). IL-10, an anti-inflammatory cytokine 
produced by macrophages, was also measured as a test for regulation of macrophage function 
or numbers by hspB1 deficiency. 
The concentrations of CXCL1, CXCL2, IL-6, IL-10 and TNFα proteins in exudate 
supernatants from mice challenged with zymosan for different times were measured by 
ELISA. The concentration of CXCL1 protein at 4 h post-zymosan was very low (Fig 3.9A), 
and the concentrations of CXCL2 and TNFα were below the level of detection at this time 
point (data not shown).  
CXCL1 and CXCL2 protein production peaked at 1 h and was increased by 2.0-fold (P ≤ 
0.05) and 1.7-fold (P ≤ 0.05), respectively, in hspB1del/del mice compared to wild-type 
controls (Fig. 3.9A and B). The concentrations of CXCL1 and CXCL2 were low at 2 h post-
zymosan and there was no difference in the concentration of these cytokines in hspB1
del/del
 
mice compared to wild-type at these timepoints (Fig 3.9A and B). 
IL-6 protein production peaked in hspB1
del/del
 mice at 4 h post-zymosan and was significantly 
increased (3.2-fold; P ≤ 0.01) relative to wild-type at this time point (Fig. 3.9C).There was an 
increase in mean IL-10 production in hspB1
del/del 
mice (2.5 fold; P ≤ 0.01) compared to wild-
type 1 h post-zymosan (Fig 3.9D). IL-10 protein production peaked at 4 h post-zymosan; 
however there was no difference in IL-10 production in hspB1
del/del
 mice compared to wild-
type mice at this time point (Fig 3.9D). The protein concentration of IL-6 and IL-10 16 h 
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post-zymosan was very low (Fig 3.9C and D). The concentration of TNFα protein was 
increased in hspB1
del/del 
mice (2.7-fold, P ≤ 0.05) compared to wild-type at 1 h post-zymosan 
(Fig. 3.9E). These cytokines could not be detected at any time post-injection with PBS 
vehicle control (data not shown).  
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Figure 3.9 The effect of hspB1 deficiency on cytokine production in air pouches at 
different times post-zymosan treatment.  
CXCL1 (A), CXCL2 (B), IL-6 (C), IL-10 (D) and TNFα (E) protein concentration in air 
pouch exudates were measured at 1 h (n = 3-15 from three experiments), 2 h (n = 5-7 from 
one experiment, 4 h (n = 5-13 from two experiments) and 16 h (n = 5-7 from one experiment) 
post-zymosan by ELISA. All graphs show mean + SEM; *P ≤ 0.05, **P ≤ 0.01. Statistical 
analysis was performed using Student’s t-tests, with Welch’s correction for unequal variance 
where necessary. 
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3.11 HspB1 deficiency increases neutrophil migration in zymosan-treated air pouches.  
The cells infiltrating the air pouch at different times after treatment with zymosan were 
counted. Cellular infiltration was very low at 1 h and commenced in wild-type mice at 2 h 
and peaked at 4 h post-zymosan (Fig. 3.10A). A statistically significant increase in infiltrating 
cells at 2 h (2.0-fold; P ≤ 0.01) and 4 h (2.3-fold; P ≤ 0.01) post-zymosan was observed in 
hspB1
del/del
 mice relative to wild-type mice, with the peak of cellular infiltration occurring at 4 
h (Fig. 3.10A). The numbers of infiltrating cells at 16 h post-zymosan were the same as those 
observed at 4 h in wild-type mice. There was no increase in the number of infiltrating cells at 
16 h post zymosan in hspB1
del/del 
mice compared to wild-type mice. No cellular infiltration 
was detected in mice injected with PBS as a vehicle control (Fig. 3.10A). 
Flow cytometry analysis with Ly-6G (Gr-1) staining confirmed that at 4 h post-zymosan 
neutrophils comprised > 90 % of the cellular infiltrate in both wild-type and hspB1
del/del
 mice 
(Fig. 3.10B), excluding the possibility that the increased cell counts in hspB1-deficient 
animals are due to infiltration by some other cell type. At 16 h post-zymosan, when monocyte 
infiltration normally commences in this model (Garcia-Ramallo, Marques et al. 2002), there 
was no effect of hspB1 deficiency on the proportions of infiltrating neutrophils or 
monocytes/macrophages as assessed by flow cytometry (Fig. 3.10C). 
There was concern that the increased neutrophil infiltration observed in air pouches of 
hspB1
del/del 
mice relative to wild-type mice might simply be due to an increase in the number 
of total circulating neutrophils caused by hspB1 deficiency. To address this, blood was 
collected by cardiac puncture and the red blood cells removed using red cell lysis buffer, 
according to the manufacturer’s instructions. The leukocytes were stained for Ly-6G and 
CD11b to identify neutrophils by flow cytometry as before. There was no difference in the 
numbers of circulating neutrophils in wild-type and hspB1
del/del
 mice (Fig 3.10D). 
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Figure 3.10 The effect of hspB1 deficiency on cellular infiltration in the zymosan-
induced air pouch model of acute inflammation. 
Air pouches were created on the dorsal surfaces of 10 – 12 week old, 12 generation backcrossed wild-
type and hspB1
del/del
 mice and were injected with 100 µl of 1 mg/ml zymosan. Exudates were retrieved 
at the indicated times. A, plot of number of infiltrating cells (n = 5-6 mice per group for 2 h post-
zymosan; n = 9-14 from two experiments each for all other times). B, graph of population of 
neutrophils as a percentage of total infiltrating cells at 4h post-zymosan identified by gating for the 
Ly-6G
hi
 CD11b
hi
 population (n = 5). C, plots showing neutrophil and macrophage populations in 
infiltrates at 16 h post-zymosan determined by flow cytometry; neutrophil gate (Ly-6G
hi
, CD11b
hi
); 
macrophage gate (Ly-6G
lo
, CD11b
lo
); (n=6). D, Plot of neutrophils in peripheral blood of 
unchallenged mice identified as in (B); (n=3-4). All graphs show mean + SEM. ** P ≤ 0.01. 
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Statistical analysis was performed using Student’s t-test with Welch’s correction for unequal variance 
where necessary.  
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3.12 HspB1 deficiency results in increased numbers of neutrophils undergoing apoptosis 
in zymosan-treated air pouches.  
The rapid decline in numbers of hspB1
del/del
 cells at 16 h and following the peak of cellular 
infiltration at 4 h post-zymosan in hspB1
del/del
 mice suggested that in addition to increased 
migration of cells to the site of inflammation, the neutrophils from hspB1
del/del
 mice may 
undergo increased apoptosis relative to wild-type neutrophils. I used Propidium iodide (PI) 
and Annexin V staining as this technique is frequently used to determine if cells are viable, 
apoptotic, or necrotic through differences in plasma membrane integrity and permeability.  
To determine if infiltrating neutrophils from hspB1
del/del
 mice were less viable than those 
from wild-type mice, the zymosan-induced air pouch experiment was repeated. At 4 h post-
stimulation the infiltrating cells were retrieved and apoptosis detected by staining with 
annexin V and PI and measured by flow cytometry. This showed a reduced proportion (P ≤ 
0.05) of viable, annexin V
lo
/PI
lo
, hspB1
del/del
 cells (46 + 5% (Fig. 3.11A, C)) compared with 
wild-type cells (66 + 4% (Fig. 3.11A, B)), consistent with reduced viability of the hspB1-
deficient cells. The proportion of annexin V
hi
/PI
hi
 cells from hspB1
del/del
 mice (41 + 5% (Fig. 
3.11A, C) was increased (P ≤ 0.01) relative to that from wild-type animals (19 + 4% (Fig. 
3.11A, B) indicating an increased proportion of apoptotic hspB1-deficient cells. Less than 10 
% of cells were identified as being in early apoptosis (Fig. 3.11A). These cells stained weakly 
for PI but positive for annexin V.  
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Figure 3.11 The effect of hspB1 deficiency on neutrophil viability and apoptosis in the 
zymosan-induced air pouch model of acute inflammation. 
A, Cell viability and apoptosis of cellular infiltrates at 4 h post-zymosan were assessed by 
flow cytometry with annexin V and PI staining (n = 8-10 from two experiments). Three cell 
populations were observed and gated for (annexin V
lo
, PI
lo
; annexin V
hi
, PI
lo
; annexin V
hi
, 
PI
hi
), representative plots with gating strategies are shown for B, wild-type and C, hspB1
del/del
 
mice. Bars show mean + SEM. *P ≤ 0.05, **P ≤ 0.01. 
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3.13 Discussion  
Previous research done in my lab showed that hspB1 depletion inhibits IL-1-induced COX-2, 
IL-6 and IL-8 protein and mRNA expression in HeLa cells and COX-2 protein and mRNA in 
primary human dermal fibroblasts (Alford, Glennie et al. 2007). The results from our 
investigations in MEF showed that, in contrast to HeLa cells and primary human fibroblasts, 
the effect of deletion of the hspB1 gene on IL-1-induced COX-2 and IL-6 protein and mRNA 
expression was small and expression tended to increase rather than decrease (Fig. 3.2, 3.3A, 
3.4A, 3.4B). Basal expression of COX-2 protein also appeared to be increased in hspB1
del/del
 
MEF compared to wild-type MEF (Fig 3.2). The poor induction by IL-1 of COX-2 and IL-6 
in MEF was unanticipated, as was the trend towards an opposite effect of hspB1 depletion on 
COX-2 and IL-6 expression observed in experiments in human cells (Alford, Glennie et al. 
2007). 
COX-2 and IL-6 mRNAs are known to be stabilised upon p38 MAPK activation (Dean, 
Brook et al. 1999; Wery-Zennaro, Zugaza et al. 2000). There was a small increase in p38 
MAPK expression and IL-1-induced p38 MAPK phosphorylation in hspB1
del/del 
MEF 
compared to wild-type cells (Fig. 3.5) which may partly account for the trend towards 
increased IL-1-induced COX-2 and IL-6 mRNA expression observed in these cells. However, 
the increase in p38 MAPK protein expression and phosphorylation in hspB1
del/del 
MEF 
compared to wild-type cells is small and again contrasts previous findings in my lab showing 
that hspB1 protein depletion inhibits p38 MAPK activation in HeLa cells (Alford, Glennie et 
al. 2007). CXCL1 protein and mRNA expression were not regulated by hspB1 in MEF 4h 
post-IL-1 (Fig. 3.3C, Fig. 3.4C).  
The data from MEF are in contrast to those of previous studies performed in our lab in human 
cells, which showed that hspB1 is required for the induction of COX-2, IL-6 and IL-8 protein 
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by IL-1 (Alford, Glennie et al. 2007). The different results obtained may well be a result of 
the different methods by which hspB1 depletion/elimination was achieved. Previous work by 
Alford et al. involved the use of siRNA-mediated transient and partial depletion of hspB1 
expression in human cells and cell lines, whereas the current study involves the use of mice 
and cells that harbour genetic and constitutive deletion of the hspB1 gene and therefore 
completely lack expression of hspB1 protein.  
An alternative explanation may be that the apparent increase in the IL-1 induced 
inflammatory response in hspB1
del/del
 MEFs is an artefact of CRE toxicity. It has been shown 
that mammalian genomes contain ‘cryptic’ or ‘pseudo’ loxP sites (Schmidt-Supprian and 
Rajewsky 2007). The sequence of these sites can deviate considerably from the loxP site, 
whilst still serving as functional recognition sites for Cre (Thyagarajan, Guimaraes et al. 
2000). It has been estimated these are present in the mouse genome at a frequency of 1.2 per 
megabase (Semprini, Troup et al. 2007). Although the affinity of Cre for these cryptic 
recognition sites is lower than for the loxP site, it is possible that DNA damage could occur 
from Cre-mediated recombination between endogenous Cre-recognition sites (Thyagarajan, 
Guimaraes et al. 2000). This ‘Cre toxicity’ phenomenon would be of particular concern in 
experiments performed using MEF isolated from mice that had not been backcrossed onto a 
C57BL/6 for many generations. However, this hypothesis was unlikely to be true as MEF 
derived from 7
th
 and 12
th
 generation backcrossed mice displayed the same phenotype as MEF 
derived from 3
rd
 generation backcrossed mice. 
There are other possible reasons why different results were obtained for the murine knockout 
or the knockdown of the human protein using RNAi. One possibility is that there is a genuine 
difference in the function of the hspB1 in murine and human cells. This could occur because 
the signalling pathways in murine and human cells may differ. Alternatively, the results may 
indicate a cell type difference, again because different signalling mechanisms may exist in 
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murine embryonic fibroblasts, human dermal fibroblasts and HeLa cells. Yet another 
possibility is that the results obtained with RNAi in human cells were due to off-target effects 
of the siRNAs used. However, it is highly unlikely that the multiple siRNAs used by Alford 
et al. would all produce the same type of off-target effect. There was little difference in the 
expression of hsp70 and hsp90 proteins in hspB1
del/del 
and wild-type MEF (Fig 3.6). Over-
expression of a compensatory protein would be unlikely in the situation where siRNA is used 
to deplete hspB1 protein, due to the transient and partial nature of the siRNA-mediated 
protein depletion.  
The C57BL/6 strain of mice was selected for use in the zymosan-induced air pouch model as 
these mice exhibit a strong inflammatory response in this model , as measured by leukocyte 
counts in the exudate, when compared to other mouse strains (Delano, Montesinos et al. 
2005). The strategy used to breed the mice was improved after the preliminary experiments, 
which resulted in the production of entire litters of wild-type or hspB1
deldel
 mice. 
Improvements to the air pouch procedure increased the accuracy and reproducibility of the 
experiment. The decision to only use male mice was based on evidence that leukocyte 
infiltration in female C57BL/6 mice has been shown to be ~50 % less compared to male 
C57BL/6 mice (Delano, Montesinos et al. 2005). Based on these findings, and the desire to 
control as many of the variables of the experiment as possible, it was decided that only male 
mice would be used for the air pouch model of acute inflammation. 
The kinetics for the progression of inflammation in the air pouch model suggest that TNFα is 
secreted by zymosan-activated resident macrophages which then induces IL-6 production by 
fibroblasts in air pouch granulation tissue. Resident macrophages and infiltrating neutrophils 
are also sources of IL-6. I showed that hspB1 deficiency caused a significant increase in cell 
migration and increased IL-6 production in response to zymosan stimulation for 4 h in 
hspB1
del/del 
mice compared to littermate wild-type mice (Fig. 3.6A, 3.7B). The air pouch 
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technique was improved and an increase in IL-6 production in hspB1
del/del 
mouse air pouches 
compared to wild-type was observed which was discernible and statistically significant 
compared to the preliminary results (Fig. 3.7B, 3.8B, 3.9C). The increased IL-6 protein 
production in hspB1
del/del
 mice air pouches compared to wild-type mice reinforces the trend 
toward IL-6 regulation by hspB1 in MEF. This may explain why the increase in IL-6 
production in hspB1-deficient mice in vivo was stronger than in hspB1-deficient MEF. An 
alternative explanation would be that in vivo IL-6 is expressed by other cell types in addition 
to fibroblasts. 
Many studies measure the expression of cytokines within the air pouch exudate at the same 
time point where the peak of cellular infiltrate is observed. IL-1-induced CXCL1 production 
was not regulated by hspB1 deficiency 4 h post-zymosan in vivo (Fig. 3. 7C, 3. 8C, 3.9 A). 
CXCL1 and CXCL2 are thought to be the chemokines responsible for driving the neutrophil 
infiltration into the air pouch in response to pro-inflammatory stimuli. Mice that lack the 
expression of CXCL1 have poor leukocyte migration in response to inflammatory stimuli in 
subcutaneous air pouches (Terkeltaub, Baird et al. 1998). The concentrations of CXCL1 and 
TNF were greater in mouse air pouches treated with zymosan for 2 h compared to 4 h 
zymosan (Fig. 3.9). These observations led to the decision to investigate the concentrations of 
these and other cytokines, at a very early time point that still allowed for accurate termination 
of the experiment at the chosen end point. A 1 h post-zymosan end point was chosen. I 
discovered that hspB1-deficient mice had increased expression of TNFα, IL-10 and the 
neutrophil chemotactic cytokines CXCL1 and CXCL2 1 h post-zymosan treatment compared 
to wild-type (Fig. 3.9), and the increased TNFα and chemokine expression provides, in part,  
a mechanism for the increased infiltration of neutrophils 4 h post-zymosan in hspB1
del/del 
mice 
compared to wild-type mice.  
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The observed early peak in the production of these cytokines suggested that zymosan had a 
direct effect on their expression in a cell type that responds to zymosan treatment. 
Macrophages are capable of producing all of these cytokines. The increased concentration of 
TNFα and IL-10 in hspB1del/del mice compared to wild-type at 1 h post-zymosan suggested the 
involvement of resident macrophages in granulation tissue. Fibroblasts are capable of 
producing CXCL1 and CXCL2; however, fibroblasts are unlikely to be the cell type 
responsible for the regulation of CXCL1 protein by hspB1, as production of this chemokine 
was not increased in hspB1-deficient MEF. However, it is worth considering that the MEF 
used is these experiments were only treated with IL-1. There is the possibility that adult 
fibroblast may respond differently to IL-1 and other stimuli. The regulation of endothelial cell 
adhesion molecule expression by hspB1 was not investigated but would be an interesting 
avenue of investigation for the future. The precise contribution of macrophages to CXCL1, 
CXCL2 and IL-6 production in this model is unclear. The early peak in the production of the 
chemokines is to my knowledge a novel discovery and suggests that zymosan is capable of 
directly inducing the production of these chemokines in the air pouch. It is also possible that 
the expression of CXC chemokines in this model was a very rapid indirect response to 
zymosan stimulation. The cell type responsible and the mechanism for the very early 
regulation by hspB1 on CXCL1 and CXCL2 production in the zymosan-induced air pouch 
model is not clear, and warrants further investigation. 
We found that hspB1 depletion did not result in a difference in the population of 
macrophages at 16 h and neutrophils at 4 and 16 h in the cellular infiltrate in air pouch 
exudates in response to zymosan (Fig 3.10B, C). The rapid decline in numbers of hspB1
del/del
 
cells following the peak of cellular infiltration and the lack of difference between wild-type 
and hspB1
del/del
 phenotypes at 16 h suggested that in addition to increased migration of cells 
to the site of inflammation, the neutrophils from hspB1
del/del
 mice were undergoing increased 
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clearance from the site of inflammation to relative to wild-type cells (Fig 3.10A). I observed 
decreased viability and increased apoptosis in neutrophils extracted from hspB1
del/del 
mice 
compared to wild-type (Fig. 3.11). This may explain the reduction in the number of infiltrated 
leukocytes in hspB1
del/del
 mice at 16 h compared to 4 h post-zymosan. 
The effect of genetic deletion of hspB1 on inflammatory gene expression in hspB1
del/del 
mice 
in vivo and MEF was the opposite to that observed following siRNA-mediated depletion of 
the protein in HeLa cells and human dermal fibroblasts. The kinetics of cytokine expression 
induced by zymosan and the types of cytokines regulated by hspB1 suggested that 
macrophages might be the major cell type responsible for the differences in inflammation 
caused by hspB1 deficiency. To investigate the contribution of macrophages in the acute 
inflammatory response in vivo, I decided to investigate 1) the effect of hspB1 deficiency on 
the response to zymosan in a model of peritoneal inflammation, which would also afford the 
opportunity to reinforce the conclusions from the air pouch model, and 2) the function of 
hspB1 in the production of inflammatory cytokines in macrophages isolated from the 
peritoneal cavity in mice. 
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Chapter 4 
The effect of hspB1 deficiency on peritoneal 
inflammation and inflammatory gene 
expression in peritoneal macrophages. 
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4.1 Introduction. 
During the investigation into the effect of hspB1 deficiency on pro-inflammatory cytokine 
expression in MEF, it was observed that it took a longer time for hspB1
del/del
 MEF to reach 
the same final confluence at each passage compared to wild-type MEF. This observation had 
implications for the results described in the last chapter on the regulation by hspB1 of 
inflammatory gene expression in MEF and murine air pouches. If hspB1
del/del 
MEF 
proliferated at a slower rate than wild-type cells, then it would be expected that there would 
be fewer hspB1
del/del 
cells than wild-type at the time point of stimulation. This would result in 
less cytokine production, and the effects of cell confluence on signalling might complicate 
the results. The magnitude of any increase in pro-inflammatory cytokine production in 
hspB1
del/del 
MEF compared to wild-type in response to IL-1 stimulation may have been under-
estimated if there were fewer hspB1
del/del 
MEF than wild-type cells when IL-1 was added. It 
was therefore decided to investigate if hspB1 deficiency resulted in a reduced rate of cell 
proliferation.  
Confidence in the role of hspB1 in pro-inflammatory cytokine expression in the air pouch 
model was reduced by the fact that the data were so variable and many hspB1
del/del 
mice 
displayed comparable numbers of infiltrating cells and cytokine levels to those in wild-type 
mice. It was decided to investigate the effects of hspB1 deficiency on acute inflammation in 
another in vivo model to determine if a more consistent increase in cellular infiltration and 
inflammatory gene expression could be observed. The injection of zymosan into the 
peritoneal cavity of  mice has been shown to produce acute inflammation, including 
leukocyte infiltration and production of inflammatory mediators (Doherty, Poubelle et al. 
1985) and is widely used as a self-resolving model to characterise peritoneal inflammation in 
mice (Rao, Currie et al. 1994; Ajuebor, Gibbs et al. 1998; Cash, White et al. 2009). 
Importantly, the zymosan-induced peritonitis model does not rely on the creation of a sterile 
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air pouch and the prior formation of granulation tissue, but instead allows for the direct 
effects on inflammatory processes to be measured. Thus, in this model the effects of hspB1 
deficiency on cell proliferation and consequential development of the granulation tissue in air 
pouches would be avoided. Zymosan was chosen as the stimulus in the peritonitis model, as 
this would allow for direct comparison of the effects of hspB1 deficiency in this model to its 
effects in the air pouch model of acute inflammation. 
The use of the peritonitis model also provided the opportunity to investigate the function of 
hspB1 deficiency in cytokine production in peritoneal macrophages. In chapter 3, I observed 
an increase the expression of TNFα, IL-6, IL-10 and neutrophil-chemoattractant proteins 
CXCL1 and CXCL2 in hspB1
del/del 
mice relative to wild-type mice in the air pouch model. 
Macrophages are resident within tissue lining of both the air pouches and peritoneal cavities 
and are thought to contribute to the production of cytokines in response to inflammatory 
challenge in these models. I decided to investigate the effect of hspB1 deficiency on cytokine 
expression in macrophages in vitro to understand the contribution of these cells to the 
production of cytokines in acute inflammation in vivo. Murine bone marrow-derived 
macrophages were not suitable for these investigations, as a previous study in my lab had 
shown that these cells do not express hspB1 protein (Alford, Glennie et al. 2007). 
Intraperitoneal injection of thioglycollate (TG) broth is a method commonly used to recruit 
leukocytes to the peritoneal cavity of mice (Spitalny 1981; Den Otter, De Groot et al. 1982; 
Leijh, van Zwet et al. 1984). TG is thought not to act as an inflammatory stimulus or result in 
the activation of TG-elicited peritoneal macrophages (TEPM) (Leijh, van Zwet et al. 1984). 
TEPM were isolated from the peritoneal cavities of wild-type and hspB1
del/del
 mice and were 
used to investigate the role of hspB1 in inflammatory gene expression in ex-vivo macrophage 
cultures. 
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4.2 The effect of hspB1 deficiency on proliferation of MEF. 
Having observed fewer hspB1
del/del 
MEF than wild-type cells during culture, it was decided to 
quantify the numbers of viable cells in wild-type and hspB1-deficient MEF cultures and to 
investigate if hspB1 regulates apoptosis or proliferation of these cells. These experiments 
were performed by Dr. Anna Aubareda. MEF were seeded at equal densities and allowed to 
proliferate for 5 days. The number of viable cells was determined by MTT assay at various 
times after seeding. The number of hspB1
del/del 
cells was reduced compared to wild-type at d 
3-5 (Fig. 4.1A). I have already demonstrated decreased cell viability and increased apoptosis 
in hspB1
del/del 
neutrophils compared to wild-type (Fig 3.13). The cytoprotective function of 
hspB1 has been well characterised in previous studies (Benn, Perrelet et al. 2002; Paul, 
Manero et al. 2002; de Graauw, Tijdens et al. 2005). It was possible that a greater proportion 
of hspB1
del/del 
MEF were less viable or undergoing spontaneous apoptosis compared to wild-
type cells. The terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) 
assay method was used to detect the amount of cells with DNA fragmentation which results 
from apoptotic signalling, however, this showed that only approximately 2 % of hspB1
del/del 
and wild-type cells were undergoing apoptosis (Fig 4.1C). Another possibility was that hspB1 
deficiency resulted in cell senescence. However, senescence-associated-β-galactosidase (SA-
β-gal) detection confirmed similar proportions of senescent hspB1del/del and wild-type MEF 
(Fig. 4D). The number of proliferating cells was measured by incorporation of 
bromodeoxyuridine (BrdU) after 24 h exposure by hspB1
del/del 
and wild-type MEF. This 
showed similar proportions of approximately 60 % proliferating cells in hspB1
del/del 
and wild-
type MEF at p 3, p5 and p8 (Fig 4.1D). A shorter exposure to BrdU for 2 h, which does not 
allow for sufficient time for all proliferating cells to uptake BrdU, showed a decrease in BrdU 
incorporation in hspB1
del/del
 MEF compared to wild-type (Fig. 4.1E). BrdU is incorporated 
into newly synthesised DNA of replicating cells during the S phase of the cell cycle, a 
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process which is controlled, in part, by a family of cyclin-dependent kinases (CDKs). 
Expression of p21
waf1
 p27
kip1
, both CDK inhibitors responsible for arresting cells in the G1 
phase of the cell cycle, was increased in hspB1
del/del 
MEF compared to wild-type MEF, 
providing an explanation for the reduced proliferation rate of hspB1-deficient cells (Fig. 
4.1F). 
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Figure 4.1 The effect of hspB1 deficiency on proliferation of MEF. 
A, Growth curve analysis of wild-type
 
and hspB1
del/del
 MEF determined by MTT assay at 
different days post-seeding (means ± SEM; n = 3). B, Plot of mean (%) TUNEL
+ve
 MEF, 
detected by fluorescence staining (± SEM, n = 3). C, staining for SA-β-galactosidase activity 
(blue) in wild-type
 
and hspB1
del/del
 MEF are shown. D, Plot of mean (%) BrdU incorporation 
following a 24 h exposure (± SEM, n = 3). E, BrdU incorporation following a 2 h exposure. 
Plot of BrdU-positive cells (mean % ± SEM) from two independent experiments performed 
in triplicate are shown. F, western blot for p21
waf1
, p27 
kip1
, hspB1 and GAPDH as a loading 
control. Experiments were performed by Dr. Anna Aubareda. 
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4.3 An investigation into distribution of hspB1 expression in murine carotid arteries. 
The observation that the rate of proliferation of hspB1-deficient MEF was reduced compared 
to wild-type MEF had implications for the interpretation of the results from the air pouch 
experiments. The injection of air at the outset of the experiment creates the air pouch cavity 
and granulation tissue is allowed to develop in the lining of the air pouch during the course of 
the experiment. If fibroblasts within the hspB1
del/del 
air pouch granulation tissue were 
proliferating at a slower rate than wild-type cells, then the granulation thickness and density 
would not be the same in hspB1
del/del
 and wild-type mice at the time point of zymosan 
injection. Vascular endothelial cells express hspB1, which has been shown to play a role in 
modulating microfilament responses to oxidative stress (Huot, Houle et al. 1997). Hence, it 
was possible that hspB1 also promotes proliferation of these cells. The tissue was stained 
with anti-CD31 antibody to identify the vascular endothelium. (Fig 4.2A). Carotid artery 
tissue from hspB1
del/del
 mice was used as a negative control for hspB1 staining (Fig. 4.2C). 
HspB1 protein staining correlated with the layer expressing CD31, confirming that vascular 
endothelial cells express hspB1 protein (Fig. 4.2B). HspB1 protein expression appeared to be 
restricted to tissues within the inside of the intima. HspB1 protein expression was not 
detected in vascular smooth muscle. 
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Figure 4.2 Vascular endothelial cells express hspB1 protein. 
Mouse carotid arteries were frozen in OCT, sectioned on a cryostat cryotome and fixed in 
acetone pre-cooled to -20
o
C. Brown colour indicates positive antigen staining.  A, CD31 
staining of wild-type mouse carotid artery to show expression in vascular endothelial cells. 
The location of the intima and vascular smooth muscle cells are also identified. B, HspB1 
staining of wild-type and C, hspB1
del/del
 mouse carotid arteries.  
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4.4 An investigation into the effect of hspB1 deficiency on the thickness and 
microvasculature density of murine air pouch skin.  
Having identified that hspB1 protein is expressed in murine vascular endothelium, it was 
therefore considered relevant to assess the effect of hspB1 deficiency on the vascularity of the 
granulation tissue. A thinner and less dense granulation tissue could possibly contain fewer 
resident macrophages, and would therefore weaken the response to zymosan. This suggested 
that the effect of hspB1 deficiency on cytokine expression in the air pouch model may have 
been underestimated. I decided to determine the histological structure of wild-type and 
hspB1
del/del
 air pouches. Skin tissue from d 5 air pouches from wild-type (Fig. 4.3C) and 
hspB1
del/del
 (Fig 4.3D) mice was harvested and fixed in 4% formaldehyde and stained with 
Masson’s Trichrome. The vessels were counted and the thickness of granulation tissue was 
measured by microscopy image capture with analysis by Image J. HspB1 deficiency did not 
result in a significant decrease in the thickness of the granulation tissue (Fig. 4.3A) or density 
of the microvasculature (Fig. 4.3B).  
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Figure 4.3 The effect of hspB1 deficiency on the thickness and microvasculature density 
of day 5 air pouch granulation tissue. 
Skin from the dorsal surfaces of male wild-type and hspB1
del/del
 mice was excised on d 5 after 
the creation of air pouch and re-inflation. Mean granulation tissue thickness from 10 
representative fields / skin section (A) and the number of blood vessels / mm skin (B) were 
calculated by microscopy. Plots show mean ± S.D (n=6). Representative skin sections from d 
5 air pouches from (C) wild-type and (D) hspB1
del/del
 mice are shown. 
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These results indicated that despite the observation that hspB1 deficiency resulted in impaired 
proliferation of MEF in vitro, the thickness and vascularity of granulation tissue in vivo in air 
pouches of hspB1
del/del
 mice is normal. However, there were many aspects of granulation 
tissue development that were not determined, such as fibroblast density and macrophage 
numbers. The Masson’s trichrome stain allows for identification of blood vessels by the 
staining of red blood cells, however, the precise effect of hspB1 deficiency on newly forming 
micro-vessels was not determined. The observation of hspB1 expression in vascular 
endothelial cells questioned if hspB1 also had a role in regulation in the proliferation of these 
cells. These complications suggested that a more straightforward approach to investigate the 
effect of hspB1 deficiency on leukocyte trafficking and associated chemokine expression 
would be to inject zymosan directly into the peritoneal cavity.  
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4.5 The effect of hspB1 deficiency in a peritonitis model of acute inflammation in vivo. 
10 - 12 week old male wild-type and hspB1
del/del 
mice were injected intraperitoneally with 
500 µl ml 1 mg/ml zymosan. The peritoneal cavity was lavaged after 4 or 24 h with 5 ml ice-
cold PBS. The infiltrating cells were stained with trypan blue and manually counted using a 
haemocytometer. In agreement with the air pouch model data, intraperitoneal injection of 
zymosan resulted in a statistically significant 2.1-fold (P ≤ 0.01) increase in infiltrating cells 
at 4 h post-zymosan in hspB1
del/del
 mice compared to wild-type controls (Fig. 4.3A). In 
contrast to the air pouch model, the numbers of infiltrating cells at 4 h post-zymosan were 
much more closely grouped and statistical significance was reached with a small number of 
mice (Fig. 4.3A). Cellular infiltration in hspB1
del/del
 mice returned to the same level as wild-
type mice after 24 h (Fig. 4.3A).  As seen in the air pouch model, cellular infiltrates at 4 h 
post-zymosan in wild-type and hspB1
del/del
 mice contained similar proportions of neutrophils 
(Fig. 4.3B). There was also a trend towards a smaller proportion of neutrophils and a greater 
proportion of macrophages in the peritoneal lavage from wild-type mice compared to 
hspB1
del/del
 mice at 24 h post-zymosan injection (Fig. 4.3C). The increase in cell infiltration at 
4 h post-zymosan in hspB1
del/del 
mice compared to wild-type mice in the peritonitis model 
was comparable to that observed in the air pouch model, although the data grouping was 
improved in the peritonitis model.  
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Figure 4.4 The effect of hspB1 deficiency on cellular infiltration in the peritonitis model 
of acute inflammation. 
1 ml of zymosan (1 mg/ml) was injected into the peritoneal cavities of 10 – 12 week-old male 
wild-type and hspB1
del/del
 mice. A, plot of the number of infiltrating cells with time of 
zymosan treatment indicated (n = 4 - 6). B, graph of population of neutrophils as a percentage 
of total infiltrating cells at 4 h post-zymosan identified by gating for the Ly-6G
hi
 CD11b
hi
 
population (n = 5). C, plots showing neutrophil and macrophage populations in infiltrates at 
24 h post-zymosan determined by flow cytometry; neutrophil gate (Ly-6G
hi
, CD11b
hi
); 
macrophage gate (Ly-6G
lo
, CD11b
lo); (n=5). ** P ≤ 0.01. Graphs show means ± SEM. 
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4.6 The effect of hspB1 deficiency on cytokine production in the zymosan-induced 
model of peritonitis. 
I decided to measure the expression of pro-inflammatory cytokines, at the time points where 
their expression was observed to be increased in hspB1
del/del
 mice compared to wild-type mice 
in the air pouch model.  The aim of this was to determine if the variability of the 
inflammatory response in hspB1
del/del 
mice to zymosan would be less in the peritonitis model 
and if a more distinct difference between groups of data for wild-type and hspB1
del/del 
mice 
could be observed. 
The peritoneal lavage fluid protein concentrations of CXCL1, CXCL2 and TNFα at 1 h, and 
IL-6, IL-10 in at 4 h post-zymosan were measured. These time points were chosen as the 
production of the cytokines measured was regulated by hspB1 at these times post-zymosan in 
the air pouch model. I also decided to measure the concentration of CCL2 (MCP-1), which is 
an important chemokine for monocyte recruitment.  
The production of CXCL1 and CXCL2 protein at 1 h post-zymosan was significantly 
increased by 2.3-fold (P ≤ 0.001) and 1.6-fold (P ≤ 0.05) respectively, in hspB1del/del mice 
compared to wild-type (Fig. 4.4A and 4.4B), in agreement with the air pouch model. In 
contrast to air pouch system, the concentration of TNFα protein at 1 h post-zymosan was very 
low or undetectable and appeared to be unaffected by hspB1 deficiency (Fig. 4.4C). IL-6 
protein expression was higher than in the air pouch model and was not regulated by hspB1 at 
4 h post-zymosan (Fig. 4.4D). HspB1 deficiency did not result in a change in expression of 
IL-10 protein, a potent anti-inflammatory cytokine (Fig 4.4E), or CCL2 (Fig 4.4F) at 4 h 
post-zymosan. 
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Figure 4.5 The effect of hspB1 deficiency on cytokine production in the zymosan-
induced model of peritonitis. 
1 ml of zymosan (1 mg/ml) was injected into the peritoneal cavities of 10 – 12 week-old male 
wild-type and hspB1
del/del
 mice. Protein concentrations of CXCL1 (A), CXCL2 (B), TNFα 
(C), at 1 h (n = 5-12) and IL-6 (D), IL-10 (E) and CCL2 (F) at 4 h post-zymosan in peritoneal 
lavages are shown (n = 5-7). Graphs show mean ± SEM. * P ≤ 0.05, *** p ≤ 0.001. 
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4.7 HspB1 deficiency results in a reduction in viability and an increase in apoptosis in 
infiltrating neutrophils in zymosan-challenged peritoneal cavities. 
The expression of IL-6 and TNFα protein and neutrophil apoptosis was increased in 
hspB1
del/del 
mice compared to wild-type mice 4 h post-zymosan in the air pouch model (Fig. 
3. 9, 3.10). IL-6 and TNFα have been shown to inhibit spontaneous apoptosis of neutrophils 
(McNamee, Bellier et al. 2005). I decided to investigate if the viability of neutrophils 
infiltrating into the peritoneal cavity at 4 h post-zymosan was affected by the lack of 
regulation of these cytokines by hspB1 at this time point. Cells infiltrating into the peritoneal 
cavity at 4 h post-zymosan in the experiment shown in Fig. 4.3 were retrieved and apoptosis 
detected by staining with annexin V and PI and measured by flow cytometry as before. This 
showed a trend towards  a reduced proportion of viable (P = 0.1682), annexin V
lo
/PI
lo
, 
hspB1
del/del
 cells (51.1 ± 4.4 %) compared to wild-type cells (62.7 ± 4.4 %), consistent with 
reduced viability of the hspB1-deficient cells observed in the air pouch model. The 
proportion of annexin V
hi
/PI
hi
 cells from hspB1
del/del
 mice (38.5 ± 5.3 %) was increased (P ≤ 
0.01) relative to that from wild-type animals (13.3 ± 3.4 %) indicating increased apoptosis of 
the hspB1-deficient cells. The proportion of cells which stained weakly for PI but positive for 
annexin V in wild-type mice (10.5 ± 2.1 %) was not significantly greater compared to 
hspB1
del/del 
mice (7.6 ± 1.5 %). Overall these results were very similar to previous 
observations made using the air pouch model. 
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Figure 4.6 The effect of hspB1 deficiency on the viability and apoptosis of neutrophils in 
the zymosan-induced peritonitis model. 
Cellular infiltrates in peritoneal lavages at 4 h post-zymosan were analysed for cell viability 
and apoptosis by flow cytometry with annexin V and PI staining (n = 5 - 6). Three cell 
populations were observed and gated (annexin V
lo
, PI
lo
; annexin V
hi
, PI
lo
; annexin V
hi
, PI
hi
). 
Bars show mean ± SEM; **P ≤ 0.01.  
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4.8 Investigation of hspB1 expression in murine neutrophils. 
To investigate if the increased numbers of neutrophils undergoing apoptosis in hspB1
del/del
 
mice compared to wild-type mice in the two in vivo models of inflammation used was due to 
an intracellular defect in cytoprotective function resulting from hspB1 deficiency, it was 
decided to determine if hspB1 protein expression could be detected in neutrophils from wild-
type mice. Cells were recruited by injection of wild-type mice with TG and were isolated 4 h 
later and washed. Neutrophils were purified in supernatants from magnetic beads coated with 
a cocktail of biotin-conjugated monoclonal antibodies raised against antigens that are not 
expressed on neutrophils. Purified cellular infiltrates were stained with Ly-6G and CD-11b to 
identify neutrophils and analysis by flow cytometry showed that the neutrophil population 
was enriched to a purity of 85.2% compared to 36.9% neutrophil purity of un-purified cells. 
The cells were lysed using whole cell lysis buffer and lysate containing 40 µg of protein was 
analysed for hspB1 and α-tubulin protein expression by western blot, together with 3 µg of 
wild-type MEF lysate as a positive control. HspB1 protein could not be detected in the 
neutrophil lysate but was readily detected in the MEF control lysate (Fig. 4.6). This 
observation suggested that it is unlikely that hspB1 protein is expressed in neutrophils and 
further suggests that hspB1 promotes neutrophil viability by a direct extracellular effect of 
the protein, or by indirect effects arising from other cells which do express hspB1. 
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Figure 4.7 HspB1 protein cannot be detected in murine neutrophil lysates by western 
blot. 
10 – 14 week old male mice were injected IP with 1 ml 4 % TG/PBS.  After 4 h the 
peritoneal cavity was lavaged with 10 ml ice-cold PBS. The neutrophil isolation kit (Miltenyi 
Biotec) was used to purify the peritoneal neutrophils. The successful enrichment of 
neutrophils (85.2%) was confirmed by Ly-6G and CD-11b detection by flow cytometry. Cells 
were lysed and 40 µg of wild-type neutrophil lysate was loaded. 3 µg wild-type MEF lysate 
loaded as a positive control for hspB1 protein expression. HspB1 and α-tubulin proteins (the 
latter as a loading control) were detected by western blot. Dotted lines delineate lanes which 
were cropped from the original western blot. 
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4.9 Expression of hspB1 in wild-type peritoneal macrophages. 
Having found that hspB1 protein could not be detected in neutrophils I decided to investigate 
if it is expressed in another myeloid cell type important for inflammatory cytokine 
expression, namely macrophages. If wild-type macrophages did not express hspB1 protein, it 
would be unlikely that it would have an intracellular role in regulation of cellular signalling 
or cytokine expression in these cells. If hspB1 protein could be detected in these cells this 
would allow the intracellular effects of hspB1 deficiency on cytokine expression by 
macrophages to be investigated. 
Brewer’s modified TG recruits macrophages, with peak numbers of macrophages observed 3 
– 4 d post TG injection (Den Otter, De Groot et al. 1982; Leijh, van Zwet et al. 1984). A 4 % 
TG broth was prepared in LPS free cell culture grade PBS and autoclaved. The 4 % TG was 
allowed to mature for 2 weeks, as this has been shown to result in a greater magnitude of 
macrophage recruitment compared to fresh TG. Male mice 12 weeks of age were injected IP 
with 1 ml 4 % TG/PBS.  After 3 d the peritoneal cavity was lavaged with 10 ml ice-cold PBS. 
TEPM were lysed with whole cell lysis buffer. 100 µg of TEPM lysate from wild-type and 
hspB1
del/del 
mice was loaded on an SDS-polyacrylamide gel. 1 µg/ml of wild-type MEF lysate 
was loaded as positive control for hspB1 protein. HspB1 and α-tubulin protein expression in 
the cell lysates was analysed by western blotting. HspB1 protein was detected in wild-type 
TEPM lysate but only at a very low level compared to that in wild-type MEF (Fig 4.8). 
HspB1 protein was not detected in hspB1
del/del 
TEPM lysates as expected (Fig 4.7). The 
positive detection of hspB1 protein in peritoneal macrophages prompted analysis of the 
function of hspB1 in cytokine expression in peritoneal macrophages. 
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Figure 4.8 Detection of hspB1 protein expression in TEPM from wild-type mice. 
Male mice 12 weeks of age were injected IP with 1 ml 4 % TG/PBS.  After 3 d the peritoneal 
cavity was lavaged with 10 ml ice-cold PBS. TEPM were lysed immediately following 
isolation.  TEPM and MEF lysates were analysed by western blot with anti-hspB1 and anti-α-
tubulin antibodies as described previously. 100 µg of wild-type and hspB1
del/del 
TEPM lysate 
was loaded. 1 µg of wild-type MEF lysate was loaded as a positive control for hspB1 protein 
expression. Western blots with molecular weight markers are shown for hspB1 and α-tubulin 
proteins.  
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4.10 The effect of hspB1 deficiency on pro-inflammatory cytokine expression in TEPM.  
To investigate cytokine responses in macrophages relevant to the in vivo models used 
previously it was decided to use zymosan to stimulate the cells.  The TLR-4 ligand, LPS, was 
also used as this is another potent and well-characterised agent that activates signalling and 
induces cytokine expression in these cells. TEPM were isolated from hspB1
del/del 
and wild-
type mice as described previously and cells counted and seeded in six-well plates. 
Preliminary experiments determined that 4 h was the optimal time point and 10 ng/ml LPS or 
100 µg/ml zymosan were the optimal concentrations for the analysis of IL-6, CXCL1 and 
TNFα protein expression as determined by ELISA. Several experiments were performed 
using these conditions with several different batches of TEPM to determine the effect of 
hspB1 deficiency on cytokine protein expression. 
4 h LPS treatment resulted in induction of TNFα and IL-6 protein, with a statistically 
significant increase in TNFα (2.1-fold; P ≤ 0.01; Fig 4.8 A) and IL-6 (3.2-fold; P ≤ 0.01; Fig 
4.8 C) production in hspB1
del/del
 TEPM compared to wild-type cells. As for zymosan, there 
was a statistically significant increase in zymosan-induced TNFα production (2.8-fold; P ≤ 
0.05; Fig. 4.8 B) in hspB1
del/del 
TEPM compared to wild-type cells, although hspB1-
dependent regulation of zymosan-induced IL-6 was not statistically significant (P = 0.10; Fig. 
4.8 D). There was a trend towards increased CXCL1 production in response to LPS (Fig. 4.8 
E) and zymosan (Fig. 4.8 F) in hspB1
del/del 
TEPM compared to wild-type, however, these 
small increases were not statistically significant. No IL-10 protein was detected in TEPM 
supernatants at 4 h post-zymosan (data not shown). Only low concentrations of cytokines 
could be detected in untreated cells and basal cytokine expression was unaffected by hspB1 
deficiency (Fig. 4.8).  
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Figure 4.9 The effect of hspB1 deficiency on pro-inflammatory cytokine expression in 
TEPM.  
TEPM were isolated and 1 x 10
6 
cells/well were seeded in six-well plates, incubated 
overnight, washed with PBS, and  treated with 10 ng/ml LPS or 100 µg/ml zymosan in 2 ml 
compete medium for 4 h. Plots show concentrations of TNFα (A, B; n = 9-13 ), IL-6 (C, D; n 
= 7-8) and CXCL1 (E, F; n = 7-11) proteins in supernatants of TEPM treated with LPS or 
zymosan (as indicated)  determined by ELISA. Graphs show mean ± SEM; * P ≤ 0.05, ** P ≤ 
0.01. 
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4.11 Experiment to investigate the effect of hspB1 deficiency on TEPM viability during 
cell culture.  
It was possible that the differences in cytokine expression in wild-type and hspB1-deficient 
TEPM were due to differences in cell viability. I decided to perform a MTT assay on 
hspB1
del/del 
and wild-type TEPM after overnight incubation (at the time point at which cells 
were stimulated in previous experiments). TEPM were isolated as before and seeded at 
350,000, 175,000 or 35,000 cells/well in a 96 well plate. 35,000 cells/well in a 96 well plate 
format is approximately the same cell density as 1x10
6
 TEPM in a 6 well plate format. There 
was an increase in A570-A690 readings for hspB1
del/del 
TEPM relative to wild-type TEPM at 
350,000 (1.9-fold), 175,000 (2.1-fold) and 35,000 (2.0-fold) cells/well (Fig. 4.9A).  
TEPM were also seeded at 1 x 10
6
 cells/well in a six-well format as before. The cells were 
incubated overnight, washed and stimulated with 10 ng/ml LPS for 4 h or left untreated. The 
supernatants were removed and the cells lysed with whole cell lysis buffer. The protein 
concentrations of the cell lysates were determined by BCA assay. The concentrations of IL-6 
and TNFα proteins in the TEPM supernatants were also measured by ELISA. As before, 
there was an increase in the concentration of IL-6 (4.3-fold, Fig. 4.9B) and TNFα (2.3-fold, 
Fig. 4.9C) in LPS stimulated hspB1
del/del 
TEPM compared to wild-type. There was a 1.7-fold 
increase in the concentration of protein in untreated and LPS treated hspB1
del/del 
TEPM 
compared to wild-type (Fig. 4.9D). I decided to investigate the effect of hspB1 deficiency of 
TEPM survival.  40 µg of TEPM cell lysate was probed by western blot for PARP and α-
tubulin, the latter as a loading control. There was no difference in the amount of PARP, or 
indication of cleaved PARP, in TEPM stimulated with LPS or left untreated from hspB1
del/del
 
mice compared to corresponding wild-type cells (Fig 4.9E). Thus hspB1 deficiency does not 
appear to affect apoptosis in peritoneal macrophages but rather, increases the adherence, 
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proliferation or metabolic activity of these cells to a commensurate degree compared to its 
effects on LPS or zymosan-induced cytokine expression.  
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Figure 4.10 The effect of hspB1 deficiency on viability/metabolic activity, total cellular 
protein and pro-inflammatory cytokine expression in TEPM. 
(A), TEPM were isolated as before and seeded in triplicate at 350,000, 175,000 or 35,000 
cells/well in a 96 well plates. The viability of TEPM after overnight incubation at 37
o
C, 5 % 
CO
2
 was determined by MTT assay (n = 4 wild-type and 2 hspB1
del/del
 mice). TEPM were 
seeded at 1x10
6
 cells/ well in a 6 well plate format. TEPM were stimulated with 10 ng/ml 
LPS for 4 h or left untreated. The concentrations of IL-6 (B) and TNFα (C) protein in the 
TEPM supernatant were determined by ELISA (n = 4 wild-type and 2 hspB1
del/del
 mice). (D), 
the cells were lysed and the protein concentration of the lysate was measured by BCA assay 
(n = 2 wild-type and 1 hspB1
del/del
 mice). Bars and plots show mean ± SD. (E), 40 µg of cell 
lysates were probed by western blot for PARP and α-tubulin, the latter as a loading control. 
Dotted lines delineate lanes which were cropped from the original western blot.  
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4.12 Investigation of hspB1 protein expression in purified TEPM. 
Re-examination of hspB1 expression in TEPM was prompted by a lack of cytokine 
expression regulation by hspB1 in these cells. The expression of hspB1 protein in TEPM was 
very weak compared to hspB1 protein expression in MEF (Fig.4.7) and there was a 
possibility that the hspB1 protein detected was produced by a small number of contaminating 
cells which strongly express the protein in TEPM isolates. I decided to determine if 
monocytes/macrophages purified with anti-CD11b microbeads from TG-treated wild-type 
mice express hspB1 protein.  
TEPM from hspB1
del/del 
and wild-type mice were isolated as before and the 
monocytes/macrophages magnetically isolated using anti-CD11b antibody-conjugated 
magnetic microbeads (Miltenyi Biotec). The purified monocyte/macrophage pellet was lysed 
in complete lysis buffer and 100 µg of purified lysate was analysed for hspB1 protein by 
western blot. 3 µg of wild-type MEF lysate was used as a positive control. HspB1 could not 
be detected in these purified monocytes/macrophages, which contrasted with the analysis of 
unpurified TEPM lysate (Fig. 4.10). 
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Figure 4.11 HspB1 protein expression cannot be detected in purified TEPM lysates by 
western blot. 
TEPM were isolated as before and the monocytes/macrophages were purified by CD11b 
conjugated magnetic beads using a kit. These cells were lysed and prepared for western blot 
as described previously. 100 µg of wild-type purified monocyte/macrophage lysate was 
loaded. 3 µg of wild-type MEF lysate was loaded as a positive control. Western blots with 
molecular weight markers are shown for hspB1 and α-tubulin proteins. Dotted lines indicate 
lanes removed from the blot for clarity of presentation. 
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4.13 Discussion 
The observation that hspB1 deficiency resulted in decreased MEF proliferation made 
interpretation of the air pouch data challenging. Previous studies have shown that the age of 
the air pouch had an impact on the thickness of the granulation tissue layer in rats (Sedgwick, 
Sin et al. 1983) and mice (Garcia-Ramallo, Marques et al. 2002). This growth of the 
granulation tissue could have been retarded in hspB1-deficient mice, which would reduce the 
number of cells exposed to zymosan. I investigated the architecture of the air pouch 
granulation tissue and found that hspB1 deficiency did not result in a difference in the 
thickness of air pouch lining granulation tissue or microvasculature density. This suggested 
that the phenotype of delayed proliferation observed in hspB1
del/del 
MEF did not result in 
gross abnormalities in the formation of air pouches in vivo. Despite this observation, I sought 
clarification on the role of the effect of hspB1-depletion on the acute inflammatory response 
in vivo.  
The effect of HspB1 deficiency on acute inflammation in the peritonitis model was similar to 
that observed in the air pouch model, shown by increased cell infiltration at 4 h post-zymosan 
treatment in hspB1
del/del
 mice compared to wild-type mice. However, in the peritonitis model 
there was better grouping of the data for cellular infiltration and CXCL1 production and 
stronger statistical significance. CXCL1 and CXCL2 protein production was increased in 
hspB1
del/del 
mice compared to wild-type mice at 1 h post-zymosan. These results supported 
the observation of increased CXCL1 and CXCL2 expression in the air pouch of hspB1-
deficient mice compared to wild-type mice. HspB1 deficiency did not result in an increase in 
TNFα or IL-6 production at 1 h and 4 h post-zymosan respectively. This differs from the 
observations from the air pouch model. This suggests that different cell types may be 
responsible for IL-6 and TNFα protein production in the two models of acute inflammation. 
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TNFα expression was low in response to zymosan at 1h which challenged the established 
dogma of the importance of the initial macrophage response to inflammatory stimuli in this 
model. The expression of IL-6 in air pouches was the most strongly increased in hspB1
del/del
 
mice relative to wild-type mice, but it was not increased in the peritonitis model. I did not 
perform a vehicle control experiment in the peritonitis model, which limits the understanding 
of whether the inflammatory cytokines measured are upregulated in response to stimulation 
by zymosan in this model. The differences in the cytokine expression profile produced by 
hspB1 deficiency in the air pouch and peritonitis models may be due the presence of different 
cell types in the tissues exposed to zymosan. The peritoneum has a lining of mesothelial cells 
and its content of macrophages and fibroblasts is also likely to be different to that of the 
lining tissue of the air pouch.  
The infiltrated neutrophils in the peritoneal cavity at 4 h post-zymosan were undergoing 
increased apoptosis in hspB1
del/del 
mice compared to wild-type mice. This result was 
supported by the same result in the air pouch model. It is thought that the increased apoptosis 
of neutrophils in hspB1
del/del 
mice explained the collapse of the total cell number after the 
peak at 4 h post-zymosan, which results in similar numbers of infiltrating cells in hspB1
del/del 
and wild-type mice at the 16 h time point in the air pouch and 24 h time point in the 
peritonitis model.  
I decided to investigate if hspB1 was expressed in neutrophils. TG was used to elicit 
neutrophils from the peritoneal cavities of mice. A 4 h time-point was employed to extract the 
maximum number of neutrophils, based on my observations of the time for peak neutrophil 
recruitment in response to zymosan in the air pouch and peritonitis models. I demonstrated 
that purified neutrophils extracted from wild-type mice do not express hspB1. This made it 
unlikely that hspB1 has a direct cytoprotective mechanism in neutrophils. It more likely that 
Chapter 4 
 
140 
 
the increased number of neutrophils into the site of zymosan-induced inflammation in 
hspB1
del/del 
mice results in an increased concentration of reactive oxygen species and 
proteases by these cells, as well as the production of pro-inflammatory cytokines by 
neutrophils and other cells, resulting in an increased oxidative, proteolytic and pro-
inflammatory environment which causes increased neutrophil apoptosis in these mice 
compared to wild-type.  
I observed increased IL-6 and TNFα protein expression and a trend toward increased CXCL-
1 protein production in LPS or zymosan stimulated TEPM from hspB1-deficient mice 
compared to wild-type cells. However, anti-CD11b microbead-isolated 
monocytes/macrophages from TEPM isolated from wild-type mice did not express hspB1 
protein. I was concerned that the differences in pro-inflammatory cytokine expression 
observed were due to an increased number of hspB1
del/del
 macrophages at the time of 
stimulation compared to wild-type macrophages rather than the regulation of cytokine 
expression by hspB1. MTT assays confirmed that there were either more hspB1
del/del 
macrophages or these cells had increased metabolic activity compared to wild-type cells after 
overnight incubation. There was also a greater concentration of total protein in lysates of 
TEPM isolated from hspB1
del/del 
mice compared to wild-type mice. There was no difference 
in the amount of cleaved PARP in LPS or untreated TEPM from  
del/del
 mice compared to the 
corresponding wild-type cells, suggesting that there was no difference in the viability of these 
cells.  
The effects of hspB1 deficiency on MTT measurements on TEPM also correlated well with 
its effects on LPS or zymosan-induced cytokine expression in these cells. This suggests that 
hspB1 protein does not regulate cytokine expression in peritoneal macrophages, and is 
consistent with the lack of expression of hspB1 protein in purified TEPM. Another possibility 
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is that hspB1
del/del 
TEPM had greater adherence to the cell culture wells compared to wild-
type cells, which would suggest that the increases in pro-inflammatory cytokine protein 
concentration in TEPM from hspB1
del/del 
mice was simply a consequence of there being more 
of these cells remaining in the wells in which they were seeded at the time of stimulation, 
compared to the number of wild-type cells. It is worth noting that the wild-type and 
hspB1
del/del 
macrophage cytokine expression profiles, in terms of the effect of hspB1 
deficiency and response to zymosan, correlate well with air-pouch data, suggesting that in 
contrast to in vitro cultures, cytokine expression in resident tissue macrophages is regulated 
by hspB1. The lack of expression of hspB1 in macrophages suggests that the difference in the 
properties of wild-type and hspB1
del/del 
TEPM are due to either extracellular hspB1 or effects of some 
other cell types that are exerted on the macrophages. 
MTT assays in MEF showed the opposite result observed in macrophages and suggested that 
cell numbers for hspB1-deficient MEF were decreased compared to wild-type MEF. The 
function of hspB1 in cell proliferation has remained unclear because many studies have been 
complicated by the anti-apoptotic function of the small heat shock protein. The only 
mechanism described so far for cell cycle control by hspB1 applies to conditions of cell stress 
(Parcellier, Brunet et al. 2006). Work done by Dr. Anna Aubareda, using BrdU incorporation 
assays and measurement of p21
waf1
 p27
kip1
 protein expression in MEF, found that entry into S 
phase is promoted by hspB1 and that it therefore controls cell proliferation directly. The 
characteristics of impaired proliferation of hspB1-deficient fibroblasts and increased acute 
inflammation in hspB1-deficient mice led to the decision to investigate the role of hspB1 in a 
physiological system where both of these factors are important. I decided to investigate the 
effect of hspB1 deficiency in a murine model of wound healing. 
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Chapter 5 
Investigation of the function of hspB1 in 
wound healing. 
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5.1 Introduction. 
The data described in chapters 3 and 4 show that hspB1 deficiency causes an increased 
inflammatory response to zymosan challenge in vivo. A trend towards increased 
inflammatory gene expression in response to IL-1 was also observed in MEF. In addition, 
hspB1 deficiency delays the progression of the cell cycle and reduces the rate of cell 
proliferation. Therefore, I decided to investigate the function of hspB1 in a physiological 
process that involves both inflammation and cellular proliferation. One such process is 
wound healing; a complex and dynamic process which restore tissue integrity and 
homeostasis following injury (Martin 1997). Wound healing involves three overlapping 
phases; inflammation, tissue formation and proliferation, and tissue remodelling (Singer and 
Clark 1999).  
The results of increased inflammation in vivo and in vitro, and reduced proliferation in vitro 
observed in hspB1
del/del
 mice and cells compared to their wild-type counterparts led us to 
establish the hypothesis that these characteristics would be deleterious to normal wound 
healing, and that wound healing in hspB1
del/del 
mice would be impaired compared to wild-type 
mice. Many studies have made use of excisional wound healing models to examine the 
effects of gene disruption (Hubner, Brauchle et al. 1996; Grose and Werner 2003; Martin, 
D'Souza et al. 2003), age (Swift, Burns et al. 2001; Carter, Sykes et al. 2009), diseases 
(Singer and Clark 1999; Norgauer, Hildenbrand et al. 2002) and drug therapy (Fu, Li et al. 
2005; Braund, Hook et al. 2009), to list only a few examples of the application of this model. 
Female mice were used for this model, as all the male mice available for experiments were 
used for the air pouch and peritonitis models of acute inflammation. The wounding technique 
technique involves shaving and decontaminating the mouse dorsum and using a 4 mm skin 
biopsy punch to create 2 pairs of full thickness wounds. These wounds are allowed to develop 
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and heal for the desired time before the mice are culled and tissue collected and prepared for 
histology or homogenised for cytokine analysis. 
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5.2 Mouse skin histology. 
Prior to performing wound healing experiments I decided to investigate the distribution of 
hspB1 protein expression in female murine skin. Skin sections from wild-type and hspB1
del/del
 
mice were stained with Masson’s trichrome (Fig. 5.1A), with staining of subsequent sections 
with an anti-hspB1 antibody (Fig. 5.1B). This identified expression of hspB1 protein in 
stratum corneum, epidermis, hair follicles and muscle as reported previously (Fig. 5.1B) 
(Huang, Min et al. 2007). No staining could be detected for hspB1
del/del
 skin with anti-hspB1 
antibody when used at the same concentration and the structure of the tissue appeared normal 
compared to wild-type skin (Fig. 5.1C). HspB1 protein was detected in wild-type vasculature 
(Fig. 5.1D), identified by staining of red blood cells inside the vessels with Masson’s 
trichrome (Fig. 5.1A). HspB1 protein was also detected at high power magnification in cells 
with fibroblast-like morphology in sudermal tissue (Fig. 5.1E). 
  
Chapter 5 
 
146 
 
Figure 5.1 Detection of hspB1 protein expression in wild-type female murine skin by 
immunohistochemistry. 
A, female wild-type skin was stained with Masson’s trichrome. B, HspB1 protein was 
detected by IHC. Brown colour indicates positive antigen staining. C, hspB1 was not detected 
in skin sections from female hspB1
del/del
 mice; bar = 100 µm. D, higher magnification image 
showing hspB1 staining in muscle and vasculature (as in B); bar = 50 µm, and (E), cells with 
fibroblast-like morphology in subdermal tissue (as for D); bar 10 µm. Arrows indicate tissue 
structures and cells Ep: epidermis, D: dermis, Hd: hypodermis, SC: stratum corneum, HF: 
fair follicle, Va: vasculature, PC: panniculus carnosus, SD: subdermis. 
A B C
D E
Vascular
Endothelial Cells
Panniculus
Carnosum
Sub-dermal
Tissue Fibroblast
SC
HF
Va
PC
SD
Ep
D
HD
Chapter 5 
 
147 
 
5.3 HspB1 deficiency results in delayed wound healing. 
Excisional cutaneous wound healing was investigated in wild-type and hspB1
del/del
 mice by 
creating wounds on the dorsal surface of mice using a 4 mm punch. Digital images of wounds 
were captured over a period of 7 days and wound areas measured. A 30 cm ruler was placed 
alongside the wounds during photography as a scale bar. There was a significant delay in the 
rate of wound healing in hspB1
del/del
 mice compared to wild-type at 3 (1.3-fold; P ≤ 0.01), 5 
(1.5-fold; P ≤ 0.05) and 7 (1.6-fold; P ≤ 0.05) days post-wounding (Fig. 5.2A). Digital images 
of representative wounds over seven days post-injury are shown (Fig. 5.2B). 
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Figure 5.2 HspB1 deficiency impairs excisional cutaneous wound healing.  
A, Four 4mm diameter wounds were created on the dorsal surface of 10-14 week-old female 
wild-type and hspB1
del/del 
mice. Digital images were taken of each wound at 0, 3, 5 and 7 days 
post-wounding. 0 d (n = 3-4 mice); 3 d (n = 11 mice from three experiments), 5 d and 7 d (n 
= 7-8 mice from two experiments). Individual data points represent mean wound area of 4 
wounds from 1 individual mouse. B, Digital images of wounds (representative of ≥ 14 
wounds); bar = 2 mm. Graph shows mean wound areas ± SEM; * P ≤ 0.05, ** P ≤ 0.01. 
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5.4 Histological analysis of day 3 and day 7 wounds. 
To investigate the function of hspB1 in wound healing in more detail, skin was taken from 
mice at 3 d and 7 d post-wounding. Skin samples were paraffin-embedded, sectioned and 
stained with Masson’s trichrome to identify collagen, epithelium, and capillaries and with an 
anti-hspB1 antibody to detect hspB1 protein expression. At 3 d, Masson’s trichrome staining 
of wild-type and hspB1
del/del
 (Fig. 5.3A, 5.3C) skin showed discrete collagen staining at the 
periphery of the wound, scab formation and proliferating dermis and epithelial tongues. The 
cellular infiltrate in hspB1
del/del 
mice (Fig 5.3C) was greater in density and more widespread 
compared to wild-type mice at 3 d (Fig 5.3A). The mean distance between epithelial tongues 
at 3 d was greater (P ≤ 0.05) in the mutant animals indicating delayed re-epithelialisation 
(Fig. 5.3E). HspB1-expressing cells were present within the granulation tissue of wild-type 
mice at 3 d (Fig. 5.5A) that are not present in unwounded granulation tissue (Fig. 5. 1B). New 
vasculature was also observed in wild-type mice (Fig. 5.5A) and hspB1
del/del 
mice (Fig. 5.5C), 
and hspB1 protein was strongly expressed by the vascular endothelium in the wild-type mice 
(Fig. 5.5A).  
At 7 d, histological analysis showed that approximately half of wild-type wounds displayed 
near-complete healing, with the other half still having a relatively thick epithelial layer and 
incomplete collagen deposition. A representative image of a 7 d wild-type wound showing 
partially re-formed epidermis and advanced collagen distribution is shown (Fig. 5.3B). None 
of the 7 d hspB1
del/del
 wounds displayed complete healing, and had relatively thick epithelial 
layers and incomplete collagen deposition (Fig. 5.3D). By d 7 there was widespread 
neovascularisation in wild-type and hspB1
del/del 
mice. Large structures had developed within 
the wound area and wound margins, which stained strongly for hspB1 protein in wild-type 
mice (Fig. 5.5B). These show morphological similarities to neuronal nerve bundles. These 
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were present in some wild-type mouse wound sections at 7 d post wounding (Fig. 5.5D), but 
not all. 
In wild-type mice, hspB1 protein staining was evident in epithelial tongues at 3 d (Fig. 5.3A), 
and fully formed epithelium at 7 d (Fig. 5.3B). HspB1 was also detected in stratum corneum, 
muscle, hair follicles, cells lining capillaries and in cells with fibroblast-like morphology in 
the dermis, at 3 d (Fig. 5.3A), and 7 d (Fig. 5.3B), as in unwounded skin (Fig. 5.1B). No 
hspB1 protein staining was seen in wounds from mutant mice (Fig. 5.3C and 5.3D), 
confirming the efficiency of the genetic deletion and specificity of anti-hspB1 protein 
staining by IHC. Fig. 5.4 shows additional representative images of the results shown in Fig. 
5.3. 
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Figure 5.3 Delayed wound healing and re-epithelialisation in hspB1
del/del 
mice. 
11-14 week age-matched female wild-type and hspB1
del/del
 mice were used. A, representative 
Masson’s trichrome staining (top) and IHC for hspB1 (below) in wild-type 3 d and B, 7 d 
wounds. C, hspB1
del/del
 wounds at 3 d and D, at 7 d. Brown colour indicates positive hspB1 
antigen staining. Arrow indicates dense cellular infiltrate; Bar = 500 µm. E, Plot of mean 
distance + SEM (n = 4 wounds per mouse, 3 mice per group) between re-epithelialisation 
margins in wild-type and hspB1
del/del mice in 3 d wounds; * P ≤ 0.05. Boxes indicate areas 
presented in at higher magnification in figure 5.5. 
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Figure 5.4 Further representative histological images showing delayed wound healing in 
hspB1
del/del 
mice. 
As shown in figure 5.3, A, representative Masson’s trichrome staining (top) and IHC for 
hspB1 (below) in wild-type 3 d and B, 7 d wounds. C, hspB1
del/del
 wounds at 3 d and D, at 7 
d. Brown colour indicates positive hspB1 antigen staining. Arrow indicates dense cellular 
infiltrate; Bar = 500 µm.  
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Figure 5.5 Detailed histological examinations of 3 d and 7 d wound granulation tissue in 
wild-type and hspB1
del/del 
mice. 
Higher magnification of wound granulation tissue from images, as presented in Fig. 5.3. A, 
representative Masson’s trichrome staining (top) and IHC for hspB1 (below) in wild-type 3 d 
and B, 7 d wounds. C, hspB1
del/del
 wounds at 3 d and D, at 7 d. Brown colour indicates 
positive hspB1 antigen staining. Bar = 100 µm. 
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5.5 Histological quantification of neutrophils in day 1 wounds. 
Increased cellular infiltrate was observed in 3 d wounds in hspB1
del/del
 mice compared to 
wild-type (Fig. 5.3). It was important to determine which leukocyte subsets comprised the 
inflammatory infiltrate in wounds, as this would give insight into how the inflammatory 
response to wounding progressed in hspB1
del/del 
and wild-type mice.  
I had already demonstrated that hspB1 deficient mice have increased neutrophil infiltration at 
early time-points using the air pouch and peritonitis models of acute inflammation. It was 
decided to investigate the number of infiltrating of neutrophils early in the inflammatory 
response to wounding in wild-type and hspB1
del/del 
mice. The hypothesis was that the delayed 
wound healing observed in hspB1
del/del 
mice compared to wild-type was attributable to 
increased infiltration of neutrophils during acute inflammation. Mice were wounded as before 
and the skin excised 24 h (1 d) post-wounding. The skin was analysed by 
immunohistochemistry for neutrophil elastase. Neutrophil infiltration was found to be 
increased in 1 d hspB1
del/del
 wounds (Fig. 5.6B) relative to wild-type wounds (Fig. 5.6A) The 
average number of neutrophils within a 165 µm
2
 field were counted by microscopy, which 
showed the increase to be significant (P ≤ 0.01) (Fig. 5.6C). Staining 3 d wound tissue with 
anti-neutrophil elastase antibody failed to positively stain any cells.  
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Figure 5.6 HspB1 deficiency results in increased neutrophil recruitment to the site of 
acute inflammation 1 d post-wounding.  
Neutrophil infiltration in 1 d wounds assessed by IHC for neutrophil elastase (NE) in A, wild-
type and B, hspB1
del/del 
mice. C, Plot shows elastase positive neutrophils (NE+) per 165µm
2 
high power field (hpf) (7 fields/wound; 2 wounds per mouse; n=4 mice). Brown colour 
indicates positive NE antigen staining. Bar = 50 µm. Graph shows mean ± SEM; ** P ≤ 0.01. 
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There was a 1.9-fold increase (P ≤ 0.01) in the number of neutrophils infiltrating the wound 
site in hspB1
del/del 
mice compared to wild-type at 1 d (Fig. 5.6C). This observation supported 
the findings from the air pouch and peritoneal models of acute inflammation. These acute 
inflammation models also demonstrated that hspB1
del/del 
mice were less viable and more 
apoptotic than wild-type neutrophils. This suggests that the increase in neutrophil infiltration 
to the wound site during acute inflammation would therefore result in a greater number of 
apoptotic cells within the wound. This apoptotic population of neutrophils would need to be 
cleared in order to facilitate the resolution of acute inflammation and allow for the 
progression of the wound healing response. The cells responsible for this are infiltrating 
macrophages. I decided to investigate these cells in the wound healing model. 
5.6 Histological quantification of macrophages in 1 d and 3 d wounds. 
I decided to investigate the effect of hspB1 deficiency on the ability of macrophages to enter 
to the wound, as deficiency in this ability might result in impaired removal of apoptotic 
neutrophils and impaired resolution of inflammation. However, an increased neutrophil influx 
might cause an increased chemotactic gradient for macrophage recruitment. 
Paraffin embedded histological skin samples were analysed for F4/80 positive cells (mature 
macrophages) in 1 d and 3 d wound area tissue. There was a 0.6-fold decrease (P ≤ 0.01) at 1 
d (Fig. 5.7C) and a 0.14-fold decrease (P ≤ 0.05) at 3 d (Fig. 5.7F) in the number of 
macrophages within the wound area of hspB1
del/del 
mouse wounds compared wild-type 
wounds. 
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Figure 5.7 HspB1 deficiency resulted in decreased macrophage recruitment to the 
wound site at 1 d and 3 d post-wounding. 
Macrophage infiltration was assessed by IHC for F4/80 in d1 wild-type (A) and hspB1
del/del
 
(B) wounds. C, plot shows F4/80 positive macrophages/hpf in d1 wounds. F4/80 positive 
cells were counted in d3 wild-type (D) and hspB1
del/del
 (E) wounds. F, plot shows F4/80 
positive macrophages/hpf in d3 wounds (7 fields/wound; 2 wounds per mouse; n = 4 mice). 
Brown colour indicates positive F4/80 antigen staining. Bar = 50 µm. All graphs show mean 
± SEM; * p ≤ 0.05 ** P ≤ 0.01. 
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During the analysis of the wound areas I noticed that within the margins of the wounds there 
was a 1.5-fold increase (P  ≤ 0.01) in the number of macrophages in hspB1del/del mouse wound 
margins, compared to wild-type wounds (Fig. 5.8C) at 1 d. There was no difference in the 
number of macrophages within the wound margin of hspB1
del/del 
and wild-type mouse wounds 
margins at 3 d. Representative images of wild-type (Fig 5.8G) and hspB1
del/del
 (Fig 5.8H) 
wounds shown the identification of the wound margin as the location where the panniculus 
carnosus and dermis is disrupted. 
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Figure 5.8 HspB1 deficiency results in an increased number of macrophages within the 
wound margin 1 d post-wounding. 
Macrophage infiltration was assessed by IHC for F4/80 in wild-type (A) and hspB1
del/del
 (B) 1 
d wound margins. C, plot shows F4/80 positive macrophages/hpf in 1 d wound margins. 
F4/80 positive cells were counted in wild-type (D) and hspB1
del/del
 (E) 3 d wounds margins; 
Bar = 50 µm. F, plot shows F4/80 positive macrophages/hpf in 3 d wound margins. (2 
fields/wound margin 4 wound margins per mouse; n = 4 mice). Representative images of 
wound margins and wound areas in wild-type (G) and hspB1
del/del 
(H) 3 d post-wounding; bar 
= 100 µm. Brown colour indicates positive F4/80 antigen staining. All graphs show mean ± 
SEM; ** P ≤ 0.01.  
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5.7 The effect of hspB1 deficiency on the number of macrophages within wounded and 
distal skin tissue. 
Macrophages were also counted in tissue distal to 1 d and 3 d wounds. Distal tissue was 
defined as unwounded skin from the dorsum of the mouse (Fig. 5.9C). This was considered 
pertinent as differences in macrophage numbers could be relevant to any differences in 
cytokine expression that I wished to investigate in the future. At 1 d, there was no difference 
in the number of macrophages within distal skin in hspB1
del/del 
and wild-type mice (Fig. 
5.9A). Macrophage numbers were reduced in wounds relative to distal tissue. At 3 d, there 
were reduced numbers of macrophages within the distal skin (P ≤ 0.05) in hspB1del/del mice 
compared to wild-type mice (Fig. 5.9B). Macrophage counts from distal tissue, wounds and 
wound margins were re-plotted together and the graphs are shown in Fig. 5.9A. 
When considering the implications of the number of macrophages within the wound area and 
the wound margins, it is important to note that wild-type mice had approximately the same 
number of macrophages within the wound area and margin on 1 d (Fig. 5.9A) and 3 d (Fig. 
5.9B). However, there was a 2.4-fold increase (P < 0.0001) in the number of macrophages 
within the wound margin compared to the wound area at 1 d (Fig. 5.9A) in hspB1
del/del 
mice. 
The greater density of macrophages within the wound margin compared to the wound area at 
d 1 in hspB1
del/del
 mice suggests that there may be increased recruitment and extravasation of 
macrophages to the site of the wound compared to wild-type mice, but the macrophages have 
difficulty in migrating into the wound site. There may be an aberrant migratory capacity of 
hspB1
del/del
 macrophages, compared to wild-type cells. 
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Figure 5.9 HspB1 deficiency results in decreased macrophage infiltration to the wound 
area in response to wounding. 
Macrophages within the skin tissue distal to wounds (Distal), wound areas (Area) and wound 
margins (Margin) from wounded mouse skin sections were stained with anti-F4/80 antibody 
and counted at 1 d (A) and 3 d (B) post-wounding. The data for number of macrophages 
within the wound area and wound margins is re-plotted from Figures 5.5 and 5.6 so that 
comparison can be made with skin distal from wounds, indicated by dotted white line (C). All 
graphs show mean ± S.E.M; * P ≤ 0.05, ** P ≤ 0.01, **** P ≤ 0.0001. 
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5.8 Quantification of the expression of pro-inflammatory cytokines in 6 h wound tissue. 
The differences in the kinetics of leukocyte recruitment to the site of injury may be  partly 
responsible for the delayed wound healing observed in hspB1
del/del 
mice compared to wild-
type mice. I have already demonstrated using the air pouch and peritonitis models of acute 
inflammation that hspB1 deficiency results in an increase in CXCL1 and IL-6 production 
during the early phases of acute inflammation in vivo. I have also shown that hspB1
del/del
 mice 
displayed increased neutrophil infiltration in 1 d wound tissue compared to wild-type tissue. 
Monocyte chemotactic protein-1 (MCP-1, CCL2) is produced by keratinocytes and 
endothelial cells local to wounded tissue and is a major chemotactic stimulus for monocytes 
during the acute inflammatory response to wounding (DiPietro, Polverini et al. 1995; 
Engelhardt, Toksoy et al. 1998). Neutrophils are also a source of CCL2 (Yoshimura and 
Takahashi 2007). These pro-inflammatory cytokines are instrumental in inducing the acute 
inflammatory response to wounding. The decision was made to investigate whether the 
expression of these pro-inflammatory cytokines in response to wounding was regulated by 
hspB1.  
I measured pro-inflammatory cytokine production 6 h post-wounding in tissue lysates from 
wounded and distal tissue from the dorsum of wounded mice. HspB1 deficiency resulted in a 
2.5-fold increase (P ≤ 0.01) in IL-6 (Fig. 5.10A), a 1.5-fold increase (P ≤ 0.05) in CXCL1 
(Fig. 5.10B) and a 1.6-fold increase (P ≤ 0.05) in CCL2 protein expression (Fig. 5.10C). 
Wounding resulted in induction of the expression of these cytokines in wild-type and 
hspB1
del/del
 mice, although CCL2 induction in wounded tissue compared to distal tissue was 
greater in hspB1
del/del 
mice compared to wild-type mice.  
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Figure 5.10 HspB1 deficiency results in increased pro-inflammatory cytokine 
production during the acute inflammatory response to excisional wounding. 
Wounded and distal tissue from female mice was harvested 6 h post-wounding. The tissue 
was homogenised and cellular lysate prepared. The protein concentrations of the lysates were 
measured by BCA assay and lysates were adjusted to give the same protein concentration for 
all samples. The concentrations of IL-6 (A), CXCL1 (B) and CCL2 (C) proteins in 
normalised lysates were determined by ELISA (n=4 mice, 4 wounds per mouse, 2 wounds 
per data point). All graphs show mean amount of cytokine (ng)/total protein in lysate (mg) ± 
SEM; * P < 0.05, ** P < 0.01. 
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The increase in CXCL1 and IL-6 protein concentration in hspB1-deficient mouse wounds 
compared to wild-type is consistent with the results observed in the acute models of 
inflammation. The increase in CXCL1 protein concentration suggests one possible 
mechanism for the increased neutrophil recruitment to the wound site in hspB1-deficient 
mice compared to wild-type mice. CCL2 was also increased at 6 h post-wounding in 
hspB1
del/del
 mice, which is consistent with the observation that there was a greater number of 
macrophages within the wound margins in these mice compared to wild-type mice.  
5.9 The effect of hspB1 deficiency on the production of chemokines responsible for 
monocyte chemotaxis in response to wounding.  
While the infiltration of neutrophils is extremely rapid, infiltration of monocytes that 
differentiate into macrophages is a slower process. Therefore, it was decided to investigate 
the effect of hspB1 depletion on CCL2 and CCL3 production at 1 d and 2 d post-wounding, 
and in unwounded tissue. CCL2 production was induced by wounding, peaking at 1 d post-
wounding. CCL3 production was also induced by wounding and was sustained until 2 d (Fig. 
5.11). There was no regulation of CCL2 or CCL3 by hspB1 deficiency at 1 d or 2 d post-
wounding. The lack of regulation of CCL2 and CCL3 expression by hspB1 at 1 d and 2 d is 
consistent with the minimal changes in macrophage numbers in wild-type relative to 
hspB1
del/del 
wounds at 3 d.  
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Figure 5.11 The effect of hspB1 deficiency on the production of CCL2 and CCL3 in 
response to wounding. 
Skin wounds were surgically isolated, homogenised, and cells lysed. The concentrations of 
CCL2 (A) and CCL3 (B), 1 d and 2 d post-wounding in wounded and unwounded tissue 
lysates normalised for total protein were determined by ELISA (n = 4 – 5 mice, 4 wounds per 
mouse, 2 wounds per data point). All graphs show mean cytokine (ng / total protein (mg) ± 
SEM. 
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5.10 An investigation to determine if alterations in macrophage polarity are responsible 
for increased pro-inflammatory cytokine expression in hspB1
del/del
 wounds compared to 
wild-type wounds.  
The expression of monocyte chemo-attractants was not regulated by hspB1. I decided to 
determine if the polarisation of macrophages infiltrating to the site of wounding was 
influenced by hspB1 depletion, as a switch to an M1-like polarisation could account for the 
increase in cytokine production in wounded hspB1
del/del
 mice compared to wild-type mice 
(Fig. 5.10).  
Macrophages are capable of transitioning from a pro-inflammatory, M1 like, phenotype to a 
reparative, ‘alternatively activated’ or M2 like, phenotype within the wound environment 
(Stein, Keshav et al. 1992; Mosser 2003; Brancato and Albina 2011). The distinct phenotypes 
of  M1 and M2 macrophages bears importance as the cytokine expression profiles of these 
two groups is very different, M1 producing predominantly pro-inflammatory cytokines and 
M2 producing anti-inflammatory cytokines, such as IL-10 (Martinez, Sica et al. 2008), and 
growth factors such as transforming growth factor beta (TGFβ) (Rappolee, Mark et al. 1988) 
and vascular endothelial growth factor (VEGF) (Nissen, Polverini et al. 1998). These growth 
factors are essential for resolving the inflammatory response and promoting cell proliferation, 
angiogenesis and re-epithelialisation in wounded tissue (Mosser and Edwards 2008). 
M1 macrophages characteristically produce IL-23 and repress the expression of IL-10 
(Krausgruber, Blazek et al. 2011). The structure of IL-23 is similar to that of IL-12 in that 
they both contain the p40 subunit. However, IL-23 is structurally distinct from IL-12 in that it 
contains a p19 subunit whereas IL-12 contains a p35 subunit. The ELISA system I used 
utilised an anti-mouse IL-23p19 capture antibody and gives accurate and precise 
measurement of IL-23 without the possibility of detection of IL-12. I measured the 
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concentration of TNFα, IL-1α and IL-1β proteins at 6 h and IL-23 protein at 1 d and 2 d as 
markers of M1 macrophage activity, and IL-10 protein 1 d and 2 d as a marker for M2 
macrophage activity, in wounded and distal tissue from the dorsum of wounded mice. 
The production of TNFα, IL-1α and IL-1β in wounded tissue was only slightly greater than 
that measured in distal tissue in wild-type and hspB1
del/del
 mice. The concentration of TNFα 
protein in hspB1
del/del 
wound tissue lysates was decreased 0.8-fold (P = 0.071) compared to 
wild-type
 
tissue lysate (Fig. 5.12A). There was increased expression of IL-1α protein in 
wound tissue lysates from wild-type and hspB1
del/del
 mice at 6h (Fig 5.12B) compared to the 
other cytokines measured at this time point (Fig. 5.10). However, there was no difference in 
the expression of IL-1α or IL-1β in hspB1-deficient mice compared to wild-type (Fig. 5.10B, 
C). There was no regulation by hspB1 of IL-23 (Fig. 5.12D) or IL-10 (Fig.5.12E) protein at 1 
d or 2 d post-wounding. However, there was a decrease in IL-23 (Fig. 5.12D) and IL-10 (Fig 
5.12E) in distal tissue for the dorsum of wounded hspB1
del/del
 compared to wild-type mice 2 d 
post-wounding. These data are consistent with the observation of decreased macrophage 
numbers in distal tissue 3 d post-wounding in hspB1-deficient mice and suggest that the 
magnitude of expression of IL-10 and IL-23 is different in wounds and the surrounding 
tissue.  These data also suggest that there is no difference in the polarity of macrophages at 1 
d and 3 d in wild-type mice compared to hspB1
del/del
 mice.  
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Figure 5.12 The effect of hspB1 deficiency on production of cytokines produced by M1 
and M2 macrophages as markers of polarisation.  
Wounds were surgically isolated, homogenised, and cells lysed. The concentrations of A, 
TNFα, B, IL-1α and C, IL-1β at 6 h, and D, IL-10 and, E IL-23 1 d and 2 d post-wounding in 
wounded and distal skin tissue lysates normalised for total protein were determined by 
ELISA (n = 4 – 5 mice, 4 wounds per mouse, 2 wounds per data point). All graphs show 
mean cytokine (ng / total protein (mg) ± SEM. * P ≤ 0.05, *** P ≤ 0.005 
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5.11 Discussion. 
The wound healing model was selected as it would allow me to investigate the effect of 
hspB1 deficiency in a physiological model that involves both cell proliferation and acute 
inflammation. I observed that the rate of wound re-epithelialisation was delayed and acute 
inflammation, characterised by PMN infiltration and pro-inflammatory cytokine expression, 
was increased in hspB1
del/del 
mice compared to wild-type mice. Strong expression of hspB1 
protein was detected in cells in the migrating epithelium at the wound margin and in cells 
with fibroblast-like morphology in the wound bed in wild-type mice. The delayed wound 
healing in hspB1
del/del 
mice at 3 d post-wounding is consistent with reduced proliferation of 
epidermal cells in hspB1-deficient mice. These results are supported by observations that 
hspB1 deficiency results in delayed cell proliferation in MEF, as described in chapter 3, and 
increased acute inflammation in the air pouch and peritonitis in vivo models, described in 
chapters 3 and 4, respectively. The lack of regulation of the production of TNFα, IL-1α and 
IL-1β by hspB1 suggests a lack of a role for hspB1 in macrophages in the acute inflammatory 
response to wounding. Although there was an increase in macrophage numbers in the wound 
margins in the early phase of the wound healing process (1 d), macrophages from hspB1
del/del
 
mice displayed deficient infiltration of the granulation tissue beneath the wound itself 
compared to wild-type cells. Infiltration of macrophages into both wild-type and hspB1
del/del
 
wound areas and margins was increased at 3 d relative to 1 d, as expected for normal murine 
wound healing but hspB1 deficiency caused little change in the cell numbers.  
One might expect a degree of synergy of the increased pro-inflammatory and impaired 
proliferation characteristics in hspB1-deficient mice to result in a comparatively strong effect 
of hspB1 deficiency in the wound healing model. The delay in re-epithelialisation in 
hspB1
del/del 
mice compared to wild-type is small compared to the comparisons in the size of 
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the wound area. In addition, the fold change in the difference in re-epithelialisation is not as 
great as the difference in the rate of MEF proliferation. This small difference in re-
epithelialisation is typical in this model at 3 d (Seth, De la Garza et al. 2013; Vorstenbosch, 
Gallant-Behm et al. 2013). Re-epithelialisation is usually complete by 7 d post-wounding, 
unless another underlying pathology further delays the healing of the wound (Seth, De la 
Garza et al. 2013). Perhaps the extent of re-epithelialisation at a time point between the 
initiation of re-epithelialisation and completion, for example at d 5, 7 and 10, would show a 
greater difference in the rate re-epithelialisation in hspB1
del/del 
and wild-type mice. One must 
also consider that the ways that these measurements are made are different; the calculations 
of the wound areas obviously involve squaring the radius, the result of which magnifies the 
degree of difference between the wild-type and hspB1
del/del 
means compared to a set of data 
where the diameter between re-epithelialisation margins is measured. However, the overall 
results did not suggest a strong synergistic effect of exacerbated inflammation and delayed 
proliferation. 
The resolution of the inflammatory phase of wound healing process is critical for the 
completion of the process. HspB1 deficiency results in increased neutrophil infiltration and 
pro-inflammatory cytokine production in two in vivo models of acute inflammation. 
Increased neutrophil infiltration was also observed in hspB1
del/del
 mice compared to wild-type 
mice 1 d post-wounding and the associated increase in CXCL1 at 6 h post-wounding provides 
a possible mechanism for this, as for my results in the air pouch and peritonitis models of 
acute inflammation. The effects of hspB1 deficiency on neutrophil infiltration were followed 
by a delay in wound healing as measured by the area of the wound and distance between re-
epithelisation frontiers at 3 d. 
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Neutrophils are well known to undergo rapid apoptosis, although I have not investigated the 
viability of neutrophils in response to wounding, the neutrophils are unlikely to be apoptotic 
upon arrival to the site of wounding considering that they were capable of responding to the 
inflammatory stimulus and undergoing transmigration to the site of inflammation. Therefore, 
they can be assumed to have contributed to the inflammatory response. These cells would 
then contribute to the apoptotic cellular load present within the wound. It is thus apparent that 
resident and infiltrating macrophages have a larger apoptotic cellular load to clear in 
hspB1
del/del 
mice compared to wild-type mice. Macrophages actively ingest apoptotic 
neutrophils and previous studies have shown that this causes a shift in macrophage phenotype 
to an anti-inflammatory, proliferation inducing phenotype (Fadok, Bratton et al. 1998). I 
measured cytokines produced by M1 and M2 macrophages as markers of their polarisation, 
but observed no difference in the production of these cytokines in hspB1-deficient mice 
compared to wild-type mice, suggesting that hspB1 does not regulate macrophage cytokine 
production in wounds. 
HspB1
del/del 
wounds did, however, contain decreased numbers of macrophages compared to 
wild-type wounds at d 1 and d 3. Surprisingly, macrophage density was greater in the wound 
margins of hspB1
del/del
 mice compared to wild-type at 1 d, suggesting that hspB1
del/del 
macrophages have a diminished ability to migrate to the wound bed and allow for the 
progression of the wound response. There were more macrophages within the unwounded 
tissue compared to wounded tissue from wild-type and hspB1
del/del 
mice at 1 d post-wounding. 
This is to be expected, as the excisional wound removes the granulation tissue in which the 
resident macrophages occupy. It is unclear if hspB1 directly affects macrophage migration in 
response to wounding, or if the results simply reflect a delay in the wound healing response 
caused by an earlier event. It is possible that the increased number of neutrophils observed 
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may be due to decreased uptake by macrophages in hspB1
del/del 
mice compared to wild-type 
mice. 
HspB1
del/del 
wounded tissue lysates, at 6 h post-wounding, displayed significantly increased 
IL-6, CXCL1 and CCL2 expression compared to wild-type wounds. CCL2 and CCL3 would 
both be expected to provide chemotactic stimuli for macrophage recruitment. The increase in 
CCL2 production at 6 h post-wounding in hspB1-deficient mice is consistent with the 
increase in macrophage numbers in wound margins at 1 d.  The lack of an effect of hspB1 
deficiency on CCL2 and CCL3 expression at 1 d and 2 d post-wounding is consistent with the 
similar numbers of macrophages in wound areas and margins at 3 d in hspB1
del/del
 mice 
compared to wild-type mice. HspB1 seems to limit the initial ‘burst’ of cytokine and 
chemokine production, early neutrophil infiltration of granulation tissue and macrophage 
infiltration of wound margins.  At later times post-wounding hspB1 appears not to be 
involved in the production of any of the cytokines that I measured or in the subsequent 
infiltration of macrophages.  
There was no evidence of neovascularisation in the wounded tissue at 1 d post-wounding. 
This suggests that macrophages migrate to the site of wounding from the established 
vasculature. Possible effects that hspB1 deficiency may result in are impairment in the ability 
of the macrophages to re-arrange their cytoskeleton for migration, the regulation of other 
chemokines that were not measured, and adhesion molecule expression.  
At 7 d the collagen deposition within hspB1
del/del 
wound areas was very dense and 
concentrated despite incomplete and delayed progression of wound healing compared to 
wild-type. Wild-type wounds that had healed completely showed collagen deposition 
throughout the dermis similar to that of unwounded skin, whereas this state of collagen 
deposition was not seen in wounds in hspB1-deficient mice at 7 d post-wounding. I did not 
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investigate the effect of collagen deposition directly, as my experiments did not include a 
time point where the wound was in a re-modelling phase. 
To conclude, hspB1 deficiency in mice results in significantly impaired wound healing 
characterised by increased pro-inflammatory cytokine expression and neutrophil infiltration 
in the early phase of the wound healing process. We have also observed impaired 
proliferation of hspB1-deficient MEF and a greater distance between the borders of re-
epithelialisation in hspB1
del/del 
mice compared to wild-type mice. The strong expression of 
hspB1 expression in the advancing epithelium and infiltrating cells in the basal granulation 
tissue in wounds suggests an additional role for hspB1 in proliferation of these cells. The 
wound healing response is a complex series of temporally overlapping phases. My data show 
that hspB1 has a significant regulatory function in these processes may be important for the 
progression of the wound healing response. 
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The function of hspB1 in inflammation was previously unclear as the results from studies 
using RNA interference to deplete the protein were inconsistent (Park, Gaynor et al. 2003; 
Alford, Glennie et al. 2007; Sur, Lyte et al. 2008; Wu, Liu et al. 2009). The work in this 
thesis involved the use of a complete genetic knockout of the hspB1 gene in mice to 
investigate the function of the protein in vivo. The results are not compromised by siRNA-
mediated off-target effects or artefacts arising from trace levels of hspB1 expression. The 
data in this thesis suggests that hspB1 limits inflammatory gene expression. This is the 
opposite conclusion to that reached from research conducted in my group (Alford, Glennie et 
al. 2007) and by other laboratories (Gorska, Liang et al. 2007; Wu, Liu et al. 2009) using 
siRNA-mediated depletion of hspB1.  
My data indicates that hspB1 regulates the production of pro-inflammatory cytokines early in 
the acute inflammatory response. The kinetics and expression of cytokines in MEF and 
TEPM in vitro, the air pouch and peritonitis models of acute inflammation and the wound 
healing model in vivo, suggests that hspB1 does not regulate cytokine production in 
macrophages. I consistently observed increased CXCL1 protein production and neutrophil 
infiltration in response to acute inflammation and injury in vivo in hspB1
del/del
 mice compared 
to wild-type, although CXCL1 protein production was not regulated by hspB1 in MEF. It is 
possible that embryonic fibroblasts differ in inflammatory gene expression compared to adult 
fibroblasts.  
I could not detect hspB1 expression in neutrophils isolated from wild-type mice, suggesting 
that it is unlikely that hspB1 directly regulates chemotaxis or inflammatory gene expression 
in these cells. The increased CXC chemokine expression in hspB1
del/del 
mice provides a 
mechanism for the increased neutrophil recruitment in these mice compared to wild-type 
mice. It is likely that fibroblast/keratinocyte-like cells and/or vascular endothelial cells are the 
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responsible cell type for increased CXC chemokine production, which may be p38 MAPK-
dependent. 
The extent of hspB1 expression in leukocytes is still controversial. I was unable to detect 
expression of hspB1 in mouse neutrophils or TEPM, and others in my group have been 
unable to show hspB1 expression in human monocytes and murine bone marrow-derived 
macrophages (Alford, Glennie et al. 2007), although hspB1 expression was observed in M-
CSF and GM-CSF-differentiated human macrophages. Others have shown hspB1 expression 
to be increased during human monocyte differentiation into macrophages and during 
macrophage polarisation (Fagone, Di Rosa et al. 2012). The expression of hspB1 in human 
macrophages could possibly be due to an in vitro artefact, although it is possible that there is 
a genuine species difference in hspB1 expression in human and mouse macrophages. I have 
not been able to eliminate the possibility of any effects of extracellular hspB1, which has 
been shown to block the differentiation of monocytes to dendritic cells (Laudanski, De et al. 
2007) however, the observation that IL-1-induced IL-6 expression is increased in hspB1-
deficient MEF suggests that hspB1 has an intracellular function in limiting inflammatory 
gene expression in cells such as fibroblasts. It would be interesting to investigate if a similar 
function exists in endothelial cells that produce various inflammatory cytokines and which 
also strongly express hspB1.  
I did not investigate the effect of hspB1 on the viability of neutrophils infiltrating into the 
wounds, although results from the air pouch and peritonitis models both demonstrated 
reduced viability of neutrophils infiltrating to the site of acute inflammation in hspB1
del/del 
mice, compared to wild-type. The data from these acute models are consistent with the 
inability to detect any elastase-positive neutrophils at 3 d post-wounding. Thus the increase in 
live neutrophil numbers in wounds of hspB1-deficient mice relative to wild-type mice is 
almost certainly transient. Neutrophils provide a chemo-attractant stimulus for monocytes 
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and produce CCL2. There was no difference in the amount of CCL2 at 1 d post-wounding in 
hspB1
del/del 
and wild-type mice, however, if the neutrophils in hspB1
del/del 
mice undergo 
apoptosis shortly after arriving to the site of the wound, this would explain why there is little 
effect of hspB1 deficiency on CCL2 expression or macrophage infiltration at 1 d post-
wounding onwards. Efficient clearance of infiltrated neutrophils by macrophages is an 
important process for the resolution of acute inflammation after wounding. Activated 
neutrophils release reactive oxygen species (ROS), proteases (e.g. elastase) and collagenases 
(e.g. matrix metalloproteinase-9) (Dovi, Szpaderska et al. 2004). These have been shown to 
damage tissue and degrade the ECM during the inflammatory phase of wound healing, 
negatively influencing tissue repair and perhaps leading to overproduction of collagen to 
compensate for the weakened structural integrity of the ECM supporting scaffold. I observed 
a trend toward increased collagen deposition 7 d post-wounding in hspB1
del/del 
wounds 
compared to wild-type wounds, and it would be interesting to quantify the effect of hspB1 
deficiency on collagenesis and wound remodelling in the future by picro-sirius red staining at 
5, 7 and 10 d post-wounding. 
Macrophages promote the production and remodelling of ECM by releasing growth factors 
such as VEGF, PGDF and TGFβ (Barrientos, Stojadinovic et al. 2008). It is difficult to 
provide direct evidence for the contribution of macrophages to the wound healing process as 
they are not the sole source of these growth factors. Keratinocytes, neutrophils, fibroblasts, 
endothelial cells and platelets are also sources of one or more of these growth factors. I 
observed very similar numbers macrophages in the wound areas of hspB1
del/del 
mice compared 
to wild-type mice 3 d post-wounding. This suggests that the macrophage-derived contribution 
to the expression of such growth factors might be similar in wild-type and hspB1
del/del
 
wounds.  Nevertheless, it would be interesting to investigate if there is impaired production of 
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these growth factors in wounded hspB1-deficent mice, as this may provide an explanation for 
the poor wound healing outcome in these mice compared to wild-type mice. 
I have demonstrated that vascular endothelial cells express hspB1. Neovascularisation was 
apparent in wounded tissue histology at 3 d and 7 d post-wounding. HspB1 activation is 
important for endothelial cell proliferation (McMullen, Bryant et al. 2005). If hspB1 regulates 
angiogenesis then this would result in a difference in the number of vessels available for 
leukocytes to migrate through in hspB1
del/del 
and wild-type mice. The Masson’s trichrome 
staining protocol, despite staining red blood cells a vivid pink colour, did not allow for the 
accurate identification of vessels. Staining of wound granulation tissue with anti-CD31 (Seth, 
De la Garza et al. 2013) or anti-factor VIII (Thuraisingam, Xu et al. 2010) antibodies would 
afford the ability to quantify the number of vessels in wounds. This would allow for the 
investigation of the effect of hspB1 deficiency on angiogenesis in response to wounding. It is 
possible that another factor involved in the regulation of cell migration is regulated by hspB1. 
HspB1 has been shown to maintain endothelial cell barrier integrity (Liu, Guevara et al. 
2009; Liu, Milia et al. 2012). I did not investigate the effect of hspB1 deficiency on 
endothelial cell vascular adhesion molecule expression or inflammatory gene expression. 
These would be interesting lines of enquiry for future research. 
The murine wound healing model has been criticised as a model of human wounding, as 
contraction plays a greater role in murine models than re-epithelialisation and granulation 
tissue formation, which are crucial for human wound healing (Davidson 1998). Recognition 
of this has led to models such as the rabbit dermal ulcer model (Ahn and Mustoe 1990; 
Mustoe, Pierce et al. 1991), which has the benefit of having the wounded tissue directly 
connected to the underlying cartilage. This provides the means to investigate the effect of 
applied growth factors/drugs or transgenic effects on granulation tissue formation and wound 
healing. A technique called splinting of full thickness excisional wounds, whereby the 
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excisional wound borders are bonded adhesively and sutured to a nylon ring, has been 
described in C57BL/6 mice (Galiano, Michaels et al. 2004). The authors observed that 
splinting did not affect the rate of re-epithelialisation and allows for the slower and gradual 
healing of the wound by granulation tissue formation, compared to rapid contractile wound 
healing in non-splinted wounds. 
I have already observed strong expression of hspB1 in fibroblast-like cells in wild-type 
wound granulation tissue at 3 d and 7 d post-wounding. The wound splinting technique, when 
applied to the wound healing model described in chapter 5, would delay the contraction of the 
wound and allow for the investigation of the effect of hspB1 deficiency on wound granulation 
tissue formation in a gradually healing wound that more accurately models the healing of 
human wounds. Further investigation into the function of hspB1 in wound healing might be 
improved by the use of fluorescent antibody staining and microscopy, which would result in 
the ability to stain the tissue for multiple proteins of interest and observe any co-localisation 
of the expression of these proteins. For example, staining wound granulation tissue with 
BrdU (Seth, De la Garza et al. 2013) and hspB1 would give insight into the number of 
proliferating cells and the level of hspB1 expression in these cells.  
Previous studies have shown the contribution of resident stem cells in the bulge region of hair 
follicles to injury repair, whereby these cells adopt an epidermal phenotype (Ito et al., 2005). 
We have demonstrated strong hspB1 expression in hair follicles in wild-type mice. The 
contribution of follicular stem cells to wound healing and possible regulation by hspB1 
warrants further investigation.   
I have not investigated the effect of hspB1 deficiency on TTP phosphorylation due to time 
limitations, although I considered if the lack of hspB1 as a substrate for phosphorylation by 
MK2 would result in a difference in the expression or activation of the shared MK2 substrate, 
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TTP, in hspB1-deficient mice compared to wild-type mice. We observed a trend toward 
COX-2, IL-6 and CXCL1 mRNA expression in hspB1-deficient MEF compared to wild-type, 
although we also did not investigate the extent of TTP expression in MEF, as these cells have 
vanishingly low expression of TTP. Furthermore, any such investigation would be hampered 
by the poor sensitivity of current anti-phosphorylated TTP antibodies available. TTP is 
strongly expressed in bone-marrow derived murine macrophages, and inhibition of TTP 
activity in these cells results in increased IL-1α, TNFα, IL-6, IL-10 (Tudor, Marchese et al. 
2009) and CXCL1 (Datta, Biswas et al. 2008) mRNA stability. However, the observation that 
TEPM from wild-type mice do not express hspB1 suggests that TTP activity would not be 
affected in TEPM from hspB1-deficient mice. 
HspB1 deficiency did not result in a reduction in protein production, as seen for inhibition of 
hsp90 (Sharma, Vabulas et al. 2012). The loss of the chaperone function and protein 
ubiquitination by hspB1 in hspB1
del/del
 mice might result in the accumulation of proteins that 
otherwise might have been sequestered for degradation by the proteasome. HspB1 provides 
cellular resistance to thermal stress (Carper, Rocheleau et al. 1997) and is phosphorylation-
independent (Knauf, Jakob et al. 1994). The effect of heat stress on hspB1-deficient mice has 
not been investigated in this thesis. All of the mice that were used were housed within a 
stable temperature range. Perhaps a dramatically increased inflammatory and apoptotic 
phenotype in hspB1
del/del 
mice compared to wild-type mice would be observed in experiments 
repeated using mice housed at a higher than average temperature, which would drive 
increased hspB1 expression and function in wild-type mice. 
Non-healing foot and leg ulcers are major pathologies that affect diabetics and patients on 
long-term glucocorticoid therapy. Chronic wounds are those which remain detained in the 
inflammatory stage for too long, which results in impaired production and promotion of the 
degradation of the ECM (Schonfelder, Abel et al. 2005). By definition, these wounds take 
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longer than three months to resolve and some may take far longer. These wounds represent a 
serious cause of morbidity, immobility, financial cost to the patient and healthcare system, 
and in extreme cases, can lead to lower extremity amputation (Snyder 2005). HspB1 
accelerates wound healing, promotes re-epithelialisation and proliferation, and diminishes 
pro-inflammatory cytokine expression and neutrophil recruitment during the acute 
inflammatory response. The increase in the expression and/or activity of hspB1, whilst 
limiting the activity of TTP, might provide a novel therapeutic approach to treating chronic 
wounds. 
While I have shown that hspB1 limits inflammatory cytokine expression in vivo and in 
embryonic fibroblasts, the precise molecular function of hspB1 in negatively regulating 
cytokine production is still unclear. The function of hspB1 is likely to be intracellular and 
may involve regulation of cell signalling via its ability to act as a chaperone but could equally 
well involve different direct chaperone effects on cytokines themselves or other proteins in 
the cell. The fact that many different proteins (p38 MAPK, p21, p27 and  numerous 
cytokines) display increased expression in hspB1-depleted cells suggest that such effects 
could be mediated by the function of hspB1 in promoting ubiquitin-mediated degradation of 
client proteins as has recently been suggested for AUF1(Li, Defren et al. 2013). It would be 
very interesting to perform proteomic analysis of wild-type and hspB1-deficient cells and to 
identify the ubiquitin ligases that might be involved. One of the reasons why I did not attempt 
such as study was due to the fact that we were unable to reconstitute the in vivo effects of 
hspB1-depletion on cytokine expression in MEF. In these cells hspB1 appears not to regulate 
CXCL1 production and IL-6 expression was not regulated by hspB1 to the same extent as in 
vivo. To perform such studies it would be firstly necessary to identify a primary cell type that 
can be easily cultured from mouse tissue which displays strong hspB1-dependent effects on 
cytokine production. I attempted to isolate grow primary adult murine lung endothelial cells 
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but these proliferated poorly and it was impossible to grow hspB1-deficient cultures of these 
cells. Adult dermal fibroblasts might be a good choice, but obtaining sufficient numbers of 
cells for mechanistic analysis would be a challenge.
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